


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T14:05:44Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12405092" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12405092</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>discon</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Discov Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Discov Oncol</journal-id><journal-id journal-id-type="pmc-domain-id">4139</journal-id><journal-id journal-id-type="pmc-domain">discon</journal-id><journal-title-group><journal-title>Discover Oncology</journal-title></journal-title-group><issn pub-type="epub">2730-6011</issn><publisher><publisher-name>Springer</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12405092</article-id><article-id pub-id-type="pmcid-ver">PMC12405092.1</article-id><article-id pub-id-type="pmcaid">12405092</article-id><article-id pub-id-type="pmcaiid">12405092</article-id><article-id pub-id-type="pmid">40897893</article-id><article-id pub-id-type="doi">10.1007/s12672-025-03542-8</article-id><article-id pub-id-type="publisher-id">3542</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Bibliometric-driven research on chemoresistance in breast cancer: knowledge mapping, hotspot evolution, and emerging insights (1994&#8211;2024)</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0068-6132</contrib-id><name name-style="western"><surname>Zhang</surname><given-names initials="H">Hao</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0009-0001-4642-8972</contrib-id><name name-style="western"><surname>Feng</surname><given-names initials="T">Ting</given-names></name><address><email>fengting150@126.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-9300-1771</contrib-id><name name-style="western"><surname>Lin</surname><given-names initials="J">Juntang</given-names></name><address><email>linjtlin@126.com</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-3295-9676</contrib-id><name name-style="western"><surname>Yahaya</surname><given-names initials="BH">Badrul Hisham</given-names></name><address><email>badrul@usm.my</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02rgb2k63</institution-id><institution-id institution-id-type="GRID">grid.11875.3a</institution-id><institution-id institution-id-type="ISNI">0000 0001 2294 3534</institution-id><institution>Department of Biomedical Sciences, Advanced Medical and Dental Institute (IPPT), </institution><institution>Universiti Sains Malaysia, SAINS@Bertam, </institution></institution-wrap>Kepala Batas, Penang, 13200 Malaysia </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02rgb2k63</institution-id><institution-id institution-id-type="GRID">grid.11875.3a</institution-id><institution-id institution-id-type="ISNI">0000 0001 2294 3534</institution-id><institution>Breast Cancer Translational Research Program (BCTRP), Advanced Medical and Dental Institute, </institution><institution>Universiti Sains Malaysia, </institution></institution-wrap>Bertam, Kepala Batas, Pulau Pinang, 13200 Malaysia </aff><aff id="Aff3"><label>3</label>Department of medical imaging center, Tianjin Xiqing Hospital, Tianjin, 300380 China </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/038hzq450</institution-id><institution-id institution-id-type="GRID">grid.412990.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 1808 322X</institution-id><institution>Henan Joint International Research Laboratory of Stem Cell Medicine, School of Medical Engineering, </institution><institution>Xinxiang Medical University, </institution></institution-wrap>Xinxiang, 453003 China </aff></contrib-group><pub-date pub-type="epub"><day>3</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2025</year></pub-date><volume>16</volume><issue-id pub-id-type="pmc-issue-id">478248</issue-id><elocation-id>1676</elocation-id><history><date date-type="received"><day>26</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>29</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 00:25:59.930"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="12672_2025_Article_3542.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Chemoresistance remains a pivotal challenge in the clinical management of breast cancer. A systematic dissection of global research trends, evolutionary hotspots, and emerging frontiers in this field is imperative for advancing therapeutic strategies.</p></sec><sec><title>Methods</title><p id="Par2">Relevant literature on breast cancer chemoresistance from 1994 to 2024 was retrieved from the Science Citation Index-Expanded (SCI-E) database of the Web of Science Core Collection (WoSCC). Bibliometric analysis was conducted using Co-Occurrence (COOC 14.5), CiteSpace (6.1.R6), and R software (v4.2.3; packages: bibliometrix, ggplot2, and tidyverse).</p></sec><sec><title>Results</title><p id="Par3">A total of 1,929 publications involving 75 countries/regions, 2,355 institutions, and 12,046 authors were analyzed. The journal <italic toggle="yes">Cancers</italic> published the highest number of articles (87). China contributed the largest share (803 articles), with Nanjing Medical University (53 articles) and researchers Ma Xin and Wang Yan (11 articles each) identified as the most productive institution and authors, respectively. Keyword analysis indicated that &#8220;triple-negative breast cancer (TNBC),&#8221; &#8220;doxorubicin resistance,&#8221; and &#8220;breast cancer stem cells&#8221; were long-standing core topics. In the context of the big-data era, bioinformatics-driven multi-omics analyses have become mainstream approaches for investigating chemoresistance mechanisms. Targeting ferroptosis-related pathways has emerged as a novel therapeutic strategy in this field. Burst detection revealed &#8220;prognostic biomarkers&#8221; and &#8220;liquid biopsy&#8221; as current research hotspots, while reference analysis further suggested &#8220;circular RNA&#8221; and &#8220;breast cancer stemness&#8221; as critical future research directions.</p></sec><sec><title>Conclusions</title><p id="Par4">Through multidimensional bibliometric analyses, this study elucidates the developmental trajectory and potential breakthroughs in breast cancer chemoresistance research, offering a theoretical framework and translational insights for deeper exploration of resistance mechanisms and the design of precision therapeutic strategies.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s12672-025-03542-8.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Breast cancer</kwd><kwd>Chemoresistance</kwd><kwd>Bibliometric</kwd><kwd>Hotspots</kwd><kwd>Trends</kwd><kwd>Global research</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Science+Business Media LLC, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">Breast cancer is one of the most common malignant tumors in women, accounting for about 30% of female cancer cases. It is a major cause of cancer-related deaths in women and poses a serious threat to their life and health [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. The year 2020 saw 2,261,419 newly diagnosed cases of breast cancer in women (11.7%), the most among all types of cancer worldwide, exceeding the 2,206,771 cases of lung cancer (11.4%) [<xref ref-type="bibr" rid="CR4">4</xref>]. The burden of breast cancer is continuously increasing globally [<xref ref-type="bibr" rid="CR5">5</xref>]. Therefore, breast cancer research warrants more attention. Various treatments are currently available, encompassing surgical procedures, chemotherapy, radiation therapy, hormonal treatments, targeted therapies, and immunotherapy. Surgery is typically the preferred treatment option for patients with early-stage breast cancer, with chemotherapy as the primary adjuvant therapy. In cases of advanced-stage breast cancer, however, chemotherapy often serves as the primary mode of treatment. Consequently, its role in managing breast cancer is pivotal.</p><p id="Par6">Chemotherapy remains the standard treatment for primary breast cancer with a high risk of recurrence, commonly administered in adjuvant or neoadjuvant settings to increase the rate of surgical resection, enhance the possibility of breast-conserving surgery, and reduce the extent of axillary lymph node dissection [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. This clinical stage also represents a critical window during which chemoresistance often emerges and directly impacts therapeutic efficacy. Common chemotherapeutic agents for breast cancer include anthracyclines, cyclophosphamide, taxanes, and fluoropyrimidines, with anthracyclines as a cornerstone due to their potent antitumor activity [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. However, despite advancements in early detection and continual optimization of chemotherapy regimens, the prognosis for certain breast cancer patients remains poor. Tekpli et al. reported a distinct breast cancer subtype characterized by an immunosuppressive tumor microenvironment (TME), with reduced immune cell infiltration and upregulation of immunoinhibitory signals, which was independently associated with an increased risk of recurrence and worse overall survival [<xref ref-type="bibr" rid="CR15">15</xref>]. Waks and Winer highlighted that metastatic breast cancer remains incurable mainly, particularly in patients with triple-negative breast cancer (TNBC), where the median overall survival typically ranges from 10 to 13 months [<xref ref-type="bibr" rid="CR16">16</xref>]. Furthermore, although precision medicine has made substantial progress, Odle noted that its clinical efficacy in advanced breast cancer is still constrained by resistance and relapse, with limited improvements in long-term survival outcomes [<xref ref-type="bibr" rid="CR17">17</xref>]. A major factor underlying this poor prognosis is chemoresistance, defined as the ability of cancer cells to survive and proliferate despite exposure to high concentrations of chemotherapeutic agents, ultimately leading to treatment failure or non-responsiveness [<xref ref-type="bibr" rid="CR18">18</xref>]. Chemoresistance has become a significant obstacle in breast cancer treatment, particularly in metastatic cases, where over 90% of therapeutic failures are directly associated with resistance to anthracyclines [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. It also drives more aggressive tumor progression, including enhanced metastatic potential and increased risk of recurrence [<xref ref-type="bibr" rid="CR21">21</xref>]. Clinical data show that the five-year survival rate for patients with localized breast cancer can reach 99% but drops drastically to approximately 26% once distant metastasis occurs [<xref ref-type="bibr" rid="CR22">22</xref>]. Although efforts to reverse resistance and restore sensitivity to conventional therapies are ongoing, the overall therapeutic efficacy remains suboptimal [<xref ref-type="bibr" rid="CR23">23</xref>]. Therefore, understanding the molecular mechanisms underlying chemoresistance in breast cancer is critical for developing novel therapeutic agents and innovative treatment strategies. Systematic summarization of research in this field helps delineate research trends and potential mechanisms and facilitates the identification of new directions and effective interventions. A thorough review of the current landscape of chemoresistance research in breast cancer is thus essential and holds significant promise for improving treatment options and patient outcomes.</p><p id="Par7">The concept of bibliometric analysis was first introduced by Professor Mulchenko [<xref ref-type="bibr" rid="CR24">24</xref>]. In 1969, Professor Pritchard defined it as &#8220;the application of mathematical and statistical methods to books and other media&#8221; [<xref ref-type="bibr" rid="CR25">25</xref>]. Over decades of evolution, bibliometric analysis has transformed into an interdisciplinary research methodology, blending statistical techniques with data visualization. This approach facilitates both qualitative and quantitative analyses of journals, countries, institutions, authors, keywords, and other elements within a specific field. It has become a pivotal research method for evaluating knowledge repositories and exploring research topics [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. At its core, bibliometrics aims to use data and statistical methods to highlight the latest trends in research fields, assess the societal impact of research outcomes, and aid policymakers, scholars, and researchers in gaining a deeper understanding of academic progress. This analytical approach is increasingly vital for formulating guidelines, evaluating research directions [<xref ref-type="bibr" rid="CR30">30</xref>], and providing profound insights into the research focus and recent developments in a given field. Presently, this analytical method has gained widespread acceptance and attention among researchers across various medical domains, including surgery [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>], medical imaging [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>], artificial intelligence [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>], traditional Chinese medicine [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>], cancer treatment [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>], biomedical studies [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR50">50</xref>], and nursing [<xref ref-type="bibr" rid="CR51">51</xref>]. However, no bibliometric analysis has yet been reported on chemoresistance in breast cancer.</p><p id="Par8">This investigation employed bibliometric methods to analyze and consolidate three decades&#8217; worth of pertinent research on chemoresistance in breast cancer. The findings illuminate the present research landscape, key focus areas, and forthcoming trends in this field. This study offers valuable insights and crucial data for the swift advancement of this domain. It is anticipated to assist researchers gain a comprehensive understanding of recent advancements in the field and explore novel perspectives in the future.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Data sources, search strategy, and data collation</title><p id="Par9">Web of Science Core Collection (WoSCC; Clarivate Analytics, USA) is one of the most systematic, authoritative, and comprehensive databases. It is unique for its uniformity and standardization of data records. This database is frequently utilized for bibliometric analysis [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref>]. Besides its inherent analytical capabilities, it also supports data export to different software for further analysis [<xref ref-type="bibr" rid="CR56">56</xref>].</p><p id="Par10">In this study, we used the Science Citation Index Expanded (SCI-E) within WoSCC as the source for literature search. We selected the advanced search option to retrieve relevant literature. For the search, we used &#8220;breast cancer&#8221; and &#8220;chemoresistance&#8221; as topic words for the title, abstract, and author keywords. We also used their free word combinations to perform comprehensive searches. The detailed search strategy is illustrated in Supplementary Material 1.</p><p id="Par11">The time range for the literature search was set from 1994-01-01 to 2024-12-31. We focused on articles and review articles, with the language restricted to English. Since WoSCC is updated daily, all search processes mentioned were completed on January 24, 2025. This approach was taken to reduce any potential bias in the results. We downloaded the complete dataset in plain text format and processed the data using the Co-Occurrence (COOC) software as follows:<list list-type="order"><list-item><p id="Par12">Duplicates were removed;</p></list-item><list-item><p id="Par13">Additional studies irrelevant to this field were excluded by reading the titles and abstracts;</p></list-item><list-item><p id="Par14">Missing information in the literature (such as country/region, institution, author, and keywords) was manually supplemented;</p></list-item><list-item><p id="Par15">Synonym merging and the removal of invalid words were applied to the authors&#8217; keyword information.</p></list-item></list></p><p id="Par16">Through this data processing, we ensured the accuracy of the data. The workflow of our study is illustrated in Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>.</p><p id="Par17">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Workflow of this study</p></caption><graphic id="d33e460" position="float" orientation="portrait" xlink:href="12672_2025_3542_Fig1_HTML.jpg"/></fig>
</p></sec><sec id="Sec4"><title>Bibliometric analysis</title><p id="Par18">A single software cannot meet the needs of literature analysis. Therefore, multiple software tools must be combined to make the analysis more comprehensive [<xref ref-type="bibr" rid="CR57">57</xref>]. In this research, we employed three tools to analyze and visualize the gathered literature data. These tools are: the COOC software (version 14.5), the &#8220;bibliometrix&#8221; package [<xref ref-type="bibr" rid="CR58">58</xref>] (version 4.1.3), &#8220;ggplot2&#8221; (version 3.4.4) and &#8220;tidyverse&#8221; package (version 2.0.0) in R (version 4.2.3), and the CiteSpace software (version 6.1.R6).</p><p id="Par19">The evaluation metrics encompassed various categories, including discipline categories, journals, countries/regions, institutions, authors, keywords, and references. Journal information was obtained from the 2023 Journal Citation Report (JCR; Clarivate Analytics, Philadelphia, PA, United States). This report provides journal rankings in the form of the JCR quartile. The evaluation is performed based on the discipline category (JCR category). All journals are sorted in descending order of their impact factors (IFs) and divided into four equal quartiles: Q1 (top 25%), Q2 (26&#8211;50%), Q3 (51&#8211;75%), and Q4 (bottom 25%). A journal&#8217;s quartile indicates its status within a specific academic field. Thus, the JCR quartile is a significant metric for assessing the influence of journals.</p><p id="Par20">COOC is an emerging and multifunctional bibliometric software [<xref ref-type="bibr" rid="CR59">59</xref>]. It has been widely used in a growing number of studies [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR61">61</xref>, <xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR63">63</xref>]. In this study, COOC was used not only for data collation but also for frequency analysis of various categories: discipline categories, journals, countries/regions, institutions, authors, keywords, and literature citations. Moreover, it facilitated collaboration analysis (for countries/regions, institutions, and authors) and the study of annual attention changes and thematic evolution paths of keywords.</p><p id="Par21">Cooperative relationships were evaluated using two indicators: cooperation rate and cooperation degree. The cooperation rate refers to the percentage of collaborative papers in a particular field, while the cooperation degree represents the average number of collaborations in papers within that field. Both indicators are calculated as follows:<disp-formula id="Equa"><alternatives><tex-math id="d33e493">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:Cooperation\:rate\:\left(x\right)=\frac{Number\:of\:Collaborative\:Papers\:\left(x\right)}{Total\:number\:of\:papers\:published}\times\:100\%$$\end{document}</tex-math><graphic position="anchor" orientation="portrait" xlink:href="12672_2025_3542_Article_Equa.gif"/></alternatives></disp-formula><disp-formula id="Equb"><alternatives><tex-math id="d33e498">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:Cooperation\:degree\:\left(x\right)=\frac{Quantity\:of\:involvement\:\left(x\right)}{Total\:number\:of\:papers\:published}$$\end{document}</tex-math><graphic position="anchor" orientation="portrait" xlink:href="12672_2025_3542_Article_Equb.gif"/></alternatives></disp-formula></p><p id="Par22">Here, &#8220;<inline-formula id="IEq1"><alternatives><tex-math id="d33e505">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:x$$\end{document}</tex-math><inline-graphic xlink:href="12672_2025_3542_Article_IEq1.gif"/></alternatives></inline-formula>&#8221; represents the country/region, institution, or author. The cooperation rate reveals the breadth of collaboration, while the cooperation degree demonstrates the depth of collaboration. They are both widely used indicators in the field of bibliometrics to measure the level of collaboration.</p><p id="Par23">The annual attention is calculated as follows:<disp-formula id="Equc"><alternatives><tex-math id="d33e513">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:Attention\:degree\:\left(n\right)\left(x\right)=\frac{Frequency\:of\:appearance\:\left(n\right)\left(x\right)}{Number\:of\:Papers\:Published\:\left(x\right)}$$\end{document}</tex-math><graphic position="anchor" orientation="portrait" xlink:href="12672_2025_3542_Article_Equc.gif"/></alternatives></disp-formula></p><p id="Par24">Here, &#8220;<inline-formula id="IEq2"><alternatives><tex-math id="d33e520">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:n$$\end{document}</tex-math><inline-graphic xlink:href="12672_2025_3542_Article_IEq2.gif"/></alternatives></inline-formula>&#8221; represents the keyword, and &#8220;<inline-formula id="IEq3"><alternatives><tex-math id="d33e526">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\:x$$\end{document}</tex-math><inline-graphic xlink:href="12672_2025_3542_Article_IEq1.gif"/></alternatives></inline-formula>&#8221; represents the year. This metric effectively reflects the trend of research topics over the years. The higher the attention, the more popular the topic is among researchers.</p><p id="Par25">The &#8220;bibliometrix&#8221; package in R, which contains bibliometric analysis functions [<xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR64">64</xref>], was used to create a global map depicting country collaboration relationships. Additionally, the evaluation results of collaboration relationships and the burst detection analysis of keywords and references were visualized using the &#8220;ggplot2&#8221; and &#8220;tidyverse&#8221; R language packages.</p><p id="Par26">CiteSpace, a fully featured bibliometric analysis and visualization tool operating within a Java framework, is notable for its text-mining ability. It discerns network connections, knowledge dynamics, and critical information, thus exposing the internal configuration, focal research topics, and developmental trajectories of specific domains [<xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR67">67</xref>]. We used CiteSpace to analyze and visualize various maps: collaboration network maps (for countries/regions, institutions, and authors), journal dual-overlay maps, co-occurrence network maps (for discipline categories and keywords), co-citation network maps (for journals and references), and cluster and burst detection analysis (for keywords and references). We also performed frequency statistics on reference citations.</p><p id="Par27">CiteSpace uses betweenness centrality to evaluate the importance of network nodes. Nodes with a centrality&#8201;&#8805;&#8201;0.1 will display a purple outer ring, indicating their role as a bridge and connection [<xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR67">67</xref>, <xref ref-type="bibr" rid="CR68">68</xref>]. The dual-overlay map analysis of journals illustrates the distribution relationship between citing journals (on the left) and cited journals (on the right). The colored paths between the two indicate knowledge flow from right to left. The purpose of clustering is to summarize various topics. If a cluster has a smaller ordinal number, it will contain more objects [<xref ref-type="bibr" rid="CR48">48</xref>]. We employed the log-likelihood ratio algorithm for clustering analysis of keywords and references. The modularity value (Q value) and silhouette value (S value) were used to evaluate the clusters. When Q&#8201;&gt;&#8201;0.3 and S&#8201;&gt;&#8201;0.7, the community structure of the clustering is considered significant, and the results are highly credible [<xref ref-type="bibr" rid="CR69">69</xref>].</p><p id="Par28">Burst detection can identify which research objects have received particular attention over certain periods, effectively pinpointing topics that suddenly emerged at different times. In conclusion, these evaluation metrics are vital for discovering research hotspots and trends in the target field.</p></sec></sec><sec id="Sec5"><title>Results</title><sec id="Sec6"><title>Publication trends</title><p id="Par29">A total of 2,909 publications were initially retrieved. After data cleaning, 1,929 articles published between 1994 and 2024 on chemoresistance in breast cancer were included in the final analysis (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>). In the early years, the annual publication count was fewer than 10 articles in 1994. Since then, there has been an upward trend, peaking in 2021 with 212 publications. In 2022, 2023, and 2024, the annual publication counts were 189, 165, and 170, respectively&#8212;slightly lower than the peak but still substantially higher than early levels (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>A). From 2017 to 2024, 1,342 publications were produced, accounting for 69.57% of the total output (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>B). Although there has been a slight decline in publication volume over the past three years, the overall output remains high, which may reflect a natural stabilization following a period of rapid growth. Collectively, research from the past decade accounts for nearly 70% of the literature, indicating that chemoresistance in breast cancer remains a prominent and actively pursued research focus within the academic community.</p><p id="Par30">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Analysis of publication volume in breast cancer chemoresistance. <bold>A</bold> The annual publication volume analysis. <bold>B</bold> The cumulative publication volume analysis</p></caption><graphic id="d33e601" position="float" orientation="portrait" xlink:href="12672_2025_3542_Fig2_HTML.jpg"/></fig>
</p></sec><sec id="Sec7"><title>Disciplines and journals</title><p id="Par31">The 1,929 articles spanned 67 disciplines, primarily in Oncology (912 articles), Biochemistry and Molecular Biology (342), and Pharmacology and Pharmacy (291) (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). Discipline co-occurrence network analysis revealed high centrality (&gt;&#8201;0.1) [<xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR67">67</xref>, <xref ref-type="bibr" rid="CR68">68</xref>] for Oncology (0.46), Biochemistry and Molecular Biology (0.30), and Pharmacology and Pharmacy (0.34), emphasizing their core contributions to the field (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>A).</p><p id="Par32">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Information on the top 15 discipline categories by frequency of occurrence</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Rank</th><th align="left" colspan="1" rowspan="1">Categories</th><th align="left" colspan="1" rowspan="1">Count</th><th align="left" colspan="1" rowspan="1">Year</th><th align="left" colspan="1" rowspan="1">Centrality</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">Oncology</td><td char="." align="char" colspan="1" rowspan="1">912</td><td char="." align="char" colspan="1" rowspan="1">1996</td><td align="left" colspan="1" rowspan="1">0.46</td></tr><tr><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">Biochemistry &amp; Molecular Biology</td><td char="." align="char" colspan="1" rowspan="1">342</td><td char="." align="char" colspan="1" rowspan="1">1995</td><td align="left" colspan="1" rowspan="1">0.30</td></tr><tr><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">Pharmacology &amp; Pharmacy</td><td char="." align="char" colspan="1" rowspan="1">291</td><td char="." align="char" colspan="1" rowspan="1">1994</td><td align="left" colspan="1" rowspan="1">0.34</td></tr><tr><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">Cell Biology</td><td char="." align="char" colspan="1" rowspan="1">258</td><td char="." align="char" colspan="1" rowspan="1">1996</td><td align="left" colspan="1" rowspan="1">0.21</td></tr><tr><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">Medicine, Research &amp; Experimental</td><td char="." align="char" colspan="1" rowspan="1">195</td><td char="." align="char" colspan="1" rowspan="1">1995</td><td align="left" colspan="1" rowspan="1">0.20</td></tr><tr><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">Chemistry, Multidisciplinary</td><td char="." align="char" colspan="1" rowspan="1">105</td><td char="." align="char" colspan="1" rowspan="1">2011</td><td align="left" colspan="1" rowspan="1">0.08</td></tr><tr><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">Genetics &amp; Heredity</td><td char="." align="char" colspan="1" rowspan="1">78</td><td char="." align="char" colspan="1" rowspan="1">1995</td><td align="left" colspan="1" rowspan="1">0.05</td></tr><tr><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">Biotechnology &amp; Applied Microbiology</td><td char="." align="char" colspan="1" rowspan="1">65</td><td char="." align="char" colspan="1" rowspan="1">1995</td><td align="left" colspan="1" rowspan="1">0.08</td></tr><tr><td align="left" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">Chemistry, Medicinal</td><td char="." align="char" colspan="1" rowspan="1">58</td><td char="." align="char" colspan="1" rowspan="1">2008</td><td align="left" colspan="1" rowspan="1">0.04</td></tr><tr><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">Biophysics</td><td char="." align="char" colspan="1" rowspan="1">55</td><td char="." align="char" colspan="1" rowspan="1">2005</td><td align="left" colspan="1" rowspan="1">0.04</td></tr><tr><td align="left" colspan="1" rowspan="1">11</td><td align="left" colspan="1" rowspan="1">Pathology</td><td char="." align="char" colspan="1" rowspan="1">47</td><td char="." align="char" colspan="1" rowspan="1">1998</td><td align="left" colspan="1" rowspan="1">0.06</td></tr><tr><td align="left" colspan="1" rowspan="1">12</td><td align="left" colspan="1" rowspan="1">Nanoscience &amp; Nanotechnology</td><td char="." align="char" colspan="1" rowspan="1">38</td><td char="." align="char" colspan="1" rowspan="1">2010</td><td align="left" colspan="1" rowspan="1">0.15</td></tr><tr><td align="left" colspan="1" rowspan="1">13</td><td align="left" colspan="1" rowspan="1">Biology</td><td char="." align="char" colspan="1" rowspan="1">28</td><td char="." align="char" colspan="1" rowspan="1">2015</td><td align="left" colspan="1" rowspan="1">0.06</td></tr><tr><td align="left" colspan="1" rowspan="1">14</td><td align="left" colspan="1" rowspan="1">Physiology</td><td char="." align="char" colspan="1" rowspan="1">27</td><td char="." align="char" colspan="1" rowspan="1">2004</td><td align="left" colspan="1" rowspan="1">0.03</td></tr><tr><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1">Materials Science, Biomaterials</td><td char="." align="char" colspan="1" rowspan="1">26</td><td char="." align="char" colspan="1" rowspan="1">2013</td><td align="left" colspan="1" rowspan="1">0</td></tr><tr><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1">Toxicology</td><td char="." align="char" colspan="1" rowspan="1">26</td><td char="." align="char" colspan="1" rowspan="1">2001</td><td align="left" colspan="1" rowspan="1">0.12</td></tr></tbody></table></table-wrap>
</p><p id="Par33">
<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Presents the discipline category, co-citation of journals, and dual-map overlay analysis in breast cancer chemoresistance. <bold>A</bold> Co-occurrence network of discipline categories. <bold>B</bold> Co-citation network of journals from reference sources. <bold>C</bold> Distribution of discipline information flowing from cited to citing journals</p></caption><graphic id="d33e844" position="float" orientation="portrait" xlink:href="12672_2025_3542_Fig3_HTML.jpg"/></fig>
</p><p id="Par34">Publications appeared in 468 journals, with the top 10 journals publishing 452 articles (23.43% of total). The leading journals included <italic toggle="yes">Cancers</italic> (87 articles, Q1), <italic toggle="yes">International Journal of Molecular Sciences</italic> (64 articles, Q1), and <italic toggle="yes">Frontiers in Oncology</italic> (63 articles, Q2) (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). Co-citation analysis identified <italic toggle="yes">Cancer Research</italic> (2,209 citations), <italic toggle="yes">Oncogene</italic> (1,742 citations), and <italic toggle="yes">Clinical Cancer Research</italic> (1,629 citations) as the most influential reference sources, providing essential knowledge support for research on chemoresistance (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>; Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>B).</p><p id="Par35">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Information on the top 10 journals by volume of publications and number of citations from reference sources</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Rank</th><th align="left" colspan="1" rowspan="1">Journal</th><th align="left" colspan="1" rowspan="1">Count</th><th align="left" colspan="1" rowspan="1">IF/JCR</th><th align="left" colspan="1" rowspan="1">Rank</th><th align="left" colspan="1" rowspan="1">Cited journal</th><th align="left" colspan="1" rowspan="1">Citations</th><th align="left" colspan="1" rowspan="1">Centrality</th><th align="left" colspan="1" rowspan="1">IF/JCR</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">Cancers</td><td char="." align="char" colspan="1" rowspan="1">87</td><td align="left" colspan="1" rowspan="1">4.5 / Q1</td><td char="." align="char" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">Cancer Research</td><td char="." align="char" colspan="1" rowspan="1">2209</td><td align="left" colspan="1" rowspan="1">0.01</td><td align="left" colspan="1" rowspan="1">12.5 / Q1</td></tr><tr><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">International Journal of Molecular Sciences</td><td char="." align="char" colspan="1" rowspan="1">64</td><td align="left" colspan="1" rowspan="1">4.9 / Q1</td><td char="." align="char" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">Oncogene</td><td char="." align="char" colspan="1" rowspan="1">1742</td><td align="left" colspan="1" rowspan="1">0.01</td><td align="left" colspan="1" rowspan="1">6.9/ Q1</td></tr><tr><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">Frontiers In Oncology</td><td char="." align="char" colspan="1" rowspan="1">63</td><td align="left" colspan="1" rowspan="1">3.5 / Q2</td><td char="." align="char" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">Clinical Cancer Research</td><td char="." align="char" colspan="1" rowspan="1">1629</td><td align="left" colspan="1" rowspan="1">0.01</td><td align="left" colspan="1" rowspan="1">10.4 / Q1</td></tr><tr><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">Breast Cancer Research and Treatment</td><td char="." align="char" colspan="1" rowspan="1">52</td><td align="left" colspan="1" rowspan="1">3.0 /Q2</td><td char="." align="char" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">Proceedings of the National Academy of Sciences of the United States of America</td><td char="." align="char" colspan="1" rowspan="1">1602</td><td align="left" colspan="1" rowspan="1">0.01</td><td align="left" colspan="1" rowspan="1">9.4 / Q1</td></tr><tr><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">Cancer Letters</td><td char="." align="char" colspan="1" rowspan="1">38</td><td align="left" colspan="1" rowspan="1">9.1 / Q1</td><td char="." align="char" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">Journal of Biological Chemistry</td><td char="." align="char" colspan="1" rowspan="1">1472</td><td align="left" colspan="1" rowspan="1">0.01</td><td align="left" colspan="1" rowspan="1">4.0 / Q2</td></tr><tr><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">Oncology Reports</td><td char="." align="char" colspan="1" rowspan="1">33</td><td align="left" colspan="1" rowspan="1">3.8/ Q2</td><td char="." align="char" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">Nature</td><td char="." align="char" colspan="1" rowspan="1">1443</td><td align="left" colspan="1" rowspan="1">0.01</td><td align="left" colspan="1" rowspan="1">50.5 / Q1</td></tr><tr><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">Biomedicine &amp; Pharmacotherapy</td><td char="." align="char" colspan="1" rowspan="1">33</td><td align="left" colspan="1" rowspan="1">6.9 / Q1</td><td char="." align="char" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">Plos One</td><td char="." align="char" colspan="1" rowspan="1">1396</td><td align="left" colspan="1" rowspan="1">0.01</td><td align="left" colspan="1" rowspan="1">2.9 / Q1</td></tr><tr><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">Oncology Letters</td><td char="." align="char" colspan="1" rowspan="1">32</td><td align="left" colspan="1" rowspan="1">2.5 /Q3</td><td char="." align="char" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">Cell</td><td char="." align="char" colspan="1" rowspan="1">1343</td><td align="left" colspan="1" rowspan="1">0.01</td><td align="left" colspan="1" rowspan="1">45.6 / Q1</td></tr><tr><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">Biochemical And Biophysical Research Communications</td><td char="." align="char" colspan="1" rowspan="1">25</td><td align="left" colspan="1" rowspan="1">2.5 / Q3</td><td char="." align="char" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">Nature Reviews Cancer</td><td char="." align="char" colspan="1" rowspan="1">1216</td><td align="left" colspan="1" rowspan="1">0.01</td><td align="left" colspan="1" rowspan="1">72.5 / Q1</td></tr><tr><td align="left" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">Oncogene</td><td char="." align="char" colspan="1" rowspan="1">25</td><td align="left" colspan="1" rowspan="1">6.9 / Q1</td><td char="." align="char" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">Breast Cancer Research and Treatment</td><td char="." align="char" colspan="1" rowspan="1">1162</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">3.0 / Q2</td></tr></tbody></table><table-wrap-foot><p>Evaluation is based on the 2023 JCR. When multiple categories have inconsistent results in the JCR quartile, the result from the highest-ranked quartile is selected</p></table-wrap-foot></table-wrap>
</p><p id="Par36">Dual-overlay journal analysis (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>C) identified two primary citation pathways: &#8220;Molecular, Biology, Genetics&#8221; journals being cited by publications in &#8220;Molecular, Biology, Immunology&#8221; and &#8220;Medicine, Medical, Clinical&#8221; journals, indicating active translation of basic research into clinical practice.</p></sec><sec id="Sec8"><title>Countries/regions, institutions, authors, and their collaborations</title><p id="Par37">The 1,929 analyzed papers involved 12,046 authors from 2,355 institutions across 75 countries/regions. China (803 articles, 41.63%), the United States (419, 21.72%), and Italy (107, 5.55%) led in publication volume (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>). The global collaboration network indicated the highest number of co-authored articles between China and the United States (77 articles). China primarily collaborated with the United States and the United Kingdom, whereas the United States collaborated widely with eight additional countries (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>A). Countries exhibiting significant centrality included the United States (0.48), Italy (0.23), China and the United Kingdom (both 0.21), France (0.15), and Germany (0.13) (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>B). The overall international collaboration rate was relatively low (22.08%), highlighting a need to strengthen global cooperation (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>C).</p><p id="Par38">
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Information on the top 10 countries/regions, institutions, and authors ranked by publication volume</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Rank</th><th align="left" colspan="1" rowspan="1">Country/Region</th><th align="left" colspan="1" rowspan="1">Count</th><th align="left" colspan="1" rowspan="1">Centrality</th><th align="left" colspan="1" rowspan="1">Rank</th><th align="left" colspan="1" rowspan="1">Institution</th><th align="left" colspan="1" rowspan="1">Count</th><th align="left" colspan="1" rowspan="1">Centrality</th><th align="left" colspan="1" rowspan="1">Rank</th><th align="left" colspan="1" rowspan="1">Author</th><th align="left" colspan="1" rowspan="1">Count</th><th align="left" colspan="1" rowspan="1">Centrality</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">China</td><td char="." align="char" colspan="1" rowspan="1">803</td><td char="." align="char" colspan="1" rowspan="1">0.21</td><td char="." align="char" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">Nanjing Medical University</td><td char="." align="char" colspan="1" rowspan="1">53</td><td char="." align="char" colspan="1" rowspan="1">0.03</td><td char="." align="char" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">Ma Xin</td><td char="." align="char" colspan="1" rowspan="1">11</td><td char="." align="char" colspan="1" rowspan="1">0.00</td></tr><tr><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">USA</td><td char="." align="char" colspan="1" rowspan="1">419</td><td char="." align="char" colspan="1" rowspan="1">0.48</td><td char="." align="char" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">China Medical University</td><td char="." align="char" colspan="1" rowspan="1">46</td><td char="." align="char" colspan="1" rowspan="1">0.09</td><td char="." align="char" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">Wang Yan</td><td char="." align="char" colspan="1" rowspan="1">11</td><td char="." align="char" colspan="1" rowspan="1">0.00</td></tr><tr><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">Italy</td><td char="." align="char" colspan="1" rowspan="1">107</td><td char="." align="char" colspan="1" rowspan="1">0.23</td><td char="." align="char" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">Zhejiang University</td><td char="." align="char" colspan="1" rowspan="1">40</td><td char="." align="char" colspan="1" rowspan="1">0.02</td><td char="." align="char" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">Zhang Jun</td><td char="." align="char" colspan="1" rowspan="1">10</td><td char="." align="char" colspan="1" rowspan="1">0.00</td></tr><tr><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">India</td><td char="." align="char" colspan="1" rowspan="1">101</td><td char="." align="char" colspan="1" rowspan="1">0.06</td><td char="." align="char" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">Fudan University</td><td char="." align="char" colspan="1" rowspan="1">38</td><td char="." align="char" colspan="1" rowspan="1">0.04</td><td char="." align="char" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">Jin Jian</td><td char="." align="char" colspan="1" rowspan="1">10</td><td char="." align="char" colspan="1" rowspan="1">0.00</td></tr><tr><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">Germany</td><td char="." align="char" colspan="1" rowspan="1">79</td><td char="." align="char" colspan="1" rowspan="1">0.13</td><td char="." align="char" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">Zhengzhou University</td><td char="." align="char" colspan="1" rowspan="1">33</td><td char="." align="char" colspan="1" rowspan="1">0.02</td><td char="." align="char" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">Chen Wei</td><td char="." align="char" colspan="1" rowspan="1">9</td><td char="." align="char" colspan="1" rowspan="1">0.00</td></tr><tr><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">England</td><td char="." align="char" colspan="1" rowspan="1">69</td><td char="." align="char" colspan="1" rowspan="1">0.21</td><td char="." align="char" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">Shanghai Jiao Tong University</td><td char="." align="char" colspan="1" rowspan="1">30</td><td char="." align="char" colspan="1" rowspan="1">0.02</td><td char="." align="char" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">Burow Matthew E</td><td char="." align="char" colspan="1" rowspan="1">8</td><td char="." align="char" colspan="1" rowspan="1">0.00</td></tr><tr><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">Iran</td><td char="." align="char" colspan="1" rowspan="1">65</td><td char="." align="char" colspan="1" rowspan="1">0.02</td><td char="." align="char" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">Sun Yat-Sen University</td><td char="." align="char" colspan="1" rowspan="1">27</td><td char="." align="char" colspan="1" rowspan="1">0.03</td><td char="." align="char" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">Wang Yu</td><td char="." align="char" colspan="1" rowspan="1">7</td><td char="." align="char" colspan="1" rowspan="1">0.00</td></tr><tr><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">South Korea</td><td char="." align="char" colspan="1" rowspan="1">62</td><td char="." align="char" colspan="1" rowspan="1">0.03</td><td char="." align="char" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">The University of Texas MD Anderson Cancer Center</td><td char="." align="char" colspan="1" rowspan="1">26</td><td char="." align="char" colspan="1" rowspan="1">0.04</td><td char="." align="char" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">Fu Ziyi</td><td char="." align="char" colspan="1" rowspan="1">7</td><td char="." align="char" colspan="1" rowspan="1">0.00</td></tr><tr><td align="left" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">Canada</td><td char="." align="char" colspan="1" rowspan="1">49</td><td char="." align="char" colspan="1" rowspan="1">0.04</td><td char="." align="char" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">Shandong University</td><td char="." align="char" colspan="1" rowspan="1">25</td><td char="." align="char" colspan="1" rowspan="1">0.02</td><td char="." align="char" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">Li J</td><td char="." align="char" colspan="1" rowspan="1">7</td><td char="." align="char" colspan="1" rowspan="1">0.00</td></tr><tr><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">France</td><td char="." align="char" colspan="1" rowspan="1">48</td><td char="." align="char" colspan="1" rowspan="1">0.15</td><td char="." align="char" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">University of Chinese Academy of Sciences</td><td char="." align="char" colspan="1" rowspan="1">23</td><td char="." align="char" colspan="1" rowspan="1">0.06</td><td char="." align="char" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">Zhao Lin</td><td char="." align="char" colspan="1" rowspan="1">7</td><td char="." align="char" colspan="1" rowspan="1">0.00</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">Wang Jing</td><td char="." align="char" colspan="1" rowspan="1">7</td><td char="." align="char" colspan="1" rowspan="1">0.00</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">Wang Bin</td><td char="." align="char" colspan="1" rowspan="1">7</td><td char="." align="char" colspan="1" rowspan="1">0.00</td></tr></tbody></table></table-wrap>
</p><p id="Par39">
<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Analyzes the publishing countries/regions for papers on breast cancer chemoresistance. <bold>A</bold> Geographic map of collaboration among publishing countries. <bold>B</bold> Network of collaboration among publishing countries/regions. <bold>C</bold> Scale of collaboration among publishing countries/regions</p></caption><graphic id="d33e1493" position="float" orientation="portrait" xlink:href="12672_2025_3542_Fig4_HTML.jpg"/></fig>
</p><p id="Par40">Institutionally, Nanjing Medical University published the most papers (53, 2.75%), followed by China Medical University (46, 2.38%) and Zhejiang University (40, 2.07%) (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>). Institutional cooperation rate was moderate (65.47%, cooperation degree: 1.22), and China Medical University had the highest collaboration centrality (0.09), indicating its key role in institutional networks (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>A-B). However, limited multi-institutional collaborations suggest opportunities for enhanced partnerships.</p><p id="Par41">
<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>Presents an analysis of the publishing institutions and authors in the field of breast cancer chemoresistance. <bold>A</bold> Network of collaboration among publishing institutions. <bold>B</bold> Scale of collaboration among publishing institutions. <bold>C</bold> Network of collaboration among authors. <bold>D</bold> Scale of collaboration among authors</p></caption><graphic id="d33e1524" position="float" orientation="portrait" xlink:href="12672_2025_3542_Fig5_HTML.jpg"/></fig>
</p><p id="Par42">At the author level, Ma Xin and Wang Yan published the highest number of articles (11 each, 0.57%), followed by Zhang Jun and Jin Jian (10 each, 0.52%) (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>). The author collaboration rate was high (98.76%, cooperation degree: 6.24), yet network analysis revealed weak interconnectedness (centralities&#8201;=&#8201;0), indicating potential to strengthen collaborative ties among researchers (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>C-D).</p></sec><sec id="Sec30"><title>Keywords analysis</title><p id="Par43">Keyword analysis offers valuable insights into the knowledge structure and evolving research hotspots within a given field [<xref ref-type="bibr" rid="CR70">70</xref>]. The top 30 keywords, ranked by frequency, are presented in Table&#160;<xref rid="Tab4" ref-type="table">4</xref>; Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>A. Breast cancer (1,034 occurrences) and chemoresistance (968) were the most frequent terms, confirming the strong thematic relevance of the included literature. Other high-frequency keywords included TNBC (294), breast cancer stem cells (BCSCs) (204), chemotherapy (181), doxorubicin resistance (157), apoptosis (140), metastasis (127), paclitaxel resistance (100), and epithelial-mesenchymal transition (EMT) (91), reflecting key focus areas in the field.</p><p id="Par44">
<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table 4</label><caption><p>Information on the top 30 keywords by frequency of occurrence</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Rank</th><th align="left" colspan="1" rowspan="1">Keywords</th><th align="left" colspan="1" rowspan="1">Count</th><th align="left" colspan="1" rowspan="1">Year</th><th align="left" colspan="1" rowspan="1">Centrality</th><th align="left" colspan="1" rowspan="1">Rank</th><th align="left" colspan="1" rowspan="1">Keywords</th><th align="left" colspan="1" rowspan="1">Count</th><th align="left" colspan="1" rowspan="1">Year</th><th align="left" colspan="1" rowspan="1">Centrality</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">Breast cancer</td><td char="." align="char" colspan="1" rowspan="1">1034</td><td char="." align="char" colspan="1" rowspan="1">1996</td><td char="." align="char" colspan="1" rowspan="1">0.80</td><td char="." align="char" colspan="1" rowspan="1">17</td><td align="left" colspan="1" rowspan="1">Cisplatin resistance</td><td char="." align="char" colspan="1" rowspan="1">49</td><td char="." align="char" colspan="1" rowspan="1">2000</td><td char="." align="char" colspan="1" rowspan="1">0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1"><p>Chemotherapy resistance</p><p>(Chemoresistance)</p></td><td char="." align="char" colspan="1" rowspan="1">968</td><td char="." align="char" colspan="1" rowspan="1">1994</td><td char="." align="char" colspan="1" rowspan="1">0.65</td><td char="." align="char" colspan="1" rowspan="1">18</td><td align="left" colspan="1" rowspan="1">Exosome</td><td char="." align="char" colspan="1" rowspan="1">45</td><td char="." align="char" colspan="1" rowspan="1">2014</td><td char="." align="char" colspan="1" rowspan="1">0.00</td></tr><tr><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">Triple-negative breast cancer</td><td char="." align="char" colspan="1" rowspan="1">294</td><td char="." align="char" colspan="1" rowspan="1">2008</td><td char="." align="char" colspan="1" rowspan="1">0.30</td><td char="." align="char" colspan="1" rowspan="1">19</td><td align="left" colspan="1" rowspan="1">Combination therapy</td><td char="." align="char" colspan="1" rowspan="1">44</td><td char="." align="char" colspan="1" rowspan="1">1996</td><td char="." align="char" colspan="1" rowspan="1">0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">Breast cancer stem cells</td><td char="." align="char" colspan="1" rowspan="1">204</td><td char="." align="char" colspan="1" rowspan="1">2007</td><td char="." align="char" colspan="1" rowspan="1">0.12</td><td char="." align="char" colspan="1" rowspan="1">20</td><td align="left" colspan="1" rowspan="1">LncRNA</td><td char="." align="char" colspan="1" rowspan="1">41</td><td char="." align="char" colspan="1" rowspan="1">2015</td><td char="." align="char" colspan="1" rowspan="1">0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">Chemotherapy</td><td char="." align="char" colspan="1" rowspan="1">181</td><td char="." align="char" colspan="1" rowspan="1">1994</td><td char="." align="char" colspan="1" rowspan="1">0.03</td><td char="." align="char" colspan="1" rowspan="1">21</td><td align="left" colspan="1" rowspan="1">Hypoxia</td><td char="." align="char" colspan="1" rowspan="1">38</td><td char="." align="char" colspan="1" rowspan="1">2006</td><td char="." align="char" colspan="1" rowspan="1">0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">Doxorubicin resistance</td><td char="." align="char" colspan="1" rowspan="1">157</td><td char="." align="char" colspan="1" rowspan="1">1994</td><td char="." align="char" colspan="1" rowspan="1">0.07</td><td char="." align="char" colspan="1" rowspan="1">22</td><td align="left" colspan="1" rowspan="1">P-glycoprotein</td><td char="." align="char" colspan="1" rowspan="1">36</td><td char="." align="char" colspan="1" rowspan="1">1997</td><td char="." align="char" colspan="1" rowspan="1">0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">Apoptosis</td><td char="." align="char" colspan="1" rowspan="1">140</td><td char="." align="char" colspan="1" rowspan="1">1998</td><td char="." align="char" colspan="1" rowspan="1">0.03</td><td char="." align="char" colspan="1" rowspan="1">23</td><td align="left" colspan="1" rowspan="1">Docetaxel resistance</td><td char="." align="char" colspan="1" rowspan="1">30</td><td char="." align="char" colspan="1" rowspan="1">2001</td><td char="." align="char" colspan="1" rowspan="1">0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">Metastasis</td><td char="." align="char" colspan="1" rowspan="1">127</td><td char="." align="char" colspan="1" rowspan="1">1997</td><td char="." align="char" colspan="1" rowspan="1">0.03</td><td char="." align="char" colspan="1" rowspan="1">24</td><td align="left" colspan="1" rowspan="1">P53</td><td char="." align="char" colspan="1" rowspan="1">28</td><td char="." align="char" colspan="1" rowspan="1">2000</td><td char="." align="char" colspan="1" rowspan="1">0.00</td></tr><tr><td align="left" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">Paclitaxel resistance</td><td char="." align="char" colspan="1" rowspan="1">100</td><td char="." align="char" colspan="1" rowspan="1">1996</td><td char="." align="char" colspan="1" rowspan="1">0.05</td><td char="." align="char" colspan="1" rowspan="1">25</td><td align="left" colspan="1" rowspan="1">DNA Damage Repair</td><td char="." align="char" colspan="1" rowspan="1">27</td><td char="." align="char" colspan="1" rowspan="1">2001</td><td char="." align="char" colspan="1" rowspan="1">0.00</td></tr><tr><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">Epithelial mesenchymal transition (EMT)</td><td char="." align="char" colspan="1" rowspan="1">91</td><td char="." align="char" colspan="1" rowspan="1">2010</td><td char="." align="char" colspan="1" rowspan="1">0.04</td><td char="." align="char" colspan="1" rowspan="1">26</td><td align="left" colspan="1" rowspan="1">Akt</td><td char="." align="char" colspan="1" rowspan="1">26</td><td char="." align="char" colspan="1" rowspan="1">2003</td><td char="." align="char" colspan="1" rowspan="1">0.00</td></tr><tr><td align="left" colspan="1" rowspan="1">11</td><td align="left" colspan="1" rowspan="1">MicroRNA</td><td char="." align="char" colspan="1" rowspan="1">75</td><td char="." align="char" colspan="1" rowspan="1">2010</td><td char="." align="char" colspan="1" rowspan="1">0.01</td><td char="." align="char" colspan="1" rowspan="1">26</td><td align="left" colspan="1" rowspan="1">Cell Cycle</td><td char="." align="char" colspan="1" rowspan="1">26</td><td char="." align="char" colspan="1" rowspan="1">1998</td><td char="." align="char" colspan="1" rowspan="1">0.00</td></tr><tr><td align="left" colspan="1" rowspan="1">12</td><td align="left" colspan="1" rowspan="1">Autophagy</td><td char="." align="char" colspan="1" rowspan="1">65</td><td char="." align="char" colspan="1" rowspan="1">2011</td><td char="." align="char" colspan="1" rowspan="1">0.01</td><td char="." align="char" colspan="1" rowspan="1">27</td><td align="left" colspan="1" rowspan="1">Mcf-7 cells</td><td char="." align="char" colspan="1" rowspan="1">25</td><td char="." align="char" colspan="1" rowspan="1">2002</td><td char="." align="char" colspan="1" rowspan="1">0.00</td></tr><tr><td align="left" colspan="1" rowspan="1">13</td><td align="left" colspan="1" rowspan="1">Prognosis</td><td char="." align="char" colspan="1" rowspan="1">63</td><td char="." align="char" colspan="1" rowspan="1">2004</td><td char="." align="char" colspan="1" rowspan="1">0.00</td><td char="." align="char" colspan="1" rowspan="1">28</td><td align="left" colspan="1" rowspan="1">Stat3</td><td char="." align="char" colspan="1" rowspan="1">24</td><td char="." align="char" colspan="1" rowspan="1">2002</td><td char="." align="char" colspan="1" rowspan="1">0.00</td></tr><tr><td align="left" colspan="1" rowspan="1">14</td><td align="left" colspan="1" rowspan="1">Chemosensitivity</td><td char="." align="char" colspan="1" rowspan="1">56</td><td char="." align="char" colspan="1" rowspan="1">1998</td><td char="." align="char" colspan="1" rowspan="1">0.01</td><td char="." align="char" colspan="1" rowspan="1">29</td><td align="left" colspan="1" rowspan="1">Proliferation</td><td char="." align="char" colspan="1" rowspan="1">23</td><td char="." align="char" colspan="1" rowspan="1">1998</td><td char="." align="char" colspan="1" rowspan="1">0.00</td></tr><tr><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1">Tumor microenvironment (TME)</td><td char="." align="char" colspan="1" rowspan="1">55</td><td char="." align="char" colspan="1" rowspan="1">2010</td><td char="." align="char" colspan="1" rowspan="1">0.01</td><td char="." align="char" colspan="1" rowspan="1">29</td><td align="left" colspan="1" rowspan="1">Invasion</td><td char="." align="char" colspan="1" rowspan="1">23</td><td char="." align="char" colspan="1" rowspan="1">2010</td><td char="." align="char" colspan="1" rowspan="1">0.00</td></tr><tr><td align="left" colspan="1" rowspan="1">16</td><td align="left" colspan="1" rowspan="1">Biomarker</td><td char="." align="char" colspan="1" rowspan="1">52</td><td char="." align="char" colspan="1" rowspan="1">2004</td><td char="." align="char" colspan="1" rowspan="1">0.00</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr></tbody></table></table-wrap>
</p><p id="Par45">
<fig id="Fig6" position="float" orientation="portrait"><label>Fig. 6</label><caption><p>Presents keyword analysis in breast cancer chemoresistance (frequency count, co-occurrence network, and annual attention trends). <bold>A</bold> Proportional distribution of the top 30 keywords by occurrence frequency. <bold>B</bold> Co-occurrence network of keywords. <bold>C</bold> Annual attention change of the top 10 keywords by occurrence frequency</p></caption><graphic id="d33e1941" position="float" orientation="portrait" xlink:href="12672_2025_3542_Fig6_HTML.jpg"/></fig>
</p><p id="Par46">The keyword co-occurrence network (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>B) identified four terms with centrality&#8201;&#8805;&#8201;0.1: breast cancer (0.80), chemoresistance (0.65), TNBC (0.30), and BCSCs (0.12), highlighting their pivotal roles in the research landscape. Beyond the core topics of breast cancer and chemoresistance, TNBC and BCSCs have emerged as prominent and influential themes.</p><p id="Par47">Figure <xref rid="Fig6" ref-type="fig">6</xref>C illustrates the annual attention trends of the top 10 high-frequency keywords. Among them, &#8220;breast cancer,&#8221; despite minor fluctuations in certain years, has consistently maintained a high level of attention, indicating its sustained role as a central research theme. Meanwhile, &#8220;TNBC&#8221; has shown a clear upward trend since 2017, with steadily increasing attention from 2022 to 2024, suggesting a growing research interest in this subtype in recent years. Other keywords exhibit varying patterns across different years, reflecting the dynamic evolution of research focus over time.</p><p id="Par48">Figure <xref rid="Fig7" ref-type="fig">7</xref> depicts the thematic evolution of the field. Since 2020, research has increasingly focused on TNBC, lncRNA, bioinformatics, metabolic regulation, transcriptomics, and ferroptosis. Among these, bioinformatics-driven multi-omics integration and ferroptosis-related mechanisms have become especially prominent, reflecting a deepening convergence between computational analysis and molecular biology. These trends signify a paradigm shift in breast cancer chemoresistance research, paving the way for interdisciplinary breakthroughs.</p><p id="Par49">
<fig id="Fig7" position="float" orientation="portrait"><label>Fig. 7</label><caption><p>Thematic evolution path of keywords</p></caption><graphic id="d33e1966" position="float" orientation="portrait" xlink:href="12672_2025_3542_Fig7_HTML.jpg"/></fig>
</p><p id="Par50">Keyword clustering enables the classification of closely related terms, revealing knowledge development trajectories and simplifying complex associations [<xref ref-type="bibr" rid="CR71">71</xref>]. As shown in Fig.&#160;<xref rid="Fig8" ref-type="fig">8</xref>A, cluster analysis yielded 14 distinct clusters with a Q value of 0.74 and an S value of 0.94, indicating a well-structured and reliable clustering outcome. These clusters can be grouped into four major categories: (1) Research objects: #0 breast cancer, #1 triple-negative breast cancer, #3 breast cancer stem cells. (2) Drug resistance: #2 doxorubicin resistance, #4 docetaxel resistance, #5 paclitaxel resistance. (3) Mechanisms of action: #6 oxidative stress, #8 ABC transporters, #9 estrogen receptor, #11 DNA methylation, #12 glucose metabolism, #13 DNA damage. (4) Therapeutic strategies: #7 targeted therapy, #10 combination therapy. These findings outline a developmental pathway in the field, moving from research objects to drug resistance, underlying mechanisms, and ultimately to treatment strategies.</p><p id="Par51">
<fig id="Fig8" position="float" orientation="portrait"><label>Fig. 8</label><caption><p>Presents keyword analysis in breast cancer chemoresistance (clustering and burst analysis). <bold>A</bold> Clustering analysis of keywords. <bold>B</bold> Timeline arrangement of keyword clustering analysis. <bold>C</bold> Burst analysis of keywords</p></caption><graphic id="d33e1994" position="float" orientation="portrait" xlink:href="12672_2025_3542_Fig8_HTML.jpg"/></fig>
</p><p id="Par52">The timeline view (Fig.&#160;<xref rid="Fig8" ref-type="fig">8</xref>B) illustrates the temporal evolution of the 14 clusters. Currently, TNBC, doxorubicin resistance, and BCSCs remain in their active research phases, highlighting their ongoing relevance.</p><p id="Par53">Figure <xref rid="Fig8" ref-type="fig">8</xref>C presents the results of keyword burst analysis. EMT exhibited the highest burst intensity (4.05), peaking in 2013 and fading by 2014. Prognostic biomarkers and liquid biopsy, both emerging in 2020, are currently in an active burst phase (2020&#8211;2024), indicating their growing prominence as emerging research hotspots and potential frontiers in breast cancer chemoresistance.</p></sec><sec id="Sec9"><title>Literature and reference analysis</title><p id="Par54">Analyzing highly cited literature helps highlight the research focus and foundational knowledge in the field of breast cancer chemoresistance. Among the top 10 most cited papers, three were reviews and seven were original research articles (Table&#160;<xref rid="Tab5" ref-type="table">5</xref>). The most cited was a review by Harari et al. (2000) published in <italic toggle="yes">Oncogene</italic> (508 citations), which discussed the role of ErbB2, a receptor-like tyrosine kinase, in promoting chemoresistance [<xref ref-type="bibr" rid="CR72">72</xref>]. This underscores the enduring interest in tyrosine kinase-mediated resistance mechanisms. The second most cited article was by Song M and Liu T et al. (2016) in <italic toggle="yes">ACS Nano</italic> (469 citations), which demonstrated that hypoxia contributes to chemoresistance in breast cancer cells [<xref ref-type="bibr" rid="CR73">73</xref>]. The third was by Knuefermann C and Lu Y et al. (2003) in <italic toggle="yes">Oncogene</italic> (386 citations), showing that AKT activation reduces the sensitivity of MCF-7 cells to chemotherapy, thereby inducing resistance [<xref ref-type="bibr" rid="CR74">74</xref>]. Collectively, these influential studies provide key theoretical foundations and serve as benchmarks for ongoing research in this domain.</p><p id="Par55">
<table-wrap id="Tab5" position="float" orientation="portrait"><label>Table 5</label><caption><p>Information on the top 10 articles ranked by number of citations</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Rank</th><th align="left" colspan="1" rowspan="1">Year</th><th align="left" colspan="1" rowspan="1">Type</th><th align="left" colspan="1" rowspan="1">Title</th><th align="left" colspan="1" rowspan="1">Journal</th><th align="left" colspan="1" rowspan="1">First Author</th><th align="left" colspan="1" rowspan="1">Country</th><th align="left" colspan="1" rowspan="1">Citations</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">1</td><td char="." align="char" colspan="1" rowspan="1">2000</td><td align="left" colspan="1" rowspan="1">Review</td><td align="left" colspan="1" rowspan="1">Molecular mechanisms underlying ErbB2/HER2 action in breast cancer</td><td align="left" colspan="1" rowspan="1">Oncogene</td><td align="left" colspan="1" rowspan="1">Harari D</td><td align="left" colspan="1" rowspan="1">Israel</td><td char="." align="char" colspan="1" rowspan="1">508</td></tr><tr><td align="left" colspan="1" rowspan="1">2</td><td char="." align="char" colspan="1" rowspan="1">2016</td><td align="left" colspan="1" rowspan="1">Article</td><td align="left" colspan="1" rowspan="1">Bioconjugated Manganese Dioxide Nanoparticles Enhance Chemotherapy Response by Priming Tumor-Associated Macrophages toward M1-like Phenotype and Attenuating Tumor Hypoxia</td><td align="left" colspan="1" rowspan="1">ACS Nano</td><td align="left" colspan="1" rowspan="1">Song M and Liu T</td><td align="left" colspan="1" rowspan="1">China USA</td><td char="." align="char" colspan="1" rowspan="1">469</td></tr><tr><td align="left" colspan="1" rowspan="1">3</td><td char="." align="char" colspan="1" rowspan="1">2003</td><td align="left" colspan="1" rowspan="1">Article</td><td align="left" colspan="1" rowspan="1"><p>HER2/PI-3&#160;K/Akt activation leads to a multidrug resistance in human</p><p>breast adenocarcinoma cells</p></td><td align="left" colspan="1" rowspan="1">Oncogene</td><td align="left" colspan="1" rowspan="1">Knuefermann C and Lu Y</td><td align="left" colspan="1" rowspan="1">USA</td><td char="." align="char" colspan="1" rowspan="1">386</td></tr><tr><td align="left" colspan="1" rowspan="1">4</td><td char="." align="char" colspan="1" rowspan="1">2013</td><td align="left" colspan="1" rowspan="1">Article</td><td align="left" colspan="1" rowspan="1">CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer</td><td align="left" colspan="1" rowspan="1">Proc Natl Acad Sci U S A</td><td align="left" colspan="1" rowspan="1">Loi S and Pommey S</td><td align="left" colspan="1" rowspan="1"><p>Australia</p><p>Canada</p></td><td char="." align="char" colspan="1" rowspan="1">376</td></tr><tr><td align="left" colspan="1" rowspan="1">5</td><td char="." align="char" colspan="1" rowspan="1">2002</td><td align="left" colspan="1" rowspan="1">Article</td><td align="left" colspan="1" rowspan="1">Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance</td><td align="left" colspan="1" rowspan="1">Oncogene</td><td align="left" colspan="1" rowspan="1">Devarajan E and Sahin AA</td><td align="left" colspan="1" rowspan="1"><p>USA</p><p>Italy</p></td><td char="." align="char" colspan="1" rowspan="1">357</td></tr><tr><td align="left" colspan="1" rowspan="1">6</td><td char="." align="char" colspan="1" rowspan="1">2019</td><td align="left" colspan="1" rowspan="1">Review</td><td align="left" colspan="1" rowspan="1">Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer&#8212;How We Can Rise to the Challenge</td><td align="left" colspan="1" rowspan="1">Cells</td><td align="left" colspan="1" rowspan="1">Nedeljkovi&#263; M</td><td align="left" colspan="1" rowspan="1">Serbia</td><td char="." align="char" colspan="1" rowspan="1">338</td></tr><tr><td align="left" colspan="1" rowspan="1">7</td><td char="." align="char" colspan="1" rowspan="1">2011</td><td align="left" colspan="1" rowspan="1">Article</td><td align="left" colspan="1" rowspan="1">Disulfiram modulated ROS&#8211;MAPK and NFkB pathways and targeted breast cancer cells with cancer stem cell-like properties</td><td align="left" colspan="1" rowspan="1">British Journal of Cancer</td><td align="left" colspan="1" rowspan="1">Yip NC and Fombon IS</td><td align="left" colspan="1" rowspan="1"><p>UK</p><p>China</p></td><td char="." align="char" colspan="1" rowspan="1">299</td></tr><tr><td align="left" colspan="1" rowspan="1">8</td><td char="." align="char" colspan="1" rowspan="1">2008</td><td align="left" colspan="1" rowspan="1">Review</td><td align="left" colspan="1" rowspan="1">Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer</td><td align="left" colspan="1" rowspan="1">Cancer Treatment Reviews</td><td align="left" colspan="1" rowspan="1">Coley HM</td><td align="left" colspan="1" rowspan="1">UK</td><td char="." align="char" colspan="1" rowspan="1">290</td></tr><tr><td align="left" colspan="1" rowspan="1">9</td><td char="." align="char" colspan="1" rowspan="1">2000</td><td align="left" colspan="1" rowspan="1">Article</td><td align="left" colspan="1" rowspan="1">Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide</td><td align="left" colspan="1" rowspan="1">Oncogene</td><td align="left" colspan="1" rowspan="1">Patel NM and Nozaki S</td><td align="left" colspan="1" rowspan="1">USA</td><td char="." align="char" colspan="1" rowspan="1">277</td></tr><tr><td align="left" colspan="1" rowspan="1">10</td><td char="." align="char" colspan="1" rowspan="1">2002</td><td align="left" colspan="1" rowspan="1">Article</td><td align="left" colspan="1" rowspan="1">Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells</td><td align="left" colspan="1" rowspan="1">Oncogene</td><td align="left" colspan="1" rowspan="1">Real PJ</td><td align="left" colspan="1" rowspan="1">Spain</td><td char="." align="char" colspan="1" rowspan="1">276</td></tr></tbody></table></table-wrap>
</p><p id="Par56">Co-citation analysis, which examines how often two articles are cited together, offers insights into the structural and thematic connections within the literature [<xref ref-type="bibr" rid="CR15">15</xref>]. Table&#160;<xref rid="Tab6" ref-type="table">6</xref> lists the top 10 most co-cited references, including four reviews and six original articles. The most cited reference was Siegel RL (2021) with 138 citations [<xref ref-type="bibr" rid="CR75">75</xref>], followed by Sung H (2021) (80 citations) [<xref ref-type="bibr" rid="CR4">4</xref>], and Bray F (2018) (46 citations) [<xref ref-type="bibr" rid="CR3">3</xref>]. These highly cited references serve as critical knowledge sources for the field.</p><p id="Par57">
<table-wrap id="Tab6" position="float" orientation="portrait"><label>Table 6</label><caption><p>Information on the top 10 references ranked by number of citations</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Rank</th><th align="left" colspan="1" rowspan="1">Year</th><th align="left" colspan="1" rowspan="1">Type</th><th align="left" colspan="1" rowspan="1">Title</th><th align="left" colspan="1" rowspan="1">Journal</th><th align="left" colspan="1" rowspan="1">First Author</th><th align="left" colspan="1" rowspan="1">Citations</th><th align="left" colspan="1" rowspan="1">Centrality</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">1</td><td char="." align="char" colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">Article</td><td align="left" colspan="1" rowspan="1">Cancer Statistics, 2021</td><td align="left" colspan="1" rowspan="1">CA CANCER J CLIN</td><td align="left" colspan="1" rowspan="1">Siegel RL</td><td char="." align="char" colspan="1" rowspan="1">138</td><td char="." align="char" colspan="1" rowspan="1">0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">2</td><td char="." align="char" colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">Article</td><td align="left" colspan="1" rowspan="1">Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries</td><td align="left" colspan="1" rowspan="1">CA CANCER J CLIN</td><td align="left" colspan="1" rowspan="1">Sung H</td><td char="." align="char" colspan="1" rowspan="1">80</td><td char="." align="char" colspan="1" rowspan="1">0.00</td></tr><tr><td align="left" colspan="1" rowspan="1">3</td><td char="." align="char" colspan="1" rowspan="1">2018</td><td align="left" colspan="1" rowspan="1">Article</td><td align="left" colspan="1" rowspan="1">Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</td><td align="left" colspan="1" rowspan="1">CA CANCER J CLIN</td><td align="left" colspan="1" rowspan="1">Bray F</td><td char="." align="char" colspan="1" rowspan="1">46</td><td char="." align="char" colspan="1" rowspan="1">0.00</td></tr><tr><td align="left" colspan="1" rowspan="1">4</td><td char="." align="char" colspan="1" rowspan="1">2019</td><td align="left" colspan="1" rowspan="1">Review</td><td align="left" colspan="1" rowspan="1">Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer-How We Can Rise to the Challenge</td><td align="left" colspan="1" rowspan="1">Cells</td><td align="left" colspan="1" rowspan="1">Nedeljkovi&#263; M</td><td char="." align="char" colspan="1" rowspan="1">44</td><td char="." align="char" colspan="1" rowspan="1">0.04</td></tr><tr><td align="left" colspan="1" rowspan="1">5</td><td char="." align="char" colspan="1" rowspan="1">2019</td><td align="left" colspan="1" rowspan="1">Review</td><td align="left" colspan="1" rowspan="1">Chemoresistance mechanisms of breast cancer and their countermeasures</td><td align="left" colspan="1" rowspan="1">Biomed Pharmacother</td><td align="left" colspan="1" rowspan="1">Ji X</td><td char="." align="char" colspan="1" rowspan="1">37</td><td char="." align="char" colspan="1" rowspan="1">0.02</td></tr><tr><td align="left" colspan="1" rowspan="1">6</td><td char="." align="char" colspan="1" rowspan="1">2016</td><td align="left" colspan="1" rowspan="1">Review</td><td align="left" colspan="1" rowspan="1"><p>Triple-negative breast cancer: challenges and opportunities of a</p><p>heterogeneous disease</p></td><td align="left" colspan="1" rowspan="1">Nat Rev Clin Oncol</td><td align="left" colspan="1" rowspan="1">Bianchini G and Balko JM Mayer IA</td><td char="." align="char" colspan="1" rowspan="1">35</td><td char="." align="char" colspan="1" rowspan="1">0.09</td></tr><tr><td align="left" colspan="1" rowspan="1">7</td><td char="." align="char" colspan="1" rowspan="1">2018</td><td align="left" colspan="1" rowspan="1">Article</td><td align="left" colspan="1" rowspan="1">Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing</td><td align="left" colspan="1" rowspan="1">Cell</td><td align="left" colspan="1" rowspan="1"><p>Kim C and</p><p>Gao R</p></td><td char="." align="char" colspan="1" rowspan="1">27</td><td char="." align="char" colspan="1" rowspan="1">0.02</td></tr><tr><td align="left" colspan="1" rowspan="1">8</td><td char="." align="char" colspan="1" rowspan="1">2019</td><td align="left" colspan="1" rowspan="1">Review</td><td align="left" colspan="1" rowspan="1">Breast cancer</td><td align="left" colspan="1" rowspan="1">Nat Rev Dis Primers</td><td align="left" colspan="1" rowspan="1">Harbeck N</td><td char="." align="char" colspan="1" rowspan="1">25</td><td char="." align="char" colspan="1" rowspan="1">0.00</td></tr><tr><td align="left" colspan="1" rowspan="1">9</td><td char="." align="char" colspan="1" rowspan="1">2015</td><td align="left" colspan="1" rowspan="1">Article</td><td align="left" colspan="1" rowspan="1">Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012</td><td align="left" colspan="1" rowspan="1">Int J Cancer</td><td align="left" colspan="1" rowspan="1">Ferlay J</td><td char="." align="char" colspan="1" rowspan="1">25</td><td char="." align="char" colspan="1" rowspan="1">0.00</td></tr><tr><td align="left" colspan="1" rowspan="1">10</td><td char="." align="char" colspan="1" rowspan="1">2012</td><td align="left" colspan="1" rowspan="1">Article</td><td align="left" colspan="1" rowspan="1">Comprehensive molecular portraits of human breast tumours</td><td align="left" colspan="1" rowspan="1">Nature</td><td align="left" colspan="1" rowspan="1">Cancer Genome Atlas Network</td><td char="." align="char" colspan="1" rowspan="1">24</td><td char="." align="char" colspan="1" rowspan="1">0.00</td></tr></tbody></table></table-wrap>
</p><p id="Par58">The reference co-citation network (Fig.&#160;<xref rid="Fig9" ref-type="fig">9</xref>A) revealed no nodes with centrality&#8201;&#8805;&#8201;0.1, though Siegel RL (2021) had the largest node size, and Bianchini G (2016) had the highest centrality (0.09), indicating its potential importance as a connecting reference [<xref ref-type="bibr" rid="CR76">76</xref>]. Timeline-based clustering of cited references produced 13 clusters with strong structural validity (Q&#8201;=&#8201;0.89, S&#8201;=&#8201;0.91) (Fig.&#160;<xref rid="Fig9" ref-type="fig">9</xref>B). These clusters were grouped into four main themes: (1) Mechanisms: #0 ABC transporter, #2 chemoresistance regulation, #3 EMT, #4 breast cancer stemness, #5 intertumor heterogeneity, #7 potential cancer stem, #8 mammary stem cell induction, #15 protein kinase, #18 modeling therapy resistance. (2) Biomarkers: #1 circular RNA (circRNA), #9 noncoding RNA. (3) Treatment strategies: #6 neoadjuvant chemotherapy. (4) Therapeutics: #16 doxorubicin. These categories demonstrate that research in this field is built on core literature related to mechanisms, biomarkers, treatment approaches, and drugs. The circRNA and breast cancer stemness currently represent the most active and evolving areas of research.</p><p id="Par59">
<fig id="Fig9" position="float" orientation="portrait"><label>Fig. 9</label><caption><p>Presents the analysis of references in breast cancer chemoresistance. <bold>A</bold> Co-citation network of references. <bold>B</bold> Timeline arrangement of reference clustering analysis. <bold>C</bold> Burst analysis of reference</p></caption><graphic id="d33e2497" position="float" orientation="portrait" xlink:href="12672_2025_3542_Fig9_HTML.jpg"/></fig>
</p><p id="Par60">Burst detection analysis (Fig.&#160;<xref rid="Fig9" ref-type="fig">9</xref>C) identified six references [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR77">77</xref>, <xref ref-type="bibr" rid="CR78">78</xref>, <xref ref-type="bibr" rid="CR79">79</xref>] with recent citation surges, indicating rising academic attention. Notably, Nedeljkovi&#263; M (2019) [<xref ref-type="bibr" rid="CR77">77</xref>] appeared among the top 10 most cited articles, top co-cited references, and recent burst publications. This review, which comprehensively discusses chemoresistance mechanisms in TNBC along with associated challenges and strategies, stands out as a key recent contribution warranting continued scholarly focus.</p></sec></sec><sec id="Sec10"><title>Discussion</title><p id="Par61">Breast cancer remains the most prevalent malignancy among women globally, with mortality ranking second only to lung and bronchial cancers [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR80">80</xref>, <xref ref-type="bibr" rid="CR81">81</xref>, <xref ref-type="bibr" rid="CR82">82</xref>, <xref ref-type="bibr" rid="CR83">83</xref>]. Thanks to advances in molecular biology, early diagnostic techniques, and the continuous innovation of treatment strategies&#8212;including surgery, neoadjuvant radiochemotherapy, hormone therapy, targeted therapy, and immunotherapy&#8212;breast cancer survival rates have improved significantly. These developments have not only prolonged patient survival but also markedly enhanced quality of life [<xref ref-type="bibr" rid="CR84">84</xref>, <xref ref-type="bibr" rid="CR85">85</xref>, <xref ref-type="bibr" rid="CR86">86</xref>, <xref ref-type="bibr" rid="CR87">87</xref>].</p><p id="Par62">Despite these achievements, prognosis for many patients remains unsatisfactory [<xref ref-type="bibr" rid="CR88">88</xref>, <xref ref-type="bibr" rid="CR89">89</xref>]. The emergence of drug resistance, particularly chemoresistance, continues to present a major barrier to successful treatment and represents a significant global public health concern [<xref ref-type="bibr" rid="CR90">90</xref>]. Although new chemotherapeutic agents, small-molecule drugs, immune checkpoint inhibitors, and combination therapies are being actively explored, resistance mechanisms often compromise their clinical efficacy.</p><p id="Par63">Chemotherapy remains a cornerstone in the management of malignant breast tumors [<xref ref-type="bibr" rid="CR91">91</xref>, <xref ref-type="bibr" rid="CR92">92</xref>], and by 2040, an estimated 2&#160;million patients globally will require chemotherapy [<xref ref-type="bibr" rid="CR13">13</xref>]. However, the effectiveness of this approach is frequently undermined by the development of chemoresistance, which accelerates tumor progression, enhances metastatic potential, and negatively impacts overall patient outcomes. Consequently, overcoming chemoresistance has become a critical challenge in modern oncology.</p><p id="Par64">In the era of information explosion, staying attuned to the dynamic shifts in research focus and rapidly assimilating emerging scientific insights are vital. Identifying key research hotspots and frontiers allows researchers to refine their scientific inquiries and contribute to breakthrough advances in understanding and managing chemoresistance in breast cancer.</p><sec id="Sec11"><title>Bibliometric characteristics</title><p id="Par65">Bibliometric analysis provides a macroscopic lens to capture the structural evolution and knowledge flow of scientific research, offering insights beyond what traditional systematic reviews can deliver. While evidence-based approaches focus on evaluating the effectiveness of specific interventions, bibliometric methods reveal underlying patterns of academic attention, collaboration dynamics, and disciplinary intersections&#8212;dimensions particularly relevant for understanding complex issues such as chemoresistance in breast cancer.</p><p id="Par66">In this study, the application of bibliometric tools uncovered a clear trajectory of intensifying global interest in breast cancer chemoresistance over the past three decades. The increase in publication volume after 2017 may reflect intensified research efforts by the scientific community to address chemoresistance, particularly in the context of TNBC and other therapeutically challenging subtypes. Interestingly, the slight downturn in recent years may be attributed to saturation in foundational research topics or shifting academic focus toward novel therapeutic modalities, such as immunotherapy and RNA-based treatments.</p><p id="Par67">Notably, the rising visibility of nanotechnology within this field points to a paradigmatic shift toward interdisciplinary integration. Nanocarrier-based drug delivery and resistance modulation represent promising strategies that transcend conventional chemotherapy paradigms. This convergence of bioengineering and cancer biology underscores the potential of cross-disciplinary approaches to generate transformative solutions.</p><p id="Par68">Moreover, IF and JCR are widely used indicators for evaluating the academic influence of journals from multiple dimensions [<xref ref-type="bibr" rid="CR93">93</xref>, <xref ref-type="bibr" rid="CR94">94</xref>]. High-impact journals play a critical role in disseminating key research findings and driving scholarly advancement within their respective fields [<xref ref-type="bibr" rid="CR95">95</xref>]. The predominance of publications in JCR Q1/Q2 journals suggests that chemoresistance research occupies a strategically important position within the scientific community. High-impact publishing patterns not only reflect academic recognition but also reinforce the field&#8217;s translational relevance. Encouragingly, China and the United States have emerged as global leaders, though the need for broader, more inclusive international collaboration remains pressing.</p><p id="Par69">Altogether, this bibliometric profile does more than map a research landscape&#8212;it reveals emerging paradigms, structural shifts, and strategic opportunities for innovation in the fight against chemoresistance.</p></sec><sec id="Sec12"><title>Development approaches</title><p id="Par70">The analysis of keyword evolution underscores the transformative impact of bioinformatics technology as a pivotal developmental approach in breast cancer chemoresistance research. Since the early 21st century, marked by the completion of the Human Genome Project, the generation of vast and complex biological datasets has reshaped life science research. Traditional analytic approaches based on small-scale, linear models are insufficient to process such data volumes, highlighting the need for more advanced computational strategies [<xref ref-type="bibr" rid="CR96">96</xref>, <xref ref-type="bibr" rid="CR97">97</xref>, <xref ref-type="bibr" rid="CR98">98</xref>, <xref ref-type="bibr" rid="CR99">99</xref>].</p><p id="Par71">In the field of chemoresistance, bioinformatics has facilitated comparative analyses of chemotherapy-sensitive and -resistant breast cancer cells, enabling the identification of resistance-associated gene mutations, transcriptional dysregulation, and disrupted signaling pathways [<xref ref-type="bibr" rid="CR100">100</xref>, <xref ref-type="bibr" rid="CR101">101</xref>, <xref ref-type="bibr" rid="CR102">102</xref>]. Notably, dysregulation of the phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) and mitogen-activated protein kinase (MAPK) pathways has been frequently implicated [<xref ref-type="bibr" rid="CR103">103</xref>].</p><p id="Par72">Multi-omics integration&#8212;encompassing genomics, transcriptomics, proteomics, and metabolomics&#8212;has significantly advanced the construction of comprehensive models of chemoresistance. By combining gene expression profiles with protein interaction networks, bioinformatics enables the identification of core molecular modules and resistance-related topologies [<xref ref-type="bibr" rid="CR100">100</xref>, <xref ref-type="bibr" rid="CR104">104</xref>]. This systems-level perspective deepens our mechanistic understanding of chemoresistance and reveals actionable intervention points.</p><p id="Par73">Importantly, bioinformatics also bridges the gap between laboratory research and clinical practice. By integrating omics and clinical datasets, it supports the development of predictive models to stratify patients based on molecular features and forecast treatment response. This facilitates the design of personalized therapeutic regimens that optimize efficacy while minimizing adverse effects [<xref ref-type="bibr" rid="CR101">101</xref>, <xref ref-type="bibr" rid="CR105">105</xref>].</p><p id="Par74">In summary, bioinformatics&#8212;especially when coupled with multi-omics integration&#8212;has transformed the study of breast cancer chemoresistance. It provides the technical foundation for precision oncology, and its continued evolution will be instrumental in driving future breakthroughs in both mechanistic research and therapeutic development.</p></sec><sec id="Sec13"><title>Focus direction</title><p id="Par75">Cluster analysis of references highlights circRNA and breast cancer stemness as two pivotal emerging directions in chemoresistance research. First identified in the 1970s, circRNAs were long regarded as non-functional splicing byproducts due to technological limitations [<xref ref-type="bibr" rid="CR106">106</xref>, <xref ref-type="bibr" rid="CR107">107</xref>, <xref ref-type="bibr" rid="CR108">108</xref>, <xref ref-type="bibr" rid="CR109">109</xref>, <xref ref-type="bibr" rid="CR110">110</xref>]. However, their covalently closed-loop structure&#8212;lacking 5&#8217; caps and 3&#8217; poly(A) tails&#8212;confers exceptional stability against exonuclease degradation [<xref ref-type="bibr" rid="CR111">111</xref>, <xref ref-type="bibr" rid="CR112">112</xref>]. Advances in high-throughput sequencing and bioinformatics have revealed that circRNA are evolutionarily conserved and exhibit tissue- and stage-specific expression [<xref ref-type="bibr" rid="CR113">113</xref>, <xref ref-type="bibr" rid="CR114">114</xref>, <xref ref-type="bibr" rid="CR115">115</xref>]. Functionally, they act as microRNAs (miRNAs) sponges, interact with RNA-binding proteins, regulate transcription, and in some cases, encode peptides.</p><p id="Par76">In breast cancer, circRNA are increasingly implicated in tumor progression and chemoresistance. They contribute to drug resistance via enhanced DNA repair, activation of oncogenic signaling, and interaction with cancer stem cells and the EMT [<xref ref-type="bibr" rid="CR106">106</xref>, <xref ref-type="bibr" rid="CR116">116</xref>, <xref ref-type="bibr" rid="CR117">117</xref>]. The circRNA also influence the TME, promoting cellular adaptation to chemotherapy. However, compared to long noncoding RNAs (lncRNAs) and miRNAs, circRNA research remains nascent in this context, presenting significant opportunities for mechanistic and translational breakthroughs [<xref ref-type="bibr" rid="CR118">118</xref>, <xref ref-type="bibr" rid="CR119">119</xref>, <xref ref-type="bibr" rid="CR120">120</xref>, <xref ref-type="bibr" rid="CR121">121</xref>].</p><p id="Par77">Concurrently, the concept of BCSCs has garnered increasing attention. First characterized by Al-Hajj et al. in 2003, BCSCs&#8212;representing&#8201;~&#8201;2% of breast tumor cells&#8212;possess stem-like traits, including self-renewal and tumor-initiating capacity [<xref ref-type="bibr" rid="CR90">90</xref>, <xref ref-type="bibr" rid="CR122">122</xref>, <xref ref-type="bibr" rid="CR123">123</xref>]. These cells play a crucial role in chemoresistance and metastasis. Mechanistically, BCSCs evade treatment through drug efflux (e.g., ATP-binding cassette transporters), quiescence in the G0 phase, and other survival strategies [<xref ref-type="bibr" rid="CR90">90</xref>, <xref ref-type="bibr" rid="CR124">124</xref>, <xref ref-type="bibr" rid="CR125">125</xref>, <xref ref-type="bibr" rid="CR126">126</xref>]. Their persistence after therapy and capacity to regenerate tumor heterogeneity make them key contributors to recurrence and poor prognosis.</p><p id="Par78">In summary, ongoing exploration of circRNA and BCSCs not only deepens our understanding of breast cancer chemoresistance but also opens new avenues for therapeutic innovation [<xref ref-type="bibr" rid="CR126">126</xref>]. Targeting these elements through integrated strategies&#8212;combining molecular interventions with existing regimens&#8212;may significantly reduce recurrence and metastasis rates, ultimately improving clinical outcomes [<xref ref-type="bibr" rid="CR127">127</xref>, <xref ref-type="bibr" rid="CR128">128</xref>, <xref ref-type="bibr" rid="CR129">129</xref>, <xref ref-type="bibr" rid="CR130">130</xref>].</p></sec><sec id="Sec14"><title>Hotspots and frontiers</title><p id="Par79">Keyword burst analysis identified prognostic biomarkers and liquid biopsy as pivotal frontiers in breast cancer chemoresistance research. Tumor biomarkers&#8212;primarily proteins or their derivatives&#8212;can be detected in tumors or bodily fluids and serve as critical indicators of cancer development and progression [<xref ref-type="bibr" rid="CR131">131</xref>, <xref ref-type="bibr" rid="CR132">132</xref>, <xref ref-type="bibr" rid="CR133">133</xref>]. Prognostic biomarkers, in particular, provide insights into disease outcomes independent of therapy, enabling the stratification of high-risk patients, evaluation of treatment responses, and personalization of therapeutic regimens [<xref ref-type="bibr" rid="CR134">134</xref>, <xref ref-type="bibr" rid="CR135">135</xref>, <xref ref-type="bibr" rid="CR136">136</xref>, <xref ref-type="bibr" rid="CR137">137</xref>]. In the precision medicine era, such markers help reduce overtreatment, minimize toxicity, and improve survival outcomes through real-time, evidence-based clinical decision-making [<xref ref-type="bibr" rid="CR137">137</xref>].</p><p id="Par80">Liquid biopsy has revolutionized biomarker research by offering a minimally invasive alternative to traditional tissue sampling. It enables the detection of circulating biomarkers&#8212;such as tumor cells, ctDNA, RNA, exosomes, and metabolites&#8212;in blood and other body fluids [<xref ref-type="bibr" rid="CR138">138</xref>, <xref ref-type="bibr" rid="CR139">139</xref>, <xref ref-type="bibr" rid="CR140">140</xref>, <xref ref-type="bibr" rid="CR141">141</xref>]. Compared to tissue biopsy, it offers higher repeatability, lower risk, and better suitability for serial monitoring, especially in patients unfit for surgery [<xref ref-type="bibr" rid="CR142">142</xref>, <xref ref-type="bibr" rid="CR143">143</xref>, <xref ref-type="bibr" rid="CR144">144</xref>, <xref ref-type="bibr" rid="CR145">145</xref>, <xref ref-type="bibr" rid="CR146">146</xref>, <xref ref-type="bibr" rid="CR147">147</xref>].</p><p id="Par81">Recent studies have demonstrated that liquid biopsy not only supports early diagnosis and relapse monitoring but also provides dynamic insights into chemoresistance mechanisms, guiding therapeutic adjustments during adjuvant or neoadjuvant treatment [<xref ref-type="bibr" rid="CR148">148</xref>, <xref ref-type="bibr" rid="CR149">149</xref>, <xref ref-type="bibr" rid="CR150">150</xref>, <xref ref-type="bibr" rid="CR151">151</xref>, <xref ref-type="bibr" rid="CR152">152</xref>]. Its integration into precision oncology expands its role across the cancer care continuum&#8212;from detection to outcome prediction&#8212;aligning with the goals of personalized medicine [<xref ref-type="bibr" rid="CR142">142</xref>, <xref ref-type="bibr" rid="CR143">143</xref>, <xref ref-type="bibr" rid="CR153">153</xref>].</p></sec><sec id="Sec15"><title>Emerging mechanisms and strategies</title><p id="Par82">Ferroptosis, a regulated form of cell death marked by iron accumulation and lipid peroxidation, has emerged as a promising mechanism for overcoming chemoresistance in cancer, including breast cancer. Unlike apoptosis, ferroptosis bypasses conventional drug resistance pathways, offering novel therapeutic potential. Recent studies have shown that suppression of ferroptosis contributes to chemoresistance in breast cancer. Literature evidence suggests that heat shock protein beta-1 (HSPB1) promotes doxorubicin resistance by protecting cancer cells from ferroptotic death via enhancement of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-&#954;B) signaling and interleukin-6 (IL-6) secretion, facilitating tumor progression and immune evasion [<xref ref-type="bibr" rid="CR154">154</xref>].</p><p id="Par83">Nanotechnology-based approaches have advanced ferroptosis-targeted therapies. A ferroptosis-inducing nanoagent co-delivering small interfering RNA (siRNA) and doxorubicin effectively inhibited glutathione synthesis and triggered iron-dependent oxidative damage in resistant breast cancer cells and patient-derived xenografts, thereby reversing resistance [<xref ref-type="bibr" rid="CR155">155</xref>].</p><p id="Par84">Moreover, targeting lipid metabolism and immune checkpoints has been proposed as a dual strategy to sensitize tumors to ferroptosis. In TNBC, modulation of the stearoyl-CoA desaturase 1 (SCD1)&#8211;tripartite motif-containing 28 (TRIM28)&#8211;programmed death-ligand 1 (PD-L1) axis was shown to impact both ferroptosis and immune escape. The combination of ferroptosis inducers with immune checkpoint blockade demonstrated potential to overcome anthracycline resistance [<xref ref-type="bibr" rid="CR156">156</xref>].</p><p id="Par85">Literature reviews have further highlighted the unique susceptibility of breast cancer cells to ferroptosis due to altered iron metabolism. Inducing ferroptosis not only enhances chemosensitivity but may also reduce systemic toxicity when combined with targeted nanoparticle delivery [<xref ref-type="bibr" rid="CR157">157</xref>].</p><p id="Par86">Collectively, these findings establish ferroptosis as a compelling therapeutic target in breast cancer. Its modulation through molecular targeting, nanotherapeutics, and immunotherapy integration represents a promising frontier for overcoming chemoresistance and advancing precision oncology.</p></sec></sec><sec id="Sec16"><title>Research contributions</title><p id="Par87">Chemoresistance remains a critical barrier in the treatment of breast cancer, significantly affecting patient prognosis and quality of life. This study applies bibliometric and visualization techniques to systematically analyze 30 years of literature on breast cancer chemoresistance, offering a comprehensive overview of its research landscape, evolving hotspots, and emerging frontiers. The key contributions are as follows:<list list-type="order"><list-item><p id="Par88">Global Research Landscape: This study maps global development trends, identifying China and the United States as leading contributors. However, limited international and inter-institutional collaboration highlights the need for broader scientific exchange. These findings provide strategic references for promoting global cooperation and optimizing resource allocation.</p></list-item><list-item><p id="Par89">Core Research Themes: Analysis of keywords and high-impact literature reveals sustained interest in topics such as &#8220;triple-negative breast cancer,&#8221; &#8220;breast cancer stem cells,&#8221; and &#8220;circular RNA.&#8221; These themes reflect the field&#8217;s focus on elucidating the molecular mechanisms of chemoresistance and identifying novel therapeutic targets, laying a foundation for personalized and precision oncology.</p></list-item><list-item><p id="Par90">Technological Drivers: Bioinformatics and Multi-Omics: The study underscores the transformative role of bioinformatics in managing high-throughput data and identifying resistance-associated genes and pathways. In particular, multi-omics integration&#8212;encompassing genomics, transcriptomics, proteomics, and metabolomics&#8212;has become essential for constructing comprehensive molecular networks and refining therapeutic strategies.</p></list-item><list-item><p id="Par91">Mechanistic Innovations: Ferroptosis and Molecular Targeting: Ferroptosis, a regulated cell death mechanism characterized by iron accumulation and lipid peroxidation, has emerged as a promising avenue to overcome chemoresistance. Targeting ferroptosis-related pathways&#8212;especially through nanotechnology and immune checkpoint combinations&#8212;offers novel opportunities for reversing drug resistance.</p></list-item><list-item><p id="Par92">Emerging Clinical Frontiers: Liquid biopsy and prognostic biomarkers are identified as high-potential tools for non-invasive disease monitoring and individualized treatment planning. Their clinical utility aligns with the objectives of precision oncology and may significantly improve patient outcomes.</p></list-item></list></p><p id="Par93">In summary, this study delivers a macroscopic synthesis of breast cancer chemoresistance research and delineates critical directions for future investigation. The insights presented here are essential for advancing translational research, guiding innovation in drug development, and improving outcomes in the era of precision medicine.</p></sec><sec id="Sec17"><title>Limitations</title><p id="Par94">To the best of our knowledge, this study represents the first comprehensive bibliometric analysis of research on chemoresistance in breast cancer, filling a notable gap in the field by synthesizing over three decades of literature. However, several limitations should be acknowledged.</p><p id="Par95">First, we relied solely on the SCI-E database within the WoSCC, which may have excluded relevant studies indexed in other databases or published in non-English languages. Additionally, the continuously updated nature of WoSCC could introduce discrepancies between the time of data extraction and the total number of published articles.</p><p id="Par96">Second, inherent limitations of bibliometric analysis exist. These include a dependence on published literature while overlooking unpublished reports or grey literature, limited consideration of study quality or methodological rigor, and potential challenges in fully capturing nuanced research insights. Keyword selection bias may also influence the scope and inclusiveness of the data retrieved.</p><p id="Par97">Third, the extended time span of the study (1994&#8211;2024) presents interpretive challenges. Variations in research methodologies, technologies, and scientific focus across different periods may influence the comparability of findings. For instance, early studies predominantly employed traditional experimental techniques, whereas recent advances&#8212;such as high-throughput sequencing, multi-omics platforms, and liquid biopsy&#8212;have shifted the research paradigm toward molecular precision and personalized medicine. Failure to contextualize findings within evolving technical landscapes may lead to misinterpretation of research trajectories.</p><p id="Par98">Lastly, while the broad time frame offers a valuable historical perspective, it may dilute more recent research trends. We suggest that future bibliometric analyses focus on shorter, more targeted intervals (e.g., the past 5&#8211;10 years) to enhance timeliness, specificity, and relevance to current clinical practice.</p><p id="Par99">Despite these limitations, this study provides meaningful insights and strategic references for future research and policy planning. Continued refinement of bibliometric methodologies and the inclusion of diverse data sources will further improve the accuracy and applicability of such analyses.</p></sec><sec id="Sec18"><title>Conclusion</title><p id="Par100">Over the past 30-plus years, breast cancer chemoresistance has emerged as a rapidly advancing research focus. Using bibliometric and visualization tools, this study maps the field&#8217;s development trajectory, key themes, and emerging frontiers, offering a comprehensive perspective for researchers and clinicians.</p><p id="Par101">Our findings highlight major trends and emphasize the value of interdisciplinary approaches. Bioinformatics, in combination with multi-omics integration&#8212;including genomics, transcriptomics, proteomics, and metabolomics&#8212;has facilitated deeper insights into resistance mechanisms and therapeutic target discovery. Additionally, ferroptosis, as a novel form of regulated cell death, presents new opportunities for overcoming drug resistance.</p><p id="Par102">Expanding international collaboration will be crucial for validating findings across diverse settings and accelerating translational progress. Meanwhile, advances in liquid biopsy and precision medicine are driving the identification of predictive biomarkers and enabling more tailored treatment strategies.</p><p id="Par103">In sum, this study provides strategic insights into the evolution of breast cancer chemoresistance research. Ongoing cross-disciplinary efforts and clinical translation will be key to addressing therapeutic resistance and improving patient outcomes.</p></sec><sec id="Sec19" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xlink:href="12672_2025_3542_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary Material 1.</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We thank the designers and developers of the Co-Occurrence software, CiteSpace software, R software, &#8220;bibliometrix&#8221; R package, and the Figdraw platform. We also thank Bullet Edits Limited for the linguistic editing and proofreading of the manuscript. Special thanks to Universiti Sains Malaysia for Internationalisation Incentive Scheme provided (R502-KR-ARP004-00AUPRM003-K134) for collaboration between Universiti Sains Malaysia and Xinxiang Medical University.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>BHY, JL, and HZ conception and design; HZ and TF literature retrieval and data processing; HZ literature analysis, chart creation, and full-text writing; BHY and JL article review and revision, supervision. All authors have read and approved the final published version of the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>The authors would like to acknowledge the Breast Cancer Translational Research Program (BCTRP@IPPT) Top-Down Research University grant scheme, Universiti Sains Malaysia (1001/CIPPT/8070033) for the funding of this project.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The datasets analysed during the current study were retrieved from the Science Citation Index Expanded (SCIE) database within the Web of Science Core Collection (https://webofscience.clarivate.cn/wos/). As the Web of Science Core Collection is a subscription-based database, the raw data cannot be shared directly. The detailed search strategies used for data retrieval are provided in the Supplementary Information. Additional information supporting the findings of this study is available from the corresponding author upon reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par104">Not applicable.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par105">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par106">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siegel</surname><given-names>RL</given-names></name><name name-style="western"><surname>Miller</surname><given-names>KD</given-names></name><name name-style="western"><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Cancer statistics, 2020</article-title><source>CA Cancer J Clin</source><year>2020</year><volume>70</volume><fpage>7</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">31912902</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21590</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7&#8211;30.<pub-id pub-id-type="pmid">31912902</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21590</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fahad Ullah</surname><given-names>M</given-names></name></person-group><article-title>Breast cancer: current perspectives on the disease status</article-title><source>Adv Exp Med Biol</source><year>2019</year><volume>1152</volume><fpage>51</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">31456179</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-3-030-20301-6_4</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Fahad Ullah M. Breast cancer: current perspectives on the disease status. Adv Exp Med Biol. 2019;1152:51&#8211;64.<pub-id pub-id-type="pmid">31456179</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-3-030-20301-6_4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bray</surname><given-names>F</given-names></name><name name-style="western"><surname>Ferlay</surname><given-names>J</given-names></name><name name-style="western"><surname>Soerjomataram</surname><given-names>I</given-names></name><etal/></person-group><article-title>Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA Cancer J Clin</source><year>2018</year><volume>68</volume><fpage>394</fpage><lpage>424</lpage><pub-id pub-id-type="pmid">30207593</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21492</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394&#8211;424.<pub-id pub-id-type="pmid">30207593</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21492</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sung</surname><given-names>H</given-names></name><name name-style="western"><surname>Ferlay</surname><given-names>J</given-names></name><name name-style="western"><surname>Siegel</surname><given-names>RL</given-names></name><etal/></person-group><article-title>Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA Cancer J Clin</source><year>2021</year><volume>71</volume><fpage>209</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">33538338</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21660</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209&#8211;49.<pub-id pub-id-type="pmid">33538338</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21660</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>W</given-names></name><name name-style="western"><surname>Chen</surname><given-names>HD</given-names></name><name name-style="western"><surname>Yu</surname><given-names>YW</given-names></name><etal/></person-group><article-title>Changing profiles of cancer burden worldwide and in china: a secondary analysis of the global cancer statistics 2020</article-title><source>Chin Med J (Engl)</source><year>2021</year><volume>134</volume><fpage>783</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">33734139</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CM9.0000000000001474</pub-id><pub-id pub-id-type="pmcid">PMC8104205</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in china: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl). 2021;134:783&#8211;91.<pub-id pub-id-type="pmid">33734139</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CM9.0000000000001474</pub-id><pub-id pub-id-type="pmcid">PMC8104205</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoogstraat</surname><given-names>M</given-names></name><name name-style="western"><surname>Lips</surname><given-names>EH</given-names></name><name name-style="western"><surname>Mayayo-Peralta</surname><given-names>I</given-names></name><etal/></person-group><article-title>Comprehensive characterization of pre- and post-treatment samples of breast cancer reveal potential mechanisms of chemotherapy resistance</article-title><source>NPJ Breast Cancer</source><year>2022</year><volume>8</volume><fpage>60</fpage><pub-id pub-id-type="pmid">35523804</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41523-022-00428-8</pub-id><pub-id pub-id-type="pmcid">PMC9076915</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Hoogstraat M, Lips EH, Mayayo-Peralta I, et al. Comprehensive characterization of pre- and post-treatment samples of breast cancer reveal potential mechanisms of chemotherapy resistance. NPJ Breast Cancer. 2022;8:60.<pub-id pub-id-type="pmid">35523804</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41523-022-00428-8</pub-id><pub-id pub-id-type="pmcid">PMC9076915</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mittendorf</surname><given-names>EA</given-names></name><name name-style="western"><surname>Jeruss</surname><given-names>JS</given-names></name><name name-style="western"><surname>Tucker</surname><given-names>SL</given-names></name><etal/></person-group><article-title>Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy</article-title><source>J Clin Oncol</source><year>2011</year><volume>29</volume><fpage>1956</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">21482989</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2010.31.8469</pub-id><pub-id pub-id-type="pmcid">PMC3107758</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Mittendorf EA, Jeruss JS, Tucker SL, et al. Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol. 2011;29:1956&#8211;62.<pub-id pub-id-type="pmid">21482989</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2010.31.8469</pub-id><pub-id pub-id-type="pmcid">PMC3107758</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Golshan</surname><given-names>M</given-names></name><name name-style="western"><surname>Cirrincione</surname><given-names>CT</given-names></name><name name-style="western"><surname>Sikov</surname><given-names>WM</given-names></name><etal/></person-group><article-title>Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance)</article-title><source>Ann Surg</source><year>2015</year><volume>262</volume><fpage>434</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">26222764</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/SLA.0000000000001417</pub-id><pub-id pub-id-type="pmcid">PMC4710511</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Golshan M, Cirrincione CT, Sikov WM, et al. Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance). Ann Surg. 2015;262:434&#8211;9. discussion 438&#8211;439.<pub-id pub-id-type="pmid">26222764</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/SLA.0000000000001417</pub-id><pub-id pub-id-type="pmcid">PMC4710511</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lehmann</surname><given-names>BD</given-names></name><name name-style="western"><surname>Pietenpol</surname><given-names>JA</given-names></name></person-group><article-title>Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes</article-title><source>J Pathol</source><year>2014</year><volume>232</volume><fpage>142</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">24114677</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/path.4280</pub-id><pub-id pub-id-type="pmcid">PMC4090031</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Lehmann BD, Pietenpol JA. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol. 2014;232:142&#8211;50.<pub-id pub-id-type="pmid">24114677</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/path.4280</pub-id><pub-id pub-id-type="pmcid">PMC4090031</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Radovich</surname><given-names>M</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>G</given-names></name><name name-style="western"><surname>Hancock</surname><given-names>BA</given-names></name><etal/></person-group><article-title>Association of Circulating tumor DNA and Circulating tumor cells after neoadjuvant chemotherapy with disease recurrence in patients with Triple-Negative breast cancer: Preplanned secondary analysis of the BRE12-158 randomized clinical trial</article-title><source>JAMA Oncol</source><year>2020</year><volume>6</volume><fpage>1410</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">32644110</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaoncol.2020.2295</pub-id><pub-id pub-id-type="pmcid">PMC7349081</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Radovich M, Jiang G, Hancock BA, et al. Association of Circulating tumor DNA and Circulating tumor cells after neoadjuvant chemotherapy with disease recurrence in patients with Triple-Negative breast cancer: Preplanned secondary analysis of the BRE12-158 randomized clinical trial. JAMA Oncol. 2020;6:1410&#8211;5.<pub-id pub-id-type="pmid">32644110</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaoncol.2020.2295</pub-id><pub-id pub-id-type="pmcid">PMC7349081</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cortazar</surname><given-names>P</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Untch</surname><given-names>M</given-names></name><etal/></person-group><article-title>Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis</article-title><source>Lancet</source><year>2014</year><volume>384</volume><fpage>164</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">24529560</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(13)62422-8</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164&#8211;72.<pub-id pub-id-type="pmid">24529560</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(13)62422-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Curigliano</surname><given-names>G</given-names></name><name name-style="western"><surname>Burstein</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Winer</surname><given-names>EP</given-names></name><etal/></person-group><article-title>De-escalating and escalating treatments for early-stage breast cancer: the st. Gallen international expert consensus conference on the primary therapy of early breast cancer 2017</article-title><source>Ann Oncol</source><year>2017</year><volume>28</volume><fpage>1700</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">28838210</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/annonc/mdx308</pub-id><pub-id pub-id-type="pmcid">PMC6246241</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Curigliano G, Burstein HJ, Winer EP, et al. De-escalating and escalating treatments for early-stage breast cancer: the st. Gallen international expert consensus conference on the primary therapy of early breast cancer 2017. Ann Oncol. 2017;28:1700&#8211;12.<pub-id pub-id-type="pmid">28838210</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/annonc/mdx308</pub-id><pub-id pub-id-type="pmcid">PMC6246241</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J</given-names></name><name name-style="western"><surname>Gu</surname><given-names>R</given-names></name><etal/></person-group><article-title>Comprehensive analysis of transcriptomics and genetic alterations identifies potential mechanisms underlying anthracycline therapy resistance in breast cancer</article-title><source>Biomolecules</source><year>2022</year><volume>12</volume><fpage>1834</fpage><pub-id pub-id-type="pmid">36551262</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biom12121834</pub-id><pub-id pub-id-type="pmcid">PMC9775906</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Liu Z, Gao J, Gu R, et al. Comprehensive analysis of transcriptomics and genetic alterations identifies potential mechanisms underlying anthracycline therapy resistance in breast cancer. Biomolecules. 2022;12:1834.<pub-id pub-id-type="pmid">36551262</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biom12121834</pub-id><pub-id pub-id-type="pmcid">PMC9775906</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zaheed</surname><given-names>M</given-names></name><name name-style="western"><surname>Wilcken</surname><given-names>N</given-names></name><name name-style="western"><surname>Willson</surname><given-names>ML</given-names></name><etal/></person-group><article-title>Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer</article-title><source>Cochrane Database Syst Rev</source><year>2019</year><volume>2</volume><fpage>Cd012873</fpage><pub-id pub-id-type="pmid">30776132</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/14651858.CD012873.pub2</pub-id><pub-id pub-id-type="pmcid">PMC6378927</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Zaheed M, Wilcken N, Willson ML, et al. Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer. Cochrane Database Syst Rev. 2019;2:Cd012873.<pub-id pub-id-type="pmid">30776132</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/14651858.CD012873.pub2</pub-id><pub-id pub-id-type="pmcid">PMC6378927</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tekpli</surname><given-names>X</given-names></name><name name-style="western"><surname>Lien</surname><given-names>T</given-names></name><name name-style="western"><surname>R&#248;ssevold</surname><given-names>AH</given-names></name><etal/></person-group><article-title>An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment</article-title><source>Nat Commun</source><year>2019</year><volume>10</volume><fpage>5499</fpage><pub-id pub-id-type="pmid">31796750</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-019-13329-5</pub-id><pub-id pub-id-type="pmcid">PMC6890706</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Tekpli X, Lien T, R&#248;ssevold AH, et al. An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment. Nat Commun. 2019;10:5499.<pub-id pub-id-type="pmid">31796750</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-019-13329-5</pub-id><pub-id pub-id-type="pmcid">PMC6890706</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Waks</surname><given-names>AG</given-names></name><name name-style="western"><surname>Winer</surname><given-names>EP</given-names></name></person-group><article-title>Breast cancer treatment: A review</article-title><source>JAMA</source><year>2019</year><volume>321</volume><fpage>288</fpage><lpage>300</lpage><pub-id pub-id-type="pmid">30667505</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2018.19323</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Waks AG, Winer EP. Breast cancer treatment: A review. JAMA. 2019;321:288&#8211;300.<pub-id pub-id-type="pmid">30667505</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2018.19323</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Odle</surname><given-names>TG</given-names></name></person-group><article-title>Precision medicine in breast cancer</article-title><source>Radiol Technol</source><year>2017</year><volume>88</volume><fpage>m401</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">28298516</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Odle TG. Precision medicine in breast cancer. Radiol Technol. 2017;88:m401&#8211;21.<pub-id pub-id-type="pmid">28298516</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miri</surname><given-names>A</given-names></name><name name-style="western"><surname>Gharechahi</surname><given-names>J</given-names></name><name name-style="western"><surname>Samiei Mosleh</surname><given-names>I</given-names></name><etal/></person-group><article-title>Identification of co-regulated genes associated with doxorubicin resistance in the MCF-7/ADR cancer cell line</article-title><source>Front Oncol</source><year>2023</year><volume>13</volume><fpage>1135836</fpage><pub-id pub-id-type="pmid">37397367</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2023.1135836</pub-id><pub-id pub-id-type="pmcid">PMC10311417</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Miri A, Gharechahi J, Samiei Mosleh I, et al. Identification of co-regulated genes associated with doxorubicin resistance in the MCF-7/ADR cancer cell line. Front Oncol. 2023;13:1135836.<pub-id pub-id-type="pmid">37397367</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2023.1135836</pub-id><pub-id pub-id-type="pmcid">PMC10311417</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Longley</surname><given-names>DB</given-names></name><name name-style="western"><surname>Johnston</surname><given-names>PG</given-names></name></person-group><article-title>Molecular mechanisms of drug resistance</article-title><source>J Pathol</source><year>2005</year><volume>205</volume><fpage>275</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">15641020</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/path.1706</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol. 2005;205:275&#8211;92.<pub-id pub-id-type="pmid">15641020</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/path.1706</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hurvitz</surname><given-names>SA</given-names></name><name name-style="western"><surname>McAndrew</surname><given-names>NP</given-names></name><name name-style="western"><surname>Bardia</surname><given-names>A</given-names></name><etal/></person-group><article-title>A careful reassessment of anthracycline use in curable breast cancer</article-title><source>NPJ Breast Cancer</source><year>2021</year><volume>7</volume><fpage>134</fpage><pub-id pub-id-type="pmid">34625570</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41523-021-00342-5</pub-id><pub-id pub-id-type="pmcid">PMC8501074</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Hurvitz SA, McAndrew NP, Bardia A, et al. A careful reassessment of anthracycline use in curable breast cancer. NPJ Breast Cancer. 2021;7:134.<pub-id pub-id-type="pmid">34625570</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41523-021-00342-5</pub-id><pub-id pub-id-type="pmcid">PMC8501074</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koual</surname><given-names>M</given-names></name><name name-style="western"><surname>Tomkiewicz</surname><given-names>C</given-names></name><name name-style="western"><surname>Cano-Sancho</surname><given-names>G</given-names></name><etal/></person-group><article-title>Environmental chemicals, breast cancer progression and drug resistance</article-title><source>Environ Health</source><year>2020</year><volume>19</volume><fpage>117</fpage><pub-id pub-id-type="pmid">33203443</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12940-020-00670-2</pub-id><pub-id pub-id-type="pmcid">PMC7672852</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Koual M, Tomkiewicz C, Cano-Sancho G, et al. Environmental chemicals, breast cancer progression and drug resistance. Environ Health. 2020;19:117.<pub-id pub-id-type="pmid">33203443</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12940-020-00670-2</pub-id><pub-id pub-id-type="pmcid">PMC7672852</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siegel</surname><given-names>RL</given-names></name><name name-style="western"><surname>Miller</surname><given-names>KD</given-names></name><name name-style="western"><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Cancer statistics, 2017</article-title><source>CA Cancer J Clin</source><year>2017</year><volume>67</volume><fpage>7</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">28055103</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21387</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7&#8211;30.<pub-id pub-id-type="pmid">28055103</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21387</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ji</surname><given-names>X</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tian</surname><given-names>H</given-names></name><etal/></person-group><article-title>Chemoresistance mechanisms of breast cancer and their countermeasures</article-title><source>Biomed Pharmacother</source><year>2019</year><volume>114</volume><fpage>108800</fpage><pub-id pub-id-type="pmid">30921705</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2019.108800</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Ji X, Lu Y, Tian H, et al. Chemoresistance mechanisms of breast cancer and their countermeasures. Biomed Pharmacother. 2019;114:108800.<pub-id pub-id-type="pmid">30921705</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2019.108800</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pritchard</surname><given-names>A</given-names></name></person-group><article-title>Statistical bibliography or bibliometrics</article-title><source>J Doc</source><year>1969</year><volume>25</volume><fpage>348</fpage></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Pritchard A. Statistical bibliography or bibliometrics. J Doc. 1969;25:348.</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Broadus</surname><given-names>RN</given-names></name></person-group><article-title>Toward a definition of bibliometrics</article-title><source>Scientometrics</source><year>1987</year><volume>12</volume><fpage>373</fpage><lpage>9</lpage></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Broadus RN. Toward a definition of bibliometrics. Scientometrics. 1987;12:373&#8211;9.</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pu</surname><given-names>QH</given-names></name><name name-style="western"><surname>Lyu</surname><given-names>QJ</given-names></name><name name-style="western"><surname>Su</surname><given-names>HY</given-names></name></person-group><article-title>Bibliometric analysis of scientific publications in transplantation journals from Mainland china, japan, South Korea and Taiwan between 2006 and 2015</article-title><source>BMJ Open</source><year>2016</year><volume>6</volume><fpage>e011623</fpage><pub-id pub-id-type="pmid">27489154</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmjopen-2016-011623</pub-id><pub-id pub-id-type="pmcid">PMC4985842</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Pu QH, Lyu QJ, Su HY. Bibliometric analysis of scientific publications in transplantation journals from Mainland china, japan, South Korea and Taiwan between 2006 and 2015. BMJ Open. 2016;6:e011623.<pub-id pub-id-type="pmid">27489154</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmjopen-2016-011623</pub-id><pub-id pub-id-type="pmcid">PMC4985842</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name><name name-style="western"><surname>Song</surname><given-names>M</given-names></name></person-group><article-title>Visualizing a field of research: A methodology of systematic scientometric reviews</article-title><source>PLoS ONE</source><year>2019</year><volume>14</volume><fpage>e0223994</fpage><pub-id pub-id-type="pmid">31671124</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0223994</pub-id><pub-id pub-id-type="pmcid">PMC6822756</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Chen C, Song M. Visualizing a field of research: A methodology of systematic scientometric reviews. PLoS ONE. 2019;14:e0223994.<pub-id pub-id-type="pmid">31671124</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0223994</pub-id><pub-id pub-id-type="pmcid">PMC6822756</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Song</surname><given-names>L</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L</given-names></name><etal/></person-group><article-title>Knowledge domain and emerging trends in ferroptosis research: A bibliometric and Knowledge-Map analysis</article-title><source>Front Oncol</source><year>2021</year><volume>11</volume><fpage>686726</fpage><pub-id pub-id-type="pmid">34150654</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2021.686726</pub-id><pub-id pub-id-type="pmcid">PMC8209495</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Zhang J, Song L, Xu L, et al. Knowledge domain and emerging trends in ferroptosis research: A bibliometric and Knowledge-Map analysis. Front Oncol. 2021;11:686726.<pub-id pub-id-type="pmid">34150654</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2021.686726</pub-id><pub-id pub-id-type="pmcid">PMC8209495</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name><name name-style="western"><surname>Dubin</surname><given-names>R</given-names></name><name name-style="western"><surname>Kim</surname><given-names>MC</given-names></name></person-group><article-title>Emerging trends and new developments in regenerative medicine: a scientometric update (2000&#8211;2014)</article-title><source>Expert Opin Biol Ther</source><year>2014</year><volume>14</volume><fpage>1295</fpage><lpage>317</lpage><pub-id pub-id-type="pmid">25077605</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/14712598.2014.920813</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Chen C, Dubin R, Kim MC. Emerging trends and new developments in regenerative medicine: a scientometric update (2000&#8211;2014). Expert Opin Biol Ther. 2014;14:1295&#8211;317.<pub-id pub-id-type="pmid">25077605</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/14712598.2014.920813</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhai</surname><given-names>X</given-names></name><etal/></person-group><article-title>Publication trends of research on diabetes mellitus and T cells (1997&#8211;2016): A 20-year bibliometric study</article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><fpage>e0184869</fpage><pub-id pub-id-type="pmid">28926600</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0184869</pub-id><pub-id pub-id-type="pmcid">PMC5604989</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Gao Y, Wang Y, Zhai X, et al. Publication trends of research on diabetes mellitus and T cells (1997&#8211;2016): A 20-year bibliometric study. PLoS ONE. 2017;12:e0184869.<pub-id pub-id-type="pmid">28926600</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0184869</pub-id><pub-id pub-id-type="pmcid">PMC5604989</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>L</given-names></name><name name-style="western"><surname>Fang</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group><article-title>The 100 most-cited articles in urological surgery: A bibliometric analysis</article-title><source>Int J Surg</source><year>2020</year><volume>75</volume><fpage>74</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">31926329</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijsu.2019.12.030</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">He L, Fang H, Wang X, et al. The 100 most-cited articles in urological surgery: A bibliometric analysis. Int J Surg. 2020;75:74&#8211;9.<pub-id pub-id-type="pmid">31926329</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijsu.2019.12.030</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>X</given-names></name><name name-style="western"><surname>Xu</surname><given-names>S</given-names></name><name name-style="western"><surname>Tang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Insights into the history and tendency of liver transplantation for liver cancer: A bibliometric-based visual analysis</article-title><source>Int J Surg</source><year>2024</year><volume>110</volume><fpage>406</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">37800536</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/JS9.0000000000000806</pub-id><pub-id pub-id-type="pmcid">PMC10793788</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">He X, Xu S, Tang L, et al. Insights into the history and tendency of liver transplantation for liver cancer: A bibliometric-based visual analysis. Int J Surg. 2024;110:406&#8211;18.<pub-id pub-id-type="pmid">37800536</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/JS9.0000000000000806</pub-id><pub-id pub-id-type="pmcid">PMC10793788</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lai</surname><given-names>S</given-names></name><etal/></person-group><article-title>Global trends and prospects in health economics of robotic surgery: A bibliometric analysis</article-title><source>Int J Surg</source><year>2023</year><volume>109</volume><fpage>3896</fpage><lpage>904</lpage><pub-id pub-id-type="pmid">37720937</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/JS9.0000000000000720</pub-id><pub-id pub-id-type="pmcid">PMC10720792</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Peng Y, Liu Y, Lai S, et al. Global trends and prospects in health economics of robotic surgery: A bibliometric analysis. Int J Surg. 2023;109:3896&#8211;904.<pub-id pub-id-type="pmid">37720937</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/JS9.0000000000000720</pub-id><pub-id pub-id-type="pmcid">PMC10720792</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weng</surname><given-names>R</given-names></name><name name-style="western"><surname>Lin</surname><given-names>DX</given-names></name><name name-style="western"><surname>Song</surname><given-names>YK</given-names></name><etal/></person-group><article-title>Bibliometric and visualized analysis of research relating to minimally invasive spine surgery reported over the period 2000&#8211;2022</article-title><source>Digit Health</source><year>2023</year><volume>9</volume><fpage>20552076231173562</fpage><pub-id pub-id-type="pmid">37163171</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/20552076231173562</pub-id><pub-id pub-id-type="pmcid">PMC10164264</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Weng R, Lin DX, Song YK, et al. Bibliometric and visualized analysis of research relating to minimally invasive spine surgery reported over the period 2000&#8211;2022. Digit Health. 2023;9:20552076231173562.<pub-id pub-id-type="pmid">37163171</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/20552076231173562</pub-id><pub-id pub-id-type="pmcid">PMC10164264</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van den Hoven</surname><given-names>AF</given-names></name><name name-style="western"><surname>Keijsers</surname><given-names>RGM</given-names></name><name name-style="western"><surname>Lam</surname><given-names>M</given-names></name><etal/></person-group><article-title>Current research topics in FAPI theranostics: a bibliometric analysis</article-title><source>Eur J Nucl Med Mol Imaging</source><year>2023</year><volume>50</volume><fpage>1014</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">36437424</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00259-022-06052-9</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">van den Hoven AF, Keijsers RGM, Lam M, et al. Current research topics in FAPI theranostics: a bibliometric analysis. Eur J Nucl Med Mol Imaging. 2023;50:1014&#8211;27.<pub-id pub-id-type="pmid">36437424</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00259-022-06052-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kocak</surname><given-names>B</given-names></name><name name-style="western"><surname>Baessler</surname><given-names>B</given-names></name><name name-style="western"><surname>Cuocolo</surname><given-names>R</given-names></name><etal/></person-group><article-title>Trends and statistics of artificial intelligence and radiomics research in radiology, nuclear medicine, and medical imaging: bibliometric analysis</article-title><source>Eur Radiol</source><year>2023</year><volume>33</volume><fpage>7542</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">37314469</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00330-023-09772-0</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Kocak B, Baessler B, Cuocolo R, et al. Trends and statistics of artificial intelligence and radiomics research in radiology, nuclear medicine, and medical imaging: bibliometric analysis. Eur Radiol. 2023;33:7542&#8211;55.<pub-id pub-id-type="pmid">37314469</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00330-023-09772-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cuocolo</surname><given-names>R</given-names></name><name name-style="western"><surname>Ponsiglione</surname><given-names>A</given-names></name><name name-style="western"><surname>Dell&#8217;Aversana</surname><given-names>S</given-names></name><etal/></person-group><article-title>The cardiac conundrum: a systematic review and bibliometric analysis of authorship in cardiac magnetic resonance imaging studies</article-title><source>Insights Imaging</source><year>2020</year><volume>11</volume><fpage>42</fpage><pub-id pub-id-type="pmid">32107649</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13244-020-00850-1</pub-id><pub-id pub-id-type="pmcid">PMC7046856</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Cuocolo R, Ponsiglione A, Dell&#8217;Aversana S, et al. The cardiac conundrum: a systematic review and bibliometric analysis of authorship in cardiac magnetic resonance imaging studies. Insights Imaging. 2020;11:42.<pub-id pub-id-type="pmid">32107649</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13244-020-00850-1</pub-id><pub-id pub-id-type="pmcid">PMC7046856</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poly</surname><given-names>TN</given-names></name><name name-style="western"><surname>Islam</surname><given-names>MM</given-names></name><name name-style="western"><surname>Walther</surname><given-names>BA</given-names></name><etal/></person-group><article-title>Artificial intelligence in diabetic retinopathy: bibliometric analysis</article-title><source>Comput Methods Programs Biomed</source><year>2023</year><volume>231</volume><fpage>107358</fpage><pub-id pub-id-type="pmid">36731310</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmpb.2023.107358</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Poly TN, Islam MM, Walther BA, et al. Artificial intelligence in diabetic retinopathy: bibliometric analysis. Comput Methods Programs Biomed. 2023;231:107358.<pub-id pub-id-type="pmid">36731310</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmpb.2023.107358</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Di&#233;guez-Santana</surname><given-names>K</given-names></name><name name-style="western"><surname>Gonz&#225;lez-D&#237;az</surname><given-names>H</given-names></name></person-group><article-title>Machine learning in antibacterial discovery and development: A bibliometric and network analysis of research hotspots and trends</article-title><source>Comput Biol Med</source><year>2023</year><volume>155</volume><fpage>106638</fpage><pub-id pub-id-type="pmid">36764155</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.compbiomed.2023.106638</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Di&#233;guez-Santana K, Gonz&#225;lez-D&#237;az H. Machine learning in antibacterial discovery and development: A bibliometric and network analysis of research hotspots and trends. Comput Biol Med. 2023;155:106638.<pub-id pub-id-type="pmid">36764155</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.compbiomed.2023.106638</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>S</given-names></name><name name-style="western"><surname>Hao</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><etal/></person-group><article-title>The interactions between traditional Chinese medicine and gut microbiota: global research status and trends</article-title><source>Front Cell Infect Microbiol</source><year>2022</year><volume>12</volume><fpage>1005730</fpage><pub-id pub-id-type="pmid">36171760</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcimb.2022.1005730</pub-id><pub-id pub-id-type="pmcid">PMC9510645</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Yang S, Hao S, Wang Q, et al. The interactions between traditional Chinese medicine and gut microbiota: global research status and trends. Front Cell Infect Microbiol. 2022;12:1005730.<pub-id pub-id-type="pmid">36171760</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcimb.2022.1005730</pub-id><pub-id pub-id-type="pmcid">PMC9510645</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fu</surname><given-names>L</given-names></name><name name-style="western"><surname>Lv</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name></person-group><article-title>Research trends of acupuncture therapy on dysmenorrhea from 2002 to 2022: A bibliometric analysis</article-title><source>Biotechnol Genet Eng Rev</source><year>2024</year><volume>40</volume><fpage>2842</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">37066859</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/02648725.2023.2202539</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Fu L, Lv H, Li Z. Research trends of acupuncture therapy on dysmenorrhea from 2002 to 2022: A bibliometric analysis. Biotechnol Genet Eng Rev. 2024;40:2842&#8211;61.<pub-id pub-id-type="pmid">37066859</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/02648725.2023.2202539</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>HY</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>T</given-names></name><etal/></person-group><article-title>Research trends and hotspots of neoadjuvant therapy in pancreatic cancer: a bibliometric analysis based on the web of science core collection</article-title><source>Clin Exp Med</source><year>2023</year><volume>23</volume><fpage>2473</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">36773211</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10238-023-01013-4</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Wu HY, Liu T, Zhong T, et al. Research trends and hotspots of neoadjuvant therapy in pancreatic cancer: a bibliometric analysis based on the web of science core collection. Clin Exp Med. 2023;23:2473&#8211;85.<pub-id pub-id-type="pmid">36773211</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10238-023-01013-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>S</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>H</given-names></name><etal/></person-group><article-title>Evolutionary patterns and research frontiers in neoadjuvant immunotherapy: a bibliometric analysis</article-title><source>Int J Surg</source><year>2023</year><volume>109</volume><fpage>2774</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">37216225</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/JS9.0000000000000492</pub-id><pub-id pub-id-type="pmcid">PMC10498839</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Jiang S, Liu Y, Zheng H, et al. Evolutionary patterns and research frontiers in neoadjuvant immunotherapy: a bibliometric analysis. Int J Surg. 2023;109:2774&#8211;83.<pub-id pub-id-type="pmid">37216225</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/JS9.0000000000000492</pub-id><pub-id pub-id-type="pmcid">PMC10498839</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jia</surname><given-names>B</given-names></name><name name-style="western"><surname>Lim</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Global research trends in radiotherapy for breast cancer: a systematic bibliometric analysis</article-title><source>Jpn J Radiol</source><year>2023</year><volume>41</volume><fpage>648</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">36607552</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11604-022-01383-x</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Jia B, Lim D, Zhang Y, et al. Global research trends in radiotherapy for breast cancer: a systematic bibliometric analysis. Jpn J Radiol. 2023;41:648&#8211;59.<pub-id pub-id-type="pmid">36607552</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11604-022-01383-x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>P</given-names></name><name name-style="western"><surname>Wen</surname><given-names>F</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Research trends of targeted therapy for cholangiocarcinoma from 2003 to 2022: a bibliometric and visual analysis</article-title><source>Clin Exp Med</source><year>2023</year><volume>23</volume><fpage>5477</fpage><pub-id pub-id-type="pmid">37535196</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10238-023-01138-6</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Huang P, Wen F, Wu Q, et al. Research trends of targeted therapy for cholangiocarcinoma from 2003 to 2022: a bibliometric and visual analysis. Clin Exp Med. 2023;23:5477.<pub-id pub-id-type="pmid">37535196</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10238-023-01138-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Yang</surname><given-names>KL</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Characterization of global research trends and prospects on Single-Cell sequencing technology: bibliometric analysis</article-title><source>J Med Internet Res</source><year>2021</year><volume>23</volume><fpage>e25789</fpage><pub-id pub-id-type="pmid">34014832</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2196/25789</pub-id><pub-id pub-id-type="pmcid">PMC8386406</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Wang Q, Yang KL, Zhang Z, et al. Characterization of global research trends and prospects on Single-Cell sequencing technology: bibliometric analysis. J Med Internet Res. 2021;23:e25789.<pub-id pub-id-type="pmid">34014832</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2196/25789</pub-id><pub-id pub-id-type="pmcid">PMC8386406</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miao</surname><given-names>YD</given-names></name><name name-style="western"><surname>Quan</surname><given-names>W</given-names></name><name name-style="western"><surname>Dong</surname><given-names>X</given-names></name><etal/></person-group><article-title>A bibliometric analysis of ferroptosis, necroptosis, pyroptosis, and Cuproptosis in cancer from 2012 to 2022</article-title><source>Cell Death Discov</source><year>2023</year><volume>9</volume><fpage>129</fpage><pub-id pub-id-type="pmid">37061535</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41420-023-01421-1</pub-id><pub-id pub-id-type="pmcid">PMC10105750</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Miao YD, Quan W, Dong X, et al. A bibliometric analysis of ferroptosis, necroptosis, pyroptosis, and Cuproptosis in cancer from 2012 to 2022. Cell Death Discov. 2023;9:129.<pub-id pub-id-type="pmid">37061535</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41420-023-01421-1</pub-id><pub-id pub-id-type="pmcid">PMC10105750</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zou</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W</given-names></name><etal/></person-group><article-title>Vascular endothelium is the basic way for stem cells to treat erectile dysfunction: a bibliometric study</article-title><source>Cell Death Discov</source><year>2023</year><volume>9</volume><fpage>143</fpage><pub-id pub-id-type="pmid">37127677</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41420-023-01443-9</pub-id><pub-id pub-id-type="pmcid">PMC10151332</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Zou H, Zhang X, Chen W, et al. Vascular endothelium is the basic way for stem cells to treat erectile dysfunction: a bibliometric study. Cell Death Discov. 2023;9:143.<pub-id pub-id-type="pmid">37127677</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41420-023-01443-9</pub-id><pub-id pub-id-type="pmcid">PMC10151332</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B</given-names></name><etal/></person-group><article-title>Global trends in PANoptosis research: bibliometrics and knowledge graph analysis</article-title><source>Apoptosis</source><year>2024</year><volume>29</volume><fpage>229</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">37751105</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10495-023-01889-3</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Zheng Y, Li J, Liu B, et al. Global trends in PANoptosis research: bibliometrics and knowledge graph analysis. Apoptosis. 2024;29:229&#8211;42.<pub-id pub-id-type="pmid">37751105</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10495-023-01889-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name><name name-style="western"><surname>Lou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>XY</given-names></name><etal/></person-group><article-title>Mapping current research and identifying hotspots on mesenchymal stem cells in cardiovascular disease</article-title><source>Stem Cell Res Ther</source><year>2020</year><volume>11</volume><fpage>498</fpage><pub-id pub-id-type="pmid">33239082</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13287-020-02009-7</pub-id><pub-id pub-id-type="pmcid">PMC7687818</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Chen C, Lou Y, Li XY, et al. Mapping current research and identifying hotspots on mesenchymal stem cells in cardiovascular disease. Stem Cell Res Ther. 2020;11:498.<pub-id pub-id-type="pmid">33239082</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13287-020-02009-7</pub-id><pub-id pub-id-type="pmcid">PMC7687818</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cao</surname><given-names>S</given-names></name><etal/></person-group><article-title>Application of artificial intelligence in geriatric care: bibliometric analysis</article-title><source>J Med Internet Res</source><year>2023</year><volume>25</volume><fpage>e46014</fpage><pub-id pub-id-type="pmid">37351923</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2196/46014</pub-id><pub-id pub-id-type="pmcid">PMC10337465</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Wang J, Liang Y, Cao S, et al. Application of artificial intelligence in geriatric care: bibliometric analysis. J Med Internet Res. 2023;25:e46014.<pub-id pub-id-type="pmid">37351923</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2196/46014</pub-id><pub-id pub-id-type="pmcid">PMC10337465</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>K</given-names></name><etal/></person-group><article-title>Structural and Temporal dynamics analysis on drug-eluting stents: history, research hotspots and emerging trends</article-title><source>Bioact Mater</source><year>2023</year><volume>23</volume><fpage>170</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">36406256</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bioactmat.2022.09.009</pub-id><pub-id pub-id-type="pmcid">PMC9663333</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Tan L, Wang X, Yuan K, et al. Structural and Temporal dynamics analysis on drug-eluting stents: history, research hotspots and emerging trends. Bioact Mater. 2023;23:170&#8211;86.<pub-id pub-id-type="pmid">36406256</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bioactmat.2022.09.009</pub-id><pub-id pub-id-type="pmcid">PMC9663333</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Global research trends in in-stent neoatherosclerosis: A CiteSpace-based visual analysis</article-title><source>Front Cardiovasc Med</source><year>2022</year><volume>9</volume><fpage>1025858</fpage><pub-id pub-id-type="pmid">36426225</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcvm.2022.1025858</pub-id><pub-id pub-id-type="pmcid">PMC9679497</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Wang H, Wang Q, Hu J, et al. Global research trends in in-stent neoatherosclerosis: A CiteSpace-based visual analysis. Front Cardiovasc Med. 2022;9:1025858.<pub-id pub-id-type="pmid">36426225</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcvm.2022.1025858</pub-id><pub-id pub-id-type="pmcid">PMC9679497</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tong</surname><given-names>L</given-names></name><etal/></person-group><article-title>Worldwide research tendency and hotspots on hip fracture: a 20-year bibliometric analysis</article-title><source>Arch Osteoporos</source><year>2021</year><volume>16</volume><fpage>73</fpage><pub-id pub-id-type="pmid">33866438</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11657-021-00929-2</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Wu H, Li Y, Tong L, et al. Worldwide research tendency and hotspots on hip fracture: a 20-year bibliometric analysis. Arch Osteoporos. 2021;16:73.<pub-id pub-id-type="pmid">33866438</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11657-021-00929-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>X</given-names></name><name name-style="western"><surname>Lu</surname><given-names>C</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Current status and trends in peptide receptor radionuclide therapy in the past 20 years (2000&#8211;2019): A bibliometric study</article-title><source>Front Pharmacol</source><year>2021</year><volume>12</volume><fpage>624534</fpage><pub-id pub-id-type="pmid">33986664</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2021.624534</pub-id><pub-id pub-id-type="pmcid">PMC8111084</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Lu X, Lu C, Yang Y, et al. Current status and trends in peptide receptor radionuclide therapy in the past 20 years (2000&#8211;2019): A bibliometric study. Front Pharmacol. 2021;12:624534.<pub-id pub-id-type="pmid">33986664</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2021.624534</pub-id><pub-id pub-id-type="pmcid">PMC8111084</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gong</surname><given-names>T</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><etal/></person-group><article-title>Global research status and trends of bronchiectasis in children from 2003 to 2022: A 20-year bibliometric analysis</article-title><source>Front Pediatr</source><year>2023</year><volume>11</volume><fpage>1095452</fpage><pub-id pub-id-type="pmid">36816374</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fped.2023.1095452</pub-id><pub-id pub-id-type="pmcid">PMC9936077</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Gong T, Wang X, Li S, et al. Global research status and trends of bronchiectasis in children from 2003 to 2022: A 20-year bibliometric analysis. Front Pediatr. 2023;11:1095452.<pub-id pub-id-type="pmid">36816374</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fped.2023.1095452</pub-id><pub-id pub-id-type="pmcid">PMC9936077</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>K</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>S</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><etal/></person-group><article-title>Knowledge mapping and research hotspots of immunotherapy in renal cell carcinoma: A text-mining study from 2002 to 2021</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><fpage>969217</fpage><pub-id pub-id-type="pmid">35967367</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.969217</pub-id><pub-id pub-id-type="pmcid">PMC9367473</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Liu K, Zhao S, Li J, et al. Knowledge mapping and research hotspots of immunotherapy in renal cell carcinoma: A text-mining study from 2002 to 2021. Front Immunol. 2022;13:969217.<pub-id pub-id-type="pmid">35967367</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.969217</pub-id><pub-id pub-id-type="pmcid">PMC9367473</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aria</surname><given-names>M</given-names></name><name name-style="western"><surname>Cuccurullo</surname><given-names>C</given-names></name></person-group><article-title>Bibliometrix: an R-tool for comprehensive science mapping analysis</article-title><source>J Informetrics</source><year>2017</year><volume>11</volume><fpage>959</fpage><lpage>75</lpage></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Aria M, Cuccurullo C. Bibliometrix: an R-tool for comprehensive science mapping analysis. J Informetrics. 2017;11:959&#8211;75.</mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><mixed-citation publication-type="other">XueShuDianDi. COOC is a software for bibliometrics and knowledge graph drawing [CP/OL]. (2025). Available online at: <ext-link ext-link-type="uri" xlink:href="https://github.com/2088904822">https://github.com/2088904822</ext-link> (accessed January 26, 2025).</mixed-citation></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>T</given-names></name><name name-style="western"><surname>Qu</surname><given-names>J</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H</given-names></name><etal/></person-group><article-title>Research trends and hotspots on montessori intervention in patients with dementia from 2000 to 2021: A bibliometric analysis</article-title><source>Front Psychiatry</source><year>2021</year><volume>12</volume><fpage>737270</fpage><pub-id pub-id-type="pmid">34566730</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fpsyt.2021.737270</pub-id><pub-id pub-id-type="pmcid">PMC8458692</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Zhou T, Qu J, Sun H, et al. Research trends and hotspots on montessori intervention in patients with dementia from 2000 to 2021: A bibliometric analysis. Front Psychiatry. 2021;12:737270.<pub-id pub-id-type="pmid">34566730</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fpsyt.2021.737270</pub-id><pub-id pub-id-type="pmcid">PMC8458692</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Ge</surname><given-names>J</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>The evolution of research on depression during COVID-19: A visual analysis using Co-Occurrence and VOSviewer</article-title><source>Front Public Health</source><year>2022</year><volume>10</volume><fpage>1061486</fpage><pub-id pub-id-type="pmid">36561872</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fpubh.2022.1061486</pub-id><pub-id pub-id-type="pmcid">PMC9764011</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Fu Q, Ge J, Xu Y, et al. The evolution of research on depression during COVID-19: A visual analysis using Co-Occurrence and VOSviewer. Front Public Health. 2022;10:1061486.<pub-id pub-id-type="pmid">36561872</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fpubh.2022.1061486</pub-id><pub-id pub-id-type="pmcid">PMC9764011</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>He</surname><given-names>M</given-names></name><etal/></person-group><article-title>Global evolution of research on green energy and environmental technologies:a bibliometric study</article-title><source>J Environ Manage</source><year>2021</year><volume>297</volume><fpage>113382</fpage><pub-id pub-id-type="pmid">34332345</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jenvman.2021.113382</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Tan H, Li J, He M, et al. Global evolution of research on green energy and environmental technologies:a bibliometric study. J Environ Manage. 2021;297:113382.<pub-id pub-id-type="pmid">34332345</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jenvman.2021.113382</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qin</surname><given-names>F</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><etal/></person-group><article-title>Biochar in the 21st century: A data-driven visualization of collaboration, frontier identification, and future trend</article-title><source>Sci Total Environ</source><year>2022</year><volume>818</volume><fpage>151774</fpage><pub-id pub-id-type="pmid">34801502</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.scitotenv.2021.151774</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">Qin F, Li J, Zhang C, et al. Biochar in the 21st century: A data-driven visualization of collaboration, frontier identification, and future trend. Sci Total Environ. 2022;818:151774.<pub-id pub-id-type="pmid">34801502</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.scitotenv.2021.151774</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>YG</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>ST</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Worldwide productivity and research trend of publications concerning tumor immune microenvironment (TIME): a bibliometric study</article-title><source>Eur J Med Res</source><year>2023</year><volume>28</volume><fpage>229</fpage><pub-id pub-id-type="pmid">37430294</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40001-023-01195-3</pub-id><pub-id pub-id-type="pmcid">PMC10332017</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Liu YG, Jiang ST, Zhang L, et al. Worldwide productivity and research trend of publications concerning tumor immune microenvironment (TIME): a bibliometric study. Eur J Med Res. 2023;28:229.<pub-id pub-id-type="pmid">37430294</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40001-023-01195-3</pub-id><pub-id pub-id-type="pmcid">PMC10332017</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name></person-group><article-title>Searching for intellectual turning points: progressive knowledge domain visualization</article-title><source>Proc Natl Acad Sci U S A</source><year>2004</year><volume>101</volume><issue>Suppl 1</issue><fpage>5303</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">14724295</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0307513100</pub-id><pub-id pub-id-type="pmcid">PMC387312</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Chen C. Searching for intellectual turning points: progressive knowledge domain visualization. Proc Natl Acad Sci U S A. 2004;101(Suppl 1):5303&#8211;10.<pub-id pub-id-type="pmid">14724295</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0307513100</pub-id><pub-id pub-id-type="pmcid">PMC387312</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name><name name-style="western"><surname>CiteSpace</surname><given-names>II</given-names></name></person-group><article-title>Detecting and visualizing emerging trends and transient patterns in scientific literature</article-title><source>J Am Soc Inform Sci Technol</source><year>2006</year><volume>57</volume><fpage>359</fpage><lpage>77</lpage></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Chen C, CiteSpace II. Detecting and visualizing emerging trends and transient patterns in scientific literature. J Am Soc Inform Sci Technol. 2006;57:359&#8211;77.</mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><etal/></person-group><article-title>Emerging trends in regenerative medicine: a scientometric analysis in CiteSpace</article-title><source>Expert Opin Biol Ther</source><year>2012</year><volume>12</volume><fpage>593</fpage><lpage>608</lpage><pub-id pub-id-type="pmid">22443895</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/14712598.2012.674507</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">Chen C, Hu Z, Liu S, et al. Emerging trends in regenerative medicine: a scientometric analysis in CiteSpace. Expert Opin Biol Ther. 2012;12:593&#8211;608.<pub-id pub-id-type="pmid">22443895</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/14712598.2012.674507</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name></person-group><article-title>Science mapping: a systematic review of the literature</article-title><source>J Data Inform Sci</source><year>2017</year><volume>2</volume><fpage>1</fpage><lpage>40</lpage></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Chen C. Science mapping: a systematic review of the literature. J Data Inform Sci. 2017;2:1&#8211;40.</mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>H</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>K</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Mapping knowledge structure and themes trends of osteoporosis in rheumatoid arthritis: A bibliometric analysis</article-title><source>Front Med (Lausanne)</source><year>2021</year><volume>8</volume><fpage>787228</fpage><pub-id pub-id-type="pmid">34888333</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmed.2021.787228</pub-id><pub-id pub-id-type="pmcid">PMC8650090</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Wu H, Cheng K, Guo Q, et al. Mapping knowledge structure and themes trends of osteoporosis in rheumatoid arthritis: A bibliometric analysis. Front Med (Lausanne). 2021;8:787228.<pub-id pub-id-type="pmid">34888333</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmed.2021.787228</pub-id><pub-id pub-id-type="pmcid">PMC8650090</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Romero</surname><given-names>L</given-names></name><name name-style="western"><surname>Portillo-Salido</surname><given-names>E</given-names></name></person-group><article-title>Trends in Sigma-1 receptor research: A 25-Year bibliometric analysis</article-title><source>Front Pharmacol</source><year>2019</year><volume>10</volume><fpage>564</fpage><pub-id pub-id-type="pmid">31178733</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2019.00564</pub-id><pub-id pub-id-type="pmcid">PMC6543269</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Romero L, Portillo-Salido E. Trends in Sigma-1 receptor research: A 25-Year bibliometric analysis. Front Pharmacol. 2019;10:564.<pub-id pub-id-type="pmid">31178733</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2019.00564</pub-id><pub-id pub-id-type="pmcid">PMC6543269</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S</given-names></name><name name-style="western"><surname>Chan</surname><given-names>CY</given-names></name><etal/></person-group><article-title>Visualization analysis of intelligent vehicles research field based on mapping knowledge domain</article-title><source>IEEE Trans Intell Transp Syst</source><year>2021</year><volume>22</volume><fpage>5721</fpage><lpage>36</lpage></element-citation><mixed-citation id="mc-CR71" publication-type="journal">He Y, Yang S, Chan CY, et al. Visualization analysis of intelligent vehicles research field based on mapping knowledge domain. IEEE Trans Intell Transp Syst. 2021;22:5721&#8211;36.</mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harari</surname><given-names>D</given-names></name><name name-style="western"><surname>Yarden</surname><given-names>Y</given-names></name></person-group><article-title>Molecular mechanisms underlying ErbB2/HER2 action in breast cancer</article-title><source>Oncogene</source><year>2000</year><volume>19</volume><fpage>6102</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">11156523</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.onc.1203973</pub-id></element-citation><mixed-citation id="mc-CR72" publication-type="journal">Harari D, Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene. 2000;19:6102&#8211;14.<pub-id pub-id-type="pmid">11156523</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.onc.1203973</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>M</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T</given-names></name><name name-style="western"><surname>Shi</surname><given-names>C</given-names></name><etal/></person-group><article-title>Bioconjugated manganese dioxide nanoparticles enhance chemotherapy response by priming tumor-Associated macrophages toward M1-like phenotype and attenuating tumor hypoxia</article-title><source>ACS Nano</source><year>2016</year><volume>10</volume><fpage>633</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">26650065</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.5b06779</pub-id><pub-id pub-id-type="pmcid">PMC5242343</pub-id></element-citation><mixed-citation id="mc-CR73" publication-type="journal">Song M, Liu T, Shi C, et al. Bioconjugated manganese dioxide nanoparticles enhance chemotherapy response by priming tumor-Associated macrophages toward M1-like phenotype and attenuating tumor hypoxia. ACS Nano. 2016;10:633&#8211;47.<pub-id pub-id-type="pmid">26650065</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.5b06779</pub-id><pub-id pub-id-type="pmcid">PMC5242343</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knuefermann</surname><given-names>C</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B</given-names></name><etal/></person-group><article-title>HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells</article-title><source>Oncogene</source><year>2003</year><volume>22</volume><fpage>3205</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">12761490</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.onc.1206394</pub-id></element-citation><mixed-citation id="mc-CR74" publication-type="journal">Knuefermann C, Lu Y, Liu B, et al. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene. 2003;22:3205&#8211;12.<pub-id pub-id-type="pmid">12761490</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.onc.1206394</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siegel</surname><given-names>RL</given-names></name><name name-style="western"><surname>Miller</surname><given-names>KD</given-names></name><name name-style="western"><surname>Fuchs</surname><given-names>HE</given-names></name><etal/></person-group><article-title>Cancer statistics, 2021</article-title><source>CA Cancer J Clin</source><year>2021</year><volume>71</volume><fpage>7</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">33433946</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21654</pub-id></element-citation><mixed-citation id="mc-CR75" publication-type="journal">Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7&#8211;33.<pub-id pub-id-type="pmid">33433946</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21654</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bianchini</surname><given-names>G</given-names></name><name name-style="western"><surname>Balko</surname><given-names>JM</given-names></name><name name-style="western"><surname>Mayer</surname><given-names>IA</given-names></name><etal/></person-group><article-title>Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease</article-title><source>Nat Rev Clin Oncol</source><year>2016</year><volume>13</volume><fpage>674</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">27184417</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrclinonc.2016.66</pub-id><pub-id pub-id-type="pmcid">PMC5461122</pub-id></element-citation><mixed-citation id="mc-CR76" publication-type="journal">Bianchini G, Balko JM, Mayer IA, et al. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13:674&#8211;90.<pub-id pub-id-type="pmid">27184417</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrclinonc.2016.66</pub-id><pub-id pub-id-type="pmcid">PMC5461122</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nedeljkovi&#263;</surname><given-names>M</given-names></name><name name-style="western"><surname>Damjanovi&#263;</surname><given-names>A</given-names></name></person-group><article-title>Mechanisms of chemotherapy resistance in Triple-Negative breast cancer-How we can rise to the challenge</article-title><source>Cells</source><year>2019</year><volume>8</volume><fpage>957</fpage><pub-id pub-id-type="pmid">31443516</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells8090957</pub-id><pub-id pub-id-type="pmcid">PMC6770896</pub-id></element-citation><mixed-citation id="mc-CR77" publication-type="journal">Nedeljkovi&#263; M, Damjanovi&#263; A. Mechanisms of chemotherapy resistance in Triple-Negative breast cancer-How we can rise to the challenge. Cells. 2019;8:957.<pub-id pub-id-type="pmid">31443516</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells8090957</pub-id><pub-id pub-id-type="pmcid">PMC6770896</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harbeck</surname><given-names>N</given-names></name><name name-style="western"><surname>Penault-Llorca</surname><given-names>F</given-names></name><name name-style="western"><surname>Cortes</surname><given-names>J</given-names></name><etal/></person-group><article-title>Breast cancer</article-title><source>Nat Rev Dis Primers</source><year>2019</year><volume>5</volume><fpage>66</fpage><pub-id pub-id-type="pmid">31548545</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41572-019-0111-2</pub-id></element-citation><mixed-citation id="mc-CR78" publication-type="journal">Harbeck N, Penault-Llorca F, Cortes J, et al. Breast cancer. Nat Rev Dis Primers. 2019;5:66.<pub-id pub-id-type="pmid">31548545</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41572-019-0111-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>L</given-names></name><name name-style="western"><surname>Duan</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Bian</surname><given-names>XW</given-names></name><etal/></person-group><article-title>Triple-negative breast cancer molecular subtyping and treatment progress</article-title><source>Breast Cancer Res</source><year>2020</year><volume>22</volume><fpage>61</fpage><pub-id pub-id-type="pmid">32517735</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13058-020-01296-5</pub-id><pub-id pub-id-type="pmcid">PMC7285581</pub-id></element-citation><mixed-citation id="mc-CR79" publication-type="journal">Yin L, Duan JJ, Bian XW, et al. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020;22:61.<pub-id pub-id-type="pmid">32517735</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13058-020-01296-5</pub-id><pub-id pub-id-type="pmcid">PMC7285581</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cosentino</surname><given-names>G</given-names></name><name name-style="western"><surname>Plantamura</surname><given-names>I</given-names></name><name name-style="western"><surname>Tagliabue</surname><given-names>E</given-names></name><etal/></person-group><article-title>Breast cancer drug resistance: overcoming the challenge by capitalizing on MicroRNA and tumor microenvironment interplay</article-title><source>Cancers (Basel)</source><year>2021</year><volume>13</volume><fpage>3691</fpage><pub-id pub-id-type="pmid">34359591</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers13153691</pub-id><pub-id pub-id-type="pmcid">PMC8345203</pub-id></element-citation><mixed-citation id="mc-CR80" publication-type="journal">Cosentino G, Plantamura I, Tagliabue E, et al. Breast cancer drug resistance: overcoming the challenge by capitalizing on MicroRNA and tumor microenvironment interplay. Cancers (Basel). 2021;13:3691.<pub-id pub-id-type="pmid">34359591</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers13153691</pub-id><pub-id pub-id-type="pmcid">PMC8345203</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saha</surname><given-names>T</given-names></name><name name-style="western"><surname>Solomon</surname><given-names>J</given-names></name><name name-style="western"><surname>Samson</surname><given-names>AO</given-names></name><etal/></person-group><article-title>Invasion and metastasis as a central hallmark of breast cancer</article-title><source>J Clin Med</source><year>2021</year><volume>10</volume><fpage>3498</fpage><pub-id pub-id-type="pmid">34441794</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm10163498</pub-id><pub-id pub-id-type="pmcid">PMC8396853</pub-id></element-citation><mixed-citation id="mc-CR81" publication-type="journal">Saha T, Solomon J, Samson AO, et al. Invasion and metastasis as a central hallmark of breast cancer. J Clin Med. 2021;10:3498.<pub-id pub-id-type="pmid">34441794</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm10163498</pub-id><pub-id pub-id-type="pmcid">PMC8396853</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR82"><label>82.</label><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siegel</surname><given-names>RL</given-names></name><name name-style="western"><surname>Miller</surname><given-names>KD</given-names></name><name name-style="western"><surname>Wagle</surname><given-names>NS</given-names></name><etal/></person-group><article-title>Cancer statistics, 2023</article-title><source>CA Cancer J Clin</source><year>2023</year><volume>73</volume><fpage>17</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">36633525</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21763</pub-id></element-citation><mixed-citation id="mc-CR82" publication-type="journal">Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17&#8211;48.<pub-id pub-id-type="pmid">36633525</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21763</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR83"><label>83.</label><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Song</surname><given-names>X</given-names></name><etal/></person-group><article-title>Metastatic heterogeneity of breast cancer: molecular mechanism and potential therapeutic targets</article-title><source>Semin Cancer Biol</source><year>2020</year><volume>60</volume><fpage>14</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">31421262</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.semcancer.2019.08.012</pub-id></element-citation><mixed-citation id="mc-CR83" publication-type="journal">Liang Y, Zhang H, Song X, et al. Metastatic heterogeneity of breast cancer: molecular mechanism and potential therapeutic targets. Semin Cancer Biol. 2020;60:14&#8211;27.<pub-id pub-id-type="pmid">31421262</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.semcancer.2019.08.012</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR84"><label>84.</label><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harbeck</surname><given-names>N</given-names></name><name name-style="western"><surname>Gnant</surname><given-names>M</given-names></name></person-group><article-title>Breast cancer</article-title><source>Lancet</source><year>2017</year><volume>389</volume><fpage>1134</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">27865536</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(16)31891-8</pub-id></element-citation><mixed-citation id="mc-CR84" publication-type="journal">Harbeck N, Gnant M. Breast cancer. Lancet. 2017;389:1134&#8211;50.<pub-id pub-id-type="pmid">27865536</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(16)31891-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR85"><label>85.</label><citation-alternatives><element-citation id="ec-CR85" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Esteva</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Hubbard-Lucey</surname><given-names>VM</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Immunotherapy and targeted therapy combinations in metastatic breast cancer</article-title><source>Lancet Oncol</source><year>2019</year><volume>20</volume><fpage>e175</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">30842061</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(19)30026-9</pub-id></element-citation><mixed-citation id="mc-CR85" publication-type="journal">Esteva FJ, Hubbard-Lucey VM, Tang J, et al. Immunotherapy and targeted therapy combinations in metastatic breast cancer. Lancet Oncol. 2019;20:e175&#8211;86.<pub-id pub-id-type="pmid">30842061</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(19)30026-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR86"><label>86.</label><citation-alternatives><element-citation id="ec-CR86" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Masoud</surname><given-names>V</given-names></name><name name-style="western"><surname>Pag&#232;s</surname><given-names>G</given-names></name></person-group><article-title>Targeted therapies in breast cancer: new challenges to fight against resistance</article-title><source>World J Clin Oncol</source><year>2017</year><volume>8</volume><fpage>120</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">28439493</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5306/wjco.v8.i2.120</pub-id><pub-id pub-id-type="pmcid">PMC5385433</pub-id></element-citation><mixed-citation id="mc-CR86" publication-type="journal">Masoud V, Pag&#232;s G. Targeted therapies in breast cancer: new challenges to fight against resistance. World J Clin Oncol. 2017;8:120&#8211;34.<pub-id pub-id-type="pmid">28439493</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5306/wjco.v8.i2.120</pub-id><pub-id pub-id-type="pmcid">PMC5385433</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR87"><label>87.</label><citation-alternatives><element-citation id="ec-CR87" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>An</surname><given-names>J</given-names></name><name name-style="western"><surname>Peng</surname><given-names>C</given-names></name><name name-style="western"><surname>Tang</surname><given-names>H</given-names></name><etal/></person-group><article-title>New advances in the research of resistance to neoadjuvant chemotherapy in breast cancer</article-title><source>Int J Mol Sci</source><year>2021</year><volume>22</volume><fpage>9644</fpage><pub-id pub-id-type="pmid">34502549</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms22179644</pub-id><pub-id pub-id-type="pmcid">PMC8431789</pub-id></element-citation><mixed-citation id="mc-CR87" publication-type="journal">An J, Peng C, Tang H, et al. New advances in the research of resistance to neoadjuvant chemotherapy in breast cancer. Int J Mol Sci. 2021;22:9644.<pub-id pub-id-type="pmid">34502549</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms22179644</pub-id><pub-id pub-id-type="pmcid">PMC8431789</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR88"><label>88.</label><citation-alternatives><element-citation id="ec-CR88" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kimbung</surname><given-names>S</given-names></name><name name-style="western"><surname>Loman</surname><given-names>N</given-names></name><name name-style="western"><surname>Hedenfalk</surname><given-names>I</given-names></name></person-group><article-title>Clinical and molecular complexity of breast cancer metastases</article-title><source>Semin Cancer Biol</source><year>2015</year><volume>35</volume><fpage>85</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">26319607</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.semcancer.2015.08.009</pub-id></element-citation><mixed-citation id="mc-CR88" publication-type="journal">Kimbung S, Loman N, Hedenfalk I. Clinical and molecular complexity of breast cancer metastases. Semin Cancer Biol. 2015;35:85&#8211;95.<pub-id pub-id-type="pmid">26319607</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.semcancer.2015.08.009</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR89"><label>89.</label><citation-alternatives><element-citation id="ec-CR89" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cai</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Xie</surname><given-names>W</given-names></name><etal/></person-group><article-title>Identification of a basement membrane-related gene signature for predicting prognosis and estimating the tumor immune microenvironment in breast cancer</article-title><source>Front Endocrinol (Lausanne)</source><year>2022</year><volume>13</volume><fpage>1065530</fpage><pub-id pub-id-type="pmid">36531485</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fendo.2022.1065530</pub-id><pub-id pub-id-type="pmcid">PMC9751030</pub-id></element-citation><mixed-citation id="mc-CR89" publication-type="journal">Cai J, Zhang X, Xie W, et al. Identification of a basement membrane-related gene signature for predicting prognosis and estimating the tumor immune microenvironment in breast cancer. Front Endocrinol (Lausanne). 2022;13:1065530.<pub-id pub-id-type="pmid">36531485</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fendo.2022.1065530</pub-id><pub-id pub-id-type="pmcid">PMC9751030</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR90"><label>90.</label><citation-alternatives><element-citation id="ec-CR90" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saha</surname><given-names>T</given-names></name><name name-style="western"><surname>Lukong</surname><given-names>KE</given-names></name></person-group><article-title>Breast cancer Stem-Like cells in drug resistance: A review of mechanisms and novel therapeutic strategies to overcome drug resistance</article-title><source>Front Oncol</source><year>2022</year><volume>12</volume><fpage>856974</fpage><pub-id pub-id-type="pmid">35392236</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2022.856974</pub-id><pub-id pub-id-type="pmcid">PMC8979779</pub-id></element-citation><mixed-citation id="mc-CR90" publication-type="journal">Saha T, Lukong KE. Breast cancer Stem-Like cells in drug resistance: A review of mechanisms and novel therapeutic strategies to overcome drug resistance. Front Oncol. 2022;12:856974.<pub-id pub-id-type="pmid">35392236</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2022.856974</pub-id><pub-id pub-id-type="pmcid">PMC8979779</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR91"><label>91.</label><citation-alternatives><element-citation id="ec-CR91" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>Y</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Identification of Immune-Related breast cancer chemotherapy resistance genes via bioinformatics approaches</article-title><source>Front Oncol</source><year>2022</year><volume>12</volume><fpage>772723</fpage><pub-id pub-id-type="pmid">35387129</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2022.772723</pub-id><pub-id pub-id-type="pmcid">PMC8978268</pub-id></element-citation><mixed-citation id="mc-CR91" publication-type="journal">Du Y, Han Y, Wang X, et al. Identification of Immune-Related breast cancer chemotherapy resistance genes via bioinformatics approaches. Front Oncol. 2022;12:772723.<pub-id pub-id-type="pmid">35387129</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2022.772723</pub-id><pub-id pub-id-type="pmcid">PMC8978268</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR92"><label>92.</label><citation-alternatives><element-citation id="ec-CR92" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saha Detroja</surname><given-names>T</given-names></name><name name-style="western"><surname>Detroja</surname><given-names>R</given-names></name><name name-style="western"><surname>Mukherjee</surname><given-names>S</given-names></name><etal/></person-group><article-title>Identifying hub genes associated with neoadjuvant chemotherapy resistance in breast cancer and potential drug repurposing for the development of precision medicine</article-title><source>Int J Mol Sci</source><year>2022</year><volume>23</volume><fpage>12628</fpage><pub-id pub-id-type="pmid">36293493</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms232012628</pub-id><pub-id pub-id-type="pmcid">PMC9603969</pub-id></element-citation><mixed-citation id="mc-CR92" publication-type="journal">Saha Detroja T, Detroja R, Mukherjee S, et al. Identifying hub genes associated with neoadjuvant chemotherapy resistance in breast cancer and potential drug repurposing for the development of precision medicine. Int J Mol Sci. 2022;23:12628.<pub-id pub-id-type="pmid">36293493</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms232012628</pub-id><pub-id pub-id-type="pmcid">PMC9603969</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR93"><label>93.</label><citation-alternatives><element-citation id="ec-CR93" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garfield</surname><given-names>E</given-names></name></person-group><article-title>The history and meaning of the journal impact factor</article-title><source>JAMA</source><year>2006</year><volume>295</volume><fpage>90</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">16391221</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.295.1.90</pub-id></element-citation><mixed-citation id="mc-CR93" publication-type="journal">Garfield E. The history and meaning of the journal impact factor. JAMA. 2006;295:90&#8211;3.<pub-id pub-id-type="pmid">16391221</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.295.1.90</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR94"><label>94.</label><citation-alternatives><element-citation id="ec-CR94" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>S</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Research on liquid biopsy for cancer: A bibliometric analysis</article-title><source>Heliyon</source><year>2023</year><volume>9</volume><fpage>e14145</fpage><pub-id pub-id-type="pmid">36915518</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.heliyon.2023.e14145</pub-id><pub-id pub-id-type="pmcid">PMC10006671</pub-id></element-citation><mixed-citation id="mc-CR94" publication-type="journal">Jiang S, Liu Y, Xu Y, et al. Research on liquid biopsy for cancer: A bibliometric analysis. Heliyon. 2023;9:e14145.<pub-id pub-id-type="pmid">36915518</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.heliyon.2023.e14145</pub-id><pub-id pub-id-type="pmcid">PMC10006671</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR95"><label>95.</label><citation-alternatives><element-citation id="ec-CR95" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Desai</surname><given-names>N</given-names></name><name name-style="western"><surname>Veras</surname><given-names>L</given-names></name><name name-style="western"><surname>Gosain</surname><given-names>A</given-names></name></person-group><article-title>Using bradford&#8217;s law of scattering to identify the core journals of pediatric surgery</article-title><source>J Surg Res</source><year>2018</year><volume>229</volume><fpage>90</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">29937022</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jss.2018.03.062</pub-id></element-citation><mixed-citation id="mc-CR95" publication-type="journal">Desai N, Veras L, Gosain A. Using bradford&#8217;s law of scattering to identify the core journals of pediatric surgery. J Surg Res. 2018;229:90&#8211;5.<pub-id pub-id-type="pmid">29937022</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jss.2018.03.062</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR96"><label>96.</label><citation-alternatives><element-citation id="ec-CR96" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akalin</surname><given-names>PK</given-names></name></person-group><article-title>Introduction to bioinformatics</article-title><source>Mol Nutr Food Res</source><year>2006</year><volume>50</volume><fpage>610</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">16810733</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mnfr.200500273</pub-id></element-citation><mixed-citation id="mc-CR96" publication-type="journal">Akalin PK. Introduction to bioinformatics. Mol Nutr Food Res. 2006;50:610&#8211;9.<pub-id pub-id-type="pmid">16810733</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mnfr.200500273</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR97"><label>97.</label><citation-alternatives><element-citation id="ec-CR97" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gauthier</surname><given-names>J</given-names></name><name name-style="western"><surname>Vincent</surname><given-names>AT</given-names></name><name name-style="western"><surname>Charette</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>A brief history of bioinformatics</article-title><source>Brief Bioinform</source><year>2019</year><volume>20</volume><fpage>1981</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">30084940</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bib/bby063</pub-id></element-citation><mixed-citation id="mc-CR97" publication-type="journal">Gauthier J, Vincent AT, Charette SJ, et al. A brief history of bioinformatics. Brief Bioinform. 2019;20:1981&#8211;96.<pub-id pub-id-type="pmid">30084940</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bib/bby063</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR98"><label>98.</label><citation-alternatives><element-citation id="ec-CR98" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Canzoneri</surname><given-names>R</given-names></name><name name-style="western"><surname>Lacunza</surname><given-names>E</given-names></name><name name-style="western"><surname>Abba</surname><given-names>MC</given-names></name></person-group><article-title>Genomics and bioinformatics as pillars of precision medicine in oncology</article-title><source>Med (B Aires)</source><year>2019</year><volume>79</volume><fpage>587</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">31864231</pub-id></element-citation><mixed-citation id="mc-CR98" publication-type="journal">Canzoneri R, Lacunza E, Abba MC. Genomics and bioinformatics as pillars of precision medicine in oncology. Med (B Aires). 2019;79:587&#8211;92.<pub-id pub-id-type="pmid">31864231</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR99"><label>99.</label><citation-alternatives><element-citation id="ec-CR99" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thind</surname><given-names>AS</given-names></name><name name-style="western"><surname>Monga</surname><given-names>I</given-names></name><name name-style="western"><surname>Thakur</surname><given-names>PK</given-names></name><etal/></person-group><article-title>Demystifying emerging bulk RNA-Seq applications: the application and utility of bioinformatic methodology</article-title><source>Brief Bioinform</source><year>2021</year><volume>22</volume><fpage>bbab259</fpage><pub-id pub-id-type="pmid">34329375</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bib/bbab259</pub-id></element-citation><mixed-citation id="mc-CR99" publication-type="journal">Thind AS, Monga I, Thakur PK, et al. Demystifying emerging bulk RNA-Seq applications: the application and utility of bioinformatic methodology. Brief Bioinform. 2021;22:bbab259.<pub-id pub-id-type="pmid">34329375</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bib/bbab259</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR100"><label>100.</label><citation-alternatives><element-citation id="ec-CR100" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hephzibah Cathryn</surname><given-names>R</given-names></name><name name-style="western"><surname>Udhaya Kumar</surname><given-names>S</given-names></name><name name-style="western"><surname>Younes</surname><given-names>S</given-names></name><etal/></person-group><article-title>A review of bioinformatics tools and web servers in different microarray platforms used in cancer research</article-title><source>Adv Protein Chem Struct Biol</source><year>2022</year><volume>131</volume><fpage>85</fpage><lpage>164</lpage><pub-id pub-id-type="pmid">35871897</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/bs.apcsb.2022.05.002</pub-id></element-citation><mixed-citation id="mc-CR100" publication-type="journal">Hephzibah Cathryn R, Udhaya Kumar S, Younes S, et al. A review of bioinformatics tools and web servers in different microarray platforms used in cancer research. Adv Protein Chem Struct Biol. 2022;131:85&#8211;164.<pub-id pub-id-type="pmid">35871897</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/bs.apcsb.2022.05.002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR101"><label>101.</label><citation-alternatives><element-citation id="ec-CR101" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>R</given-names></name><name name-style="western"><surname>Kaur</surname><given-names>G</given-names></name><name name-style="western"><surname>Bansal</surname><given-names>P</given-names></name><etal/></person-group><article-title>Bioinformatics paradigms in drug discovery and drug development</article-title><source>Curr Top Med Chem</source><year>2023</year><volume>23</volume><fpage>579</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">36582059</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1568026623666221229113456</pub-id></element-citation><mixed-citation id="mc-CR101" publication-type="journal">Sharma R, Kaur G, Bansal P, et al. Bioinformatics paradigms in drug discovery and drug development. Curr Top Med Chem. 2023;23:579&#8211;88.<pub-id pub-id-type="pmid">36582059</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1568026623666221229113456</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR102"><label>102.</label><citation-alternatives><element-citation id="ec-CR102" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marcotte</surname><given-names>R</given-names></name><name name-style="western"><surname>Sayad</surname><given-names>A</given-names></name><name name-style="western"><surname>Brown</surname><given-names>KR</given-names></name><etal/></person-group><article-title>Functional genomic landscape of human breast cancer drivers, vulnerabilities, and resistance</article-title><source>Cell</source><year>2016</year><volume>164</volume><fpage>293</fpage><lpage>309</lpage><pub-id pub-id-type="pmid">26771497</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2015.11.062</pub-id><pub-id pub-id-type="pmcid">PMC4724865</pub-id></element-citation><mixed-citation id="mc-CR102" publication-type="journal">Marcotte R, Sayad A, Brown KR, et al. Functional genomic landscape of human breast cancer drivers, vulnerabilities, and resistance. Cell. 2016;164:293&#8211;309.<pub-id pub-id-type="pmid">26771497</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2015.11.062</pub-id><pub-id pub-id-type="pmcid">PMC4724865</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR103"><label>103.</label><citation-alternatives><element-citation id="ec-CR103" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>J</given-names></name><name name-style="western"><surname>Tan</surname><given-names>L</given-names></name><name name-style="western"><surname>Yin</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Bioinformatics analysis identifies potential chemoresistance-associated genes across multiple types of cancer</article-title><source>Oncol Lett</source><year>2019</year><volume>18</volume><fpage>2576</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">31402953</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ol.2019.10533</pub-id><pub-id pub-id-type="pmcid">PMC6676748</pub-id></element-citation><mixed-citation id="mc-CR103" publication-type="journal">Yuan J, Tan L, Yin Z, et al. Bioinformatics analysis identifies potential chemoresistance-associated genes across multiple types of cancer. Oncol Lett. 2019;18:2576&#8211;83.<pub-id pub-id-type="pmid">31402953</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ol.2019.10533</pub-id><pub-id pub-id-type="pmcid">PMC6676748</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR104"><label>104.</label><citation-alternatives><element-citation id="ec-CR104" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cha</surname><given-names>HK</given-names></name><name name-style="western"><surname>Cheon</surname><given-names>S</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H</given-names></name><etal/></person-group><article-title>Discovery of proteins responsible for resistance to three chemotherapy drugs in breast cancer cells using proteomics and bioinformatics analysis</article-title><source>Molecules</source><year>2022</year><volume>27</volume><fpage>1762</fpage><pub-id pub-id-type="pmid">35335125</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/molecules27061762</pub-id><pub-id pub-id-type="pmcid">PMC8954867</pub-id></element-citation><mixed-citation id="mc-CR104" publication-type="journal">Cha HK, Cheon S, Kim H, et al. Discovery of proteins responsible for resistance to three chemotherapy drugs in breast cancer cells using proteomics and bioinformatics analysis. Molecules. 2022;27:1762.<pub-id pub-id-type="pmid">35335125</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/molecules27061762</pub-id><pub-id pub-id-type="pmcid">PMC8954867</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR105"><label>105.</label><citation-alternatives><element-citation id="ec-CR105" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>Q</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Z</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X</given-names></name><etal/></person-group><article-title>miR-26b-5p suppresses chemoresistance in breast cancer by targeting serglycin</article-title><source>Anticancer Drugs</source><year>2022</year><volume>33</volume><fpage>308</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">34924500</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CAD.0000000000001268</pub-id><pub-id pub-id-type="pmcid">PMC8812413</pub-id></element-citation><mixed-citation id="mc-CR105" publication-type="journal">Du Q, Yuan Z, Huang X, et al. miR-26b-5p suppresses chemoresistance in breast cancer by targeting serglycin. Anticancer Drugs. 2022;33:308&#8211;19.<pub-id pub-id-type="pmid">34924500</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CAD.0000000000001268</pub-id><pub-id pub-id-type="pmcid">PMC8812413</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR106"><label>106.</label><citation-alternatives><element-citation id="ec-CR106" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cui</surname><given-names>C</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><etal/></person-group><article-title>Functions and mechanisms of circular RNAs in cancer radiotherapy and chemotherapy resistance</article-title><source>Mol Cancer</source><year>2020</year><volume>19</volume><fpage>58</fpage><pub-id pub-id-type="pmid">32171304</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12943-020-01180-y</pub-id><pub-id pub-id-type="pmcid">PMC7071709</pub-id></element-citation><mixed-citation id="mc-CR106" publication-type="journal">Cui C, Yang J, Li X, et al. Functions and mechanisms of circular RNAs in cancer radiotherapy and chemotherapy resistance. Mol Cancer. 2020;19:58.<pub-id pub-id-type="pmid">32171304</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12943-020-01180-y</pub-id><pub-id pub-id-type="pmcid">PMC7071709</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR107"><label>107.</label><citation-alternatives><element-citation id="ec-CR107" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanger</surname><given-names>HL</given-names></name><name name-style="western"><surname>Klotz</surname><given-names>G</given-names></name><name name-style="western"><surname>Riesner</surname><given-names>D</given-names></name><etal/></person-group><article-title>Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures</article-title><source>Proc Natl Acad Sci U S A</source><year>1976</year><volume>73</volume><fpage>3852</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">1069269</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.73.11.3852</pub-id><pub-id pub-id-type="pmcid">PMC431239</pub-id></element-citation><mixed-citation id="mc-CR107" publication-type="journal">Sanger HL, Klotz G, Riesner D, et al. Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures. Proc Natl Acad Sci U S A. 1976;73:3852&#8211;6.<pub-id pub-id-type="pmid">1069269</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.73.11.3852</pub-id><pub-id pub-id-type="pmcid">PMC431239</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR108"><label>108.</label><citation-alternatives><element-citation id="ec-CR108" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kolakofsky</surname><given-names>D</given-names></name></person-group><article-title>Isolation and characterization of Sendai virus DI-RNAs</article-title><source>Cell</source><year>1976</year><volume>8</volume><fpage>547</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">182384</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0092-8674(76)90223-3</pub-id></element-citation><mixed-citation id="mc-CR108" publication-type="journal">Kolakofsky D. Isolation and characterization of Sendai virus DI-RNAs. Cell. 1976;8:547&#8211;55.<pub-id pub-id-type="pmid">182384</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0092-8674(76)90223-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR109"><label>109.</label><citation-alternatives><element-citation id="ec-CR109" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsu</surname><given-names>M-T</given-names></name><name name-style="western"><surname>Coca-Prados</surname><given-names>M</given-names></name></person-group><article-title>Electron microscopic evidence for the circular form of RNA in the cytoplasm of eukaryotic cells</article-title><source>Nature</source><year>1979</year><volume>280</volume><fpage>339</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">460409</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/280339a0</pub-id></element-citation><mixed-citation id="mc-CR109" publication-type="journal">Hsu M-T, Coca-Prados M. Electron microscopic evidence for the circular form of RNA in the cytoplasm of eukaryotic cells. Nature. 1979;280:339&#8211;40.<pub-id pub-id-type="pmid">460409</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/280339a0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR110"><label>110.</label><citation-alternatives><element-citation id="ec-CR110" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cocquerelle</surname><given-names>C</given-names></name><name name-style="western"><surname>Mascrez</surname><given-names>B</given-names></name><name name-style="western"><surname>H&#233;tuin</surname><given-names>D</given-names></name><etal/></person-group><article-title>Mis-splicing yields circular RNA molecules</article-title><source>Faseb J</source><year>1993</year><volume>7</volume><fpage>155</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">7678559</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1096/fasebj.7.1.7678559</pub-id></element-citation><mixed-citation id="mc-CR110" publication-type="journal">Cocquerelle C, Mascrez B, H&#233;tuin D, et al. Mis-splicing yields circular RNA molecules. Faseb J. 1993;7:155&#8211;60.<pub-id pub-id-type="pmid">7678559</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1096/fasebj.7.1.7678559</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR111"><label>111.</label><citation-alternatives><element-citation id="ec-CR111" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dragomir</surname><given-names>M</given-names></name><name name-style="western"><surname>Calin</surname><given-names>GA</given-names></name></person-group><article-title>Circular RNAs in Cancer - Lessons learned from MicroRNAs</article-title><source>Front Oncol</source><year>2018</year><volume>8</volume><fpage>179</fpage><pub-id pub-id-type="pmid">29911069</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2018.00179</pub-id><pub-id pub-id-type="pmcid">PMC5992376</pub-id></element-citation><mixed-citation id="mc-CR111" publication-type="journal">Dragomir M, Calin GA. Circular RNAs in Cancer - Lessons learned from MicroRNAs. Front Oncol. 2018;8:179.<pub-id pub-id-type="pmid">29911069</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2018.00179</pub-id><pub-id pub-id-type="pmcid">PMC5992376</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR112"><label>112.</label><citation-alternatives><element-citation id="ec-CR112" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gao</surname><given-names>G</given-names></name><etal/></person-group><article-title>The biogenesis, function and clinical significance of circular RNAs in breast cancer</article-title><source>Cancer Biol Med</source><year>2021</year><volume>19</volume><fpage>14</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">34110722</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.20892/j.issn.2095-3941.2020.0485</pub-id><pub-id pub-id-type="pmcid">PMC8763001</pub-id></element-citation><mixed-citation id="mc-CR112" publication-type="journal">Zeng Y, Zou Y, Gao G, et al. The biogenesis, function and clinical significance of circular RNAs in breast cancer. Cancer Biol Med. 2021;19:14&#8211;29.<pub-id pub-id-type="pmid">34110722</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.20892/j.issn.2095-3941.2020.0485</pub-id><pub-id pub-id-type="pmcid">PMC8763001</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR113"><label>113.</label><citation-alternatives><element-citation id="ec-CR113" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Sun</surname><given-names>D</given-names></name><name name-style="western"><surname>Pu</surname><given-names>W</given-names></name><etal/></person-group><article-title>Circular RNAs in cancer: biogenesis, function, and clinical significance</article-title><source>Trends Cancer</source><year>2020</year><volume>6</volume><fpage>319</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">32209446</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.trecan.2020.01.012</pub-id></element-citation><mixed-citation id="mc-CR113" publication-type="journal">Li J, Sun D, Pu W, et al. Circular RNAs in cancer: biogenesis, function, and clinical significance. Trends Cancer. 2020;6:319&#8211;36.<pub-id pub-id-type="pmid">32209446</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.trecan.2020.01.012</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR114"><label>114.</label><citation-alternatives><element-citation id="ec-CR114" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kristensen</surname><given-names>LS</given-names></name><name name-style="western"><surname>Jakobsen</surname><given-names>T</given-names></name><name name-style="western"><surname>Hager</surname><given-names>H</given-names></name><etal/></person-group><article-title>The emerging roles of circrnas in cancer and oncology</article-title><source>Nat Rev Clin Oncol</source><year>2022</year><volume>19</volume><fpage>188</fpage><lpage>206</lpage><pub-id pub-id-type="pmid">34912049</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41571-021-00585-y</pub-id></element-citation><mixed-citation id="mc-CR114" publication-type="journal">Kristensen LS, Jakobsen T, Hager H, et al. The emerging roles of circrnas in cancer and oncology. Nat Rev Clin Oncol. 2022;19:188&#8211;206.<pub-id pub-id-type="pmid">34912049</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41571-021-00585-y</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR115"><label>115.</label><citation-alternatives><element-citation id="ec-CR115" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>LL</given-names></name></person-group><article-title>The biogenesis and emerging roles of circular RNAs</article-title><source>Nat Rev Mol Cell Biol</source><year>2016</year><volume>17</volume><fpage>205</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">26908011</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrm.2015.32</pub-id></element-citation><mixed-citation id="mc-CR115" publication-type="journal">Chen LL. The biogenesis and emerging roles of circular RNAs. Nat Rev Mol Cell Biol. 2016;17:205&#8211;11.<pub-id pub-id-type="pmid">26908011</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrm.2015.32</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR116"><label>116.</label><citation-alternatives><element-citation id="ec-CR116" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B</given-names></name><etal/></person-group><article-title>Screening circular RNA related to chemotherapeutic resistance in breast cancer</article-title><source>Epigenomics</source><year>2017</year><volume>9</volume><fpage>1175</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">28803498</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2217/epi-2017-0055</pub-id></element-citation><mixed-citation id="mc-CR116" publication-type="journal">Gao D, Zhang X, Liu B, et al. Screening circular RNA related to chemotherapeutic resistance in breast cancer. Epigenomics. 2017;9:1175&#8211;88.<pub-id pub-id-type="pmid">28803498</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2217/epi-2017-0055</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR117"><label>117.</label><citation-alternatives><element-citation id="ec-CR117" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L</given-names></name><etal/></person-group><article-title>Circular RNA&#8211;MTO1 suppresses breast cancer cell viability and reverses monastrol resistance through regulating the TRAF4/Eg5 axis</article-title><source>Int J Oncol</source><year>2018</year><volume>53</volume><fpage>1752</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">30015883</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ijo.2018.4485</pub-id></element-citation><mixed-citation id="mc-CR117" publication-type="journal">Liu Y, Dong Y, Zhao L, et al. Circular RNA&#8211;MTO1 suppresses breast cancer cell viability and reverses monastrol resistance through regulating the TRAF4/Eg5 axis. Int J Oncol. 2018;53:1752&#8211;62.<pub-id pub-id-type="pmid">30015883</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ijo.2018.4485</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR118"><label>118.</label><citation-alternatives><element-citation id="ec-CR118" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rastgoo</surname><given-names>N</given-names></name><name name-style="western"><surname>Abdi</surname><given-names>J</given-names></name><name name-style="western"><surname>Hou</surname><given-names>J</given-names></name><etal/></person-group><article-title>Role of epigenetics-microRNA axis in drug resistance of multiple myeloma</article-title><source>J Hematol Oncol</source><year>2017</year><volume>10</volume><fpage>121</fpage><pub-id pub-id-type="pmid">28623912</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13045-017-0492-1</pub-id><pub-id pub-id-type="pmcid">PMC5474298</pub-id></element-citation><mixed-citation id="mc-CR118" publication-type="journal">Rastgoo N, Abdi J, Hou J, et al. Role of epigenetics-microRNA axis in drug resistance of multiple myeloma. J Hematol Oncol. 2017;10:121.<pub-id pub-id-type="pmid">28623912</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13045-017-0492-1</pub-id><pub-id pub-id-type="pmcid">PMC5474298</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR119"><label>119.</label><citation-alternatives><element-citation id="ec-CR119" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J</given-names></name><etal/></person-group><article-title>Role of long non-coding RNA in tumor drug resistance</article-title><source>Tumour Biol</source><year>2016</year><volume>37</volume><fpage>11623</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">27380056</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13277-016-5125-8</pub-id></element-citation><mixed-citation id="mc-CR119" publication-type="journal">Deng H, Zhang J, Shi J, et al. Role of long non-coding RNA in tumor drug resistance. Tumour Biol. 2016;37:11623&#8211;31.<pub-id pub-id-type="pmid">27380056</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13277-016-5125-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR120"><label>120.</label><citation-alternatives><element-citation id="ec-CR120" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Fang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Hong</surname><given-names>M</given-names></name><etal/></person-group><article-title>Long-noncoding RNAs (lncRNAs) in drug metabolism and disposition, implications in cancer chemo-resistance</article-title><source>Acta Pharm Sin B</source><year>2020</year><volume>10</volume><fpage>105</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">31993309</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2019.09.011</pub-id><pub-id pub-id-type="pmcid">PMC6976993</pub-id></element-citation><mixed-citation id="mc-CR120" publication-type="journal">Wang Y, Fang Z, Hong M, et al. Long-noncoding RNAs (lncRNAs) in drug metabolism and disposition, implications in cancer chemo-resistance. Acta Pharm Sin B. 2020;10:105&#8211;12.<pub-id pub-id-type="pmid">31993309</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2019.09.011</pub-id><pub-id pub-id-type="pmcid">PMC6976993</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR121"><label>121.</label><citation-alternatives><element-citation id="ec-CR121" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>An</surname><given-names>X</given-names></name><name name-style="western"><surname>Sarmiento</surname><given-names>C</given-names></name><name name-style="western"><surname>Tan</surname><given-names>T</given-names></name><etal/></person-group><article-title>Regulation of multidrug resistance by MicroRNAs in anti-cancer therapy</article-title><source>Acta Pharm Sin B</source><year>2017</year><volume>7</volume><fpage>38</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">28119807</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2016.09.002</pub-id><pub-id pub-id-type="pmcid">PMC5237711</pub-id></element-citation><mixed-citation id="mc-CR121" publication-type="journal">An X, Sarmiento C, Tan T, et al. Regulation of multidrug resistance by MicroRNAs in anti-cancer therapy. Acta Pharm Sin B. 2017;7:38&#8211;51.<pub-id pub-id-type="pmid">28119807</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2016.09.002</pub-id><pub-id pub-id-type="pmcid">PMC5237711</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR122"><label>122.</label><citation-alternatives><element-citation id="ec-CR122" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>KL</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>YC</given-names></name><name name-style="western"><surname>Ho</surname><given-names>YS</given-names></name><etal/></person-group><article-title>Triple-Negative breast cancer: current Understanding and future therapeutic breakthrough targeting cancer stemness</article-title><source>Cancers (Basel)</source><year>2019</year><volume>11</volume><fpage>1334</fpage><pub-id pub-id-type="pmid">31505803</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers11091334</pub-id><pub-id pub-id-type="pmcid">PMC6769912</pub-id></element-citation><mixed-citation id="mc-CR122" publication-type="journal">Lee KL, Kuo YC, Ho YS, et al. Triple-Negative breast cancer: current Understanding and future therapeutic breakthrough targeting cancer stemness. Cancers (Basel). 2019;11:1334.<pub-id pub-id-type="pmid">31505803</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers11091334</pub-id><pub-id pub-id-type="pmcid">PMC6769912</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR123"><label>123.</label><citation-alternatives><element-citation id="ec-CR123" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Hajj</surname><given-names>M</given-names></name><name name-style="western"><surname>Wicha</surname><given-names>MS</given-names></name><name name-style="western"><surname>Benito-Hernandez</surname><given-names>A</given-names></name><etal/></person-group><article-title>Prospective identification of tumorigenic breast cancer cells</article-title><source>Proc Natl Acad Sci U S A</source><year>2003</year><volume>100</volume><fpage>3983</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">12629218</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0530291100</pub-id><pub-id pub-id-type="pmcid">PMC153034</pub-id></element-citation><mixed-citation id="mc-CR123" publication-type="journal">Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:3983&#8211;8.<pub-id pub-id-type="pmid">12629218</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0530291100</pub-id><pub-id pub-id-type="pmcid">PMC153034</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR124"><label>124.</label><citation-alternatives><element-citation id="ec-CR124" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niu</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>W</given-names></name></person-group><article-title>MicroRNA regulation of cancer stem cells in the pathogenesis of breast cancer</article-title><source>Cancer Cell Int</source><year>2021</year><volume>21</volume><fpage>31</fpage><pub-id pub-id-type="pmid">33413418</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12935-020-01716-8</pub-id><pub-id pub-id-type="pmcid">PMC7792222</pub-id></element-citation><mixed-citation id="mc-CR124" publication-type="journal">Niu T, Zhang W, Xiao W. MicroRNA regulation of cancer stem cells in the pathogenesis of breast cancer. Cancer Cell Int. 2021;21:31.<pub-id pub-id-type="pmid">33413418</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12935-020-01716-8</pub-id><pub-id pub-id-type="pmcid">PMC7792222</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR125"><label>125.</label><citation-alternatives><element-citation id="ec-CR125" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Z</given-names></name><etal/></person-group><article-title>A novel method to limit breast cancer stem cells in States of quiescence, proliferation or differentiation: use of gel stress in combination with stem cell growth factors</article-title><source>Oncol Lett</source><year>2016</year><volume>12</volume><fpage>1355</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">27446437</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ol.2016.4757</pub-id><pub-id pub-id-type="pmcid">PMC4950051</pub-id></element-citation><mixed-citation id="mc-CR125" publication-type="journal">Wang J, Liu X, Jiang Z, et al. A novel method to limit breast cancer stem cells in States of quiescence, proliferation or differentiation: use of gel stress in combination with stem cell growth factors. Oncol Lett. 2016;12:1355&#8211;60.<pub-id pub-id-type="pmid">27446437</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ol.2016.4757</pub-id><pub-id pub-id-type="pmcid">PMC4950051</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR126"><label>126.</label><citation-alternatives><element-citation id="ec-CR126" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hatina</surname><given-names>J</given-names></name></person-group><article-title>The dynamics of cancer stem cells</article-title><source>Neoplasma</source><year>2012</year><volume>59</volume><fpage>700</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">22862171</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4149/neo_2012_092</pub-id></element-citation><mixed-citation id="mc-CR126" publication-type="journal">Hatina J. The dynamics of cancer stem cells. Neoplasma. 2012;59:700&#8211;7.<pub-id pub-id-type="pmid">22862171</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4149/neo_2012_092</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR127"><label>127.</label><citation-alternatives><element-citation id="ec-CR127" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Hajj</surname><given-names>M</given-names></name><name name-style="western"><surname>Becker</surname><given-names>MW</given-names></name><name name-style="western"><surname>Wicha</surname><given-names>M</given-names></name><etal/></person-group><article-title>Therapeutic implications of cancer stem cells</article-title><source>Curr Opin Genet Dev</source><year>2004</year><volume>14</volume><fpage>43</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">15108804</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.gde.2003.11.007</pub-id></element-citation><mixed-citation id="mc-CR127" publication-type="journal">Al-Hajj M, Becker MW, Wicha M, et al. Therapeutic implications of cancer stem cells. Curr Opin Genet Dev. 2004;14:43&#8211;7.<pub-id pub-id-type="pmid">15108804</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.gde.2003.11.007</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR128"><label>128.</label><citation-alternatives><element-citation id="ec-CR128" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pinto</surname><given-names>CA</given-names></name><name name-style="western"><surname>Widodo</surname><given-names>E</given-names></name><name name-style="western"><surname>Waltham</surname><given-names>M</given-names></name><etal/></person-group><article-title>Breast cancer stem cells and epithelial mesenchymal plasticity &#8211; Implications for chemoresistance</article-title><source>Cancer Lett</source><year>2013</year><volume>341</volume><fpage>56</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">23830804</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.canlet.2013.06.003</pub-id></element-citation><mixed-citation id="mc-CR128" publication-type="journal">Pinto CA, Widodo E, Waltham M, et al. Breast cancer stem cells and epithelial mesenchymal plasticity &#8211; Implications for chemoresistance. Cancer Lett. 2013;341:56&#8211;62.<pub-id pub-id-type="pmid">23830804</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.canlet.2013.06.003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR129"><label>129.</label><citation-alternatives><element-citation id="ec-CR129" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Banerjee</surname><given-names>A</given-names></name><name name-style="western"><surname>Birts</surname><given-names>CN</given-names></name><name name-style="western"><surname>Darley</surname><given-names>M</given-names></name><etal/></person-group><article-title>Stem cell-like breast cancer cells with acquired resistance to Metformin are sensitive to inhibitors of NADH-dependent CtBP dimerization</article-title><source>Carcinogenesis</source><year>2019</year><volume>40</volume><fpage>871</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">30668646</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/carcin/bgy174</pub-id></element-citation><mixed-citation id="mc-CR129" publication-type="journal">Banerjee A, Birts CN, Darley M, et al. Stem cell-like breast cancer cells with acquired resistance to Metformin are sensitive to inhibitors of NADH-dependent CtBP dimerization. Carcinogenesis. 2019;40:871&#8211;82.<pub-id pub-id-type="pmid">30668646</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/carcin/bgy174</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR130"><label>130.</label><citation-alternatives><element-citation id="ec-CR130" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>M</given-names></name><name name-style="western"><surname>Wicha</surname><given-names>MS</given-names></name></person-group><article-title>Targeting cancer stem cell redox metabolism to enhance therapy responses</article-title><source>Semin Radiat Oncol</source><year>2019</year><volume>29</volume><fpage>42</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">30573183</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.semradonc.2018.10.003</pub-id><pub-id pub-id-type="pmcid">PMC6614864</pub-id></element-citation><mixed-citation id="mc-CR130" publication-type="journal">Luo M, Wicha MS. Targeting cancer stem cell redox metabolism to enhance therapy responses. Semin Radiat Oncol. 2019;29:42&#8211;54.<pub-id pub-id-type="pmid">30573183</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.semradonc.2018.10.003</pub-id><pub-id pub-id-type="pmcid">PMC6614864</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR131"><label>131.</label><mixed-citation publication-type="other">Veiga GLD, Silva R, Pereira EC et al. The role of Survivin as a biomarker and potential prognostic factor for breast cancer. Rev Assoc Med Bras (1992). 2019; 65: 893&#8211;901.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1590/1806-9282.65.6.893</pub-id><pub-id pub-id-type="pmid">31340322</pub-id></mixed-citation></ref><ref id="CR132"><label>132.</label><citation-alternatives><element-citation id="ec-CR132" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Almeida</surname><given-names>J</given-names></name><name name-style="western"><surname>Pedrosa</surname><given-names>N</given-names></name><name name-style="western"><surname>Leite</surname><given-names>J</given-names></name><etal/></person-group><article-title>Marcadores tumorais: Revis&#227;o de literatura</article-title><source>Revista Brasileira De Cancerologia</source><year>2007</year><volume>53</volume><fpage>305</fpage><lpage>16</lpage></element-citation><mixed-citation id="mc-CR132" publication-type="journal">Almeida J, Pedrosa N, Leite J, et al. Marcadores tumorais: Revis&#227;o de literatura. Revista Brasileira De Cancerologia. 2007;53:305&#8211;16.</mixed-citation></citation-alternatives></ref><ref id="CR133"><label>133.</label><citation-alternatives><element-citation id="ec-CR133" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuniyoshi</surname><given-names>RK</given-names></name><name name-style="western"><surname>Gehrke Fde</surname><given-names>S</given-names></name><name name-style="western"><surname>Alves</surname><given-names>BC</given-names></name><etal/></person-group><article-title>Gene profiling and Circulating tumor cells as biomarker to prognostic of patients with locoregional breast cancer</article-title><source>Tumour Biol</source><year>2015</year><volume>36</volume><fpage>8075</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">25976504</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13277-015-3529-5</pub-id></element-citation><mixed-citation id="mc-CR133" publication-type="journal">Kuniyoshi RK, Gehrke Fde S, Alves BC, et al. Gene profiling and Circulating tumor cells as biomarker to prognostic of patients with locoregional breast cancer. Tumour Biol. 2015;36:8075&#8211;83.<pub-id pub-id-type="pmid">25976504</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13277-015-3529-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR134"><label>134.</label><citation-alternatives><element-citation id="ec-CR134" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Najjar</surname><given-names>S</given-names></name><name name-style="western"><surname>Allison</surname><given-names>KH</given-names></name></person-group><article-title>Updates on breast biomarkers</article-title><source>Virchows Arch</source><year>2022</year><volume>480</volume><fpage>163</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">35029776</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00428-022-03267-x</pub-id></element-citation><mixed-citation id="mc-CR134" publication-type="journal">Najjar S, Allison KH. Updates on breast biomarkers. Virchows Arch. 2022;480:163&#8211;76.<pub-id pub-id-type="pmid">35029776</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00428-022-03267-x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR135"><label>135.</label><citation-alternatives><element-citation id="ec-CR135" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pritzker</surname><given-names>KP</given-names></name></person-group><article-title>Predictive and prognostic cancer biomarkers revisited</article-title><source>Expert Rev Mol Diagn</source><year>2015</year><volume>15</volume><fpage>971</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">26134385</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/14737159.2015.1063421</pub-id></element-citation><mixed-citation id="mc-CR135" publication-type="journal">Pritzker KP. Predictive and prognostic cancer biomarkers revisited. Expert Rev Mol Diagn. 2015;15:971&#8211;4.<pub-id pub-id-type="pmid">26134385</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/14737159.2015.1063421</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR136"><label>136.</label><citation-alternatives><element-citation id="ec-CR136" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tarighati</surname><given-names>E</given-names></name><name name-style="western"><surname>Keivan</surname><given-names>H</given-names></name><name name-style="western"><surname>Mahani</surname><given-names>H</given-names></name></person-group><article-title>A review of prognostic and predictive biomarkers in breast cancer</article-title><source>Clin Exp Med</source><year>2023</year><volume>23</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">35031885</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10238-021-00781-1</pub-id></element-citation><mixed-citation id="mc-CR136" publication-type="journal">Tarighati E, Keivan H, Mahani H. A review of prognostic and predictive biomarkers in breast cancer. Clin Exp Med. 2023;23:1&#8211;16.<pub-id pub-id-type="pmid">35031885</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10238-021-00781-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR137"><label>137.</label><citation-alternatives><element-citation id="ec-CR137" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koulis</surname><given-names>C</given-names></name><name name-style="western"><surname>Yap</surname><given-names>R</given-names></name><name name-style="western"><surname>Engel</surname><given-names>R</given-names></name><etal/></person-group><article-title>Personalized Medicine-Current and emerging predictive and prognostic biomarkers in colorectal cancer</article-title><source>Cancers (Basel)</source><year>2020</year><volume>12</volume><fpage>812</fpage><pub-id pub-id-type="pmid">32231042</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers12040812</pub-id><pub-id pub-id-type="pmcid">PMC7225926</pub-id></element-citation><mixed-citation id="mc-CR137" publication-type="journal">Koulis C, Yap R, Engel R, et al. Personalized Medicine-Current and emerging predictive and prognostic biomarkers in colorectal cancer. Cancers (Basel). 2020;12:812.<pub-id pub-id-type="pmid">32231042</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers12040812</pub-id><pub-id pub-id-type="pmcid">PMC7225926</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR138"><label>138.</label><citation-alternatives><element-citation id="ec-CR138" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pantel</surname><given-names>K</given-names></name><name name-style="western"><surname>Alix-Panabi&#232;res</surname><given-names>C</given-names></name></person-group><article-title>Circulating tumour cells in cancer patients: challenges and perspectives</article-title><source>Trends Mol Med</source><year>2010</year><volume>16</volume><fpage>398</fpage><lpage>406</lpage><pub-id pub-id-type="pmid">20667783</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molmed.2010.07.001</pub-id></element-citation><mixed-citation id="mc-CR138" publication-type="journal">Pantel K, Alix-Panabi&#232;res C. Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med. 2010;16:398&#8211;406.<pub-id pub-id-type="pmid">20667783</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molmed.2010.07.001</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR139"><label>139.</label><citation-alternatives><element-citation id="ec-CR139" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ziegler</surname><given-names>A</given-names></name><name name-style="western"><surname>Zangemeister-Wittke</surname><given-names>U</given-names></name><name name-style="western"><surname>Stahel</surname><given-names>RA</given-names></name></person-group><article-title>Circulating DNA: a new diagnostic gold mine?</article-title><source>Cancer Treat Rev</source><year>2002</year><volume>28</volume><fpage>255</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">12435372</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0305-7372(02)00077-4</pub-id></element-citation><mixed-citation id="mc-CR139" publication-type="journal">Ziegler A, Zangemeister-Wittke U, Stahel RA. Circulating DNA: a new diagnostic gold mine? Cancer Treat Rev. 2002;28:255&#8211;71.<pub-id pub-id-type="pmid">12435372</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0305-7372(02)00077-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR140"><label>140.</label><citation-alternatives><element-citation id="ec-CR140" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>P&#233;rez-Callejo</surname><given-names>D</given-names></name><name name-style="western"><surname>Romero</surname><given-names>A</given-names></name><name name-style="western"><surname>Provencio</surname><given-names>M</given-names></name><etal/></person-group><article-title>Liquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring</article-title><source>Transl Lung Cancer Res</source><year>2016</year><volume>5</volume><fpage>455</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">27826527</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/tlcr.2016.10.07</pub-id><pub-id pub-id-type="pmcid">PMC5099509</pub-id></element-citation><mixed-citation id="mc-CR140" publication-type="journal">P&#233;rez-Callejo D, Romero A, Provencio M, et al. Liquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring. Transl Lung Cancer Res. 2016;5:455&#8211;65.<pub-id pub-id-type="pmid">27826527</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/tlcr.2016.10.07</pub-id><pub-id pub-id-type="pmcid">PMC5099509</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR141"><label>141.</label><citation-alternatives><element-citation id="ec-CR141" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murtaza</surname><given-names>M</given-names></name><name name-style="western"><surname>Dawson</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Pogrebniak</surname><given-names>K</given-names></name><etal/></person-group><article-title>Multifocal clonal evolution characterized using Circulating tumour DNA in a case of metastatic breast cancer</article-title><source>Nat Commun</source><year>2015</year><volume>6</volume><fpage>8760</fpage><pub-id pub-id-type="pmid">26530965</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms9760</pub-id><pub-id pub-id-type="pmcid">PMC4659935</pub-id></element-citation><mixed-citation id="mc-CR141" publication-type="journal">Murtaza M, Dawson SJ, Pogrebniak K, et al. Multifocal clonal evolution characterized using Circulating tumour DNA in a case of metastatic breast cancer. Nat Commun. 2015;6:8760.<pub-id pub-id-type="pmid">26530965</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms9760</pub-id><pub-id pub-id-type="pmcid">PMC4659935</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR142"><label>142.</label><citation-alternatives><element-citation id="ec-CR142" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tay</surname><given-names>TKY</given-names></name><name name-style="western"><surname>Tan</surname><given-names>PH</given-names></name></person-group><article-title>Liquid biopsy in breast cancer: A focused review</article-title><source>Arch Pathol Lab Med</source><year>2021</year><volume>145</volume><fpage>678</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">32045277</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5858/arpa.2019-0559-RA</pub-id></element-citation><mixed-citation id="mc-CR142" publication-type="journal">Tay TKY, Tan PH. Liquid biopsy in breast cancer: A focused review. Arch Pathol Lab Med. 2021;145:678&#8211;86.<pub-id pub-id-type="pmid">32045277</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5858/arpa.2019-0559-RA</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR143"><label>143.</label><citation-alternatives><element-citation id="ec-CR143" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alimirzaie</surname><given-names>S</given-names></name><name name-style="western"><surname>Bagherzadeh</surname><given-names>M</given-names></name><name name-style="western"><surname>Akbari</surname><given-names>MR</given-names></name></person-group><article-title>Liquid biopsy in breast cancer: A comprehensive review</article-title><source>Clin Genet</source><year>2019</year><volume>95</volume><fpage>643</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">30671931</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cge.13514</pub-id></element-citation><mixed-citation id="mc-CR143" publication-type="journal">Alimirzaie S, Bagherzadeh M, Akbari MR. Liquid biopsy in breast cancer: A comprehensive review. Clin Genet. 2019;95:643&#8211;60.<pub-id pub-id-type="pmid">30671931</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cge.13514</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR144"><label>144.</label><citation-alternatives><element-citation id="ec-CR144" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eigeliene</surname><given-names>N</given-names></name><name name-style="western"><surname>Saarenheimo</surname><given-names>J</given-names></name><name name-style="western"><surname>Jekunen</surname><given-names>A</given-names></name></person-group><article-title>Potential of liquid biopsies for breast cancer screening, diagnosis, and response to treatment</article-title><source>Oncology</source><year>2019</year><volume>96</volume><fpage>115</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">30654364</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000495615</pub-id></element-citation><mixed-citation id="mc-CR144" publication-type="journal">Eigeliene N, Saarenheimo J, Jekunen A. Potential of liquid biopsies for breast cancer screening, diagnosis, and response to treatment. Oncology. 2019;96:115&#8211;24.<pub-id pub-id-type="pmid">30654364</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000495615</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR145"><label>145.</label><citation-alternatives><element-citation id="ec-CR145" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tellez-Gabriel</surname><given-names>M</given-names></name><name name-style="western"><surname>Knutsen</surname><given-names>E</given-names></name><name name-style="western"><surname>Perander</surname><given-names>M</given-names></name></person-group><article-title>Current status of Circulating tumor cells, Circulating tumor DNA, and exosomes in breast cancer liquid biopsies</article-title><source>Int J Mol Sci</source><year>2020</year><volume>21</volume><fpage>9457</fpage><pub-id pub-id-type="pmid">33322643</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms21249457</pub-id><pub-id pub-id-type="pmcid">PMC7763984</pub-id></element-citation><mixed-citation id="mc-CR145" publication-type="journal">Tellez-Gabriel M, Knutsen E, Perander M. Current status of Circulating tumor cells, Circulating tumor DNA, and exosomes in breast cancer liquid biopsies. Int J Mol Sci. 2020;21:9457.<pub-id pub-id-type="pmid">33322643</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms21249457</pub-id><pub-id pub-id-type="pmcid">PMC7763984</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR146"><label>146.</label><citation-alternatives><element-citation id="ec-CR146" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crowley</surname><given-names>E</given-names></name><name name-style="western"><surname>Di Nicolantonio</surname><given-names>F</given-names></name><name name-style="western"><surname>Loupakis</surname><given-names>F</given-names></name><etal/></person-group><article-title>Liquid biopsy: monitoring cancer-genetics in the blood</article-title><source>Nat Rev Clin Oncol</source><year>2013</year><volume>10</volume><fpage>472</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">23836314</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrclinonc.2013.110</pub-id></element-citation><mixed-citation id="mc-CR146" publication-type="journal">Crowley E, Di Nicolantonio F, Loupakis F, et al. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013;10:472&#8211;84.<pub-id pub-id-type="pmid">23836314</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrclinonc.2013.110</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR147"><label>147.</label><citation-alternatives><element-citation id="ec-CR147" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Mattos-Arruda</surname><given-names>L</given-names></name><name name-style="western"><surname>Caldas</surname><given-names>C</given-names></name></person-group><article-title>Cell-free Circulating tumour DNA as a liquid biopsy in breast cancer</article-title><source>Mol Oncol</source><year>2016</year><volume>10</volume><fpage>464</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">26776681</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molonc.2015.12.001</pub-id><pub-id pub-id-type="pmcid">PMC5528975</pub-id></element-citation><mixed-citation id="mc-CR147" publication-type="journal">De Mattos-Arruda L, Caldas C. Cell-free Circulating tumour DNA as a liquid biopsy in breast cancer. Mol Oncol. 2016;10:464&#8211;74.<pub-id pub-id-type="pmid">26776681</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molonc.2015.12.001</pub-id><pub-id pub-id-type="pmcid">PMC5528975</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR148"><label>148.</label><citation-alternatives><element-citation id="ec-CR148" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bardelli</surname><given-names>A</given-names></name><name name-style="western"><surname>Pantel</surname><given-names>K</given-names></name></person-group><article-title>Liquid biopsies, what we do not know (Yet)</article-title><source>Cancer Cell</source><year>2017</year><volume>31</volume><fpage>172</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">28196593</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccell.2017.01.002</pub-id></element-citation><mixed-citation id="mc-CR148" publication-type="journal">Bardelli A, Pantel K. Liquid biopsies, what we do not know (Yet). Cancer Cell. 2017;31:172&#8211;9.<pub-id pub-id-type="pmid">28196593</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccell.2017.01.002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR149"><label>149.</label><citation-alternatives><element-citation id="ec-CR149" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pantel</surname><given-names>K</given-names></name><name name-style="western"><surname>Alix-Panabi&#232;res</surname><given-names>C</given-names></name></person-group><article-title>Liquid biopsy and minimal residual disease - latest advances and implications for cure</article-title><source>Nat Rev Clin Oncol</source><year>2019</year><volume>16</volume><fpage>409</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">30796368</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41571-019-0187-3</pub-id></element-citation><mixed-citation id="mc-CR149" publication-type="journal">Pantel K, Alix-Panabi&#232;res C. Liquid biopsy and minimal residual disease - latest advances and implications for cure. Nat Rev Clin Oncol. 2019;16:409&#8211;24.<pub-id pub-id-type="pmid">30796368</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41571-019-0187-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR150"><label>150.</label><citation-alternatives><element-citation id="ec-CR150" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L</given-names></name><name name-style="western"><surname>Song</surname><given-names>J</given-names></name><etal/></person-group><article-title>Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer</article-title><source>Mol Cancer</source><year>2022</year><volume>21</volume><fpage>86</fpage><pub-id pub-id-type="pmid">35337361</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12943-022-01556-2</pub-id><pub-id pub-id-type="pmcid">PMC8951719</pub-id></element-citation><mixed-citation id="mc-CR150" publication-type="journal">Zhou H, Zhu L, Song J, et al. Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer. Mol Cancer. 2022;21:86.<pub-id pub-id-type="pmid">35337361</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12943-022-01556-2</pub-id><pub-id pub-id-type="pmcid">PMC8951719</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR151"><label>151.</label><citation-alternatives><element-citation id="ec-CR151" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>TT</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Prognostic and predictive blood biomarkers in gastric cancer and the potential application of Circulating tumor cells</article-title><source>World J Gastroenterol</source><year>2018</year><volume>24</volume><fpage>2236</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">29881233</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3748/wjg.v24.i21.2236</pub-id><pub-id pub-id-type="pmcid">PMC5989238</pub-id></element-citation><mixed-citation id="mc-CR151" publication-type="journal">Li TT, Liu H, Yu J, et al. Prognostic and predictive blood biomarkers in gastric cancer and the potential application of Circulating tumor cells. World J Gastroenterol. 2018;24:2236&#8211;46.<pub-id pub-id-type="pmid">29881233</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3748/wjg.v24.i21.2236</pub-id><pub-id pub-id-type="pmcid">PMC5989238</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR152"><label>152.</label><citation-alternatives><element-citation id="ec-CR152" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jelski</surname><given-names>W</given-names></name><name name-style="western"><surname>Mroczko</surname><given-names>B</given-names></name></person-group><article-title>Molecular and Circulating biomarkers of gastric cancer</article-title><source>Int J Mol Sci</source><year>2022</year><volume>23</volume><fpage>7588</fpage><pub-id pub-id-type="pmid">35886934</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms23147588</pub-id><pub-id pub-id-type="pmcid">PMC9322632</pub-id></element-citation><mixed-citation id="mc-CR152" publication-type="journal">Jelski W, Mroczko B. Molecular and Circulating biomarkers of gastric cancer. Int J Mol Sci. 2022;23:7588.<pub-id pub-id-type="pmid">35886934</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms23147588</pub-id><pub-id pub-id-type="pmcid">PMC9322632</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR153"><label>153.</label><citation-alternatives><element-citation id="ec-CR153" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kilgour</surname><given-names>E</given-names></name><name name-style="western"><surname>Rothwell</surname><given-names>DG</given-names></name><name name-style="western"><surname>Brady</surname><given-names>G</given-names></name><etal/></person-group><article-title>Liquid Biopsy-Based biomarkers of treatment response and resistance</article-title><source>Cancer Cell</source><year>2020</year><volume>37</volume><fpage>485</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">32289272</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccell.2020.03.012</pub-id></element-citation><mixed-citation id="mc-CR153" publication-type="journal">Kilgour E, Rothwell DG, Brady G, et al. Liquid Biopsy-Based biomarkers of treatment response and resistance. Cancer Cell. 2020;37:485&#8211;95.<pub-id pub-id-type="pmid">32289272</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccell.2020.03.012</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR154"><label>154.</label><citation-alternatives><element-citation id="ec-CR154" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>HSPB1 facilitates chemoresistance through inhibiting ferroptotic cancer cell death and regulating NF-&#954;B signaling pathway in breast cancer</article-title><source>Cell Death Dis</source><year>2023</year><volume>14</volume><issue>7</issue><fpage>434</fpage><pub-id pub-id-type="pmid">37454220</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-023-05972-0</pub-id><pub-id pub-id-type="pmcid">PMC10349816</pub-id></element-citation><mixed-citation id="mc-CR154" publication-type="journal">Liang Y, Wang Y, Zhang Y, et al. HSPB1 facilitates chemoresistance through inhibiting ferroptotic cancer cell death and regulating NF-&#954;B signaling pathway in breast cancer. Cell Death Dis. 2023;14(7):434.<pub-id pub-id-type="pmid">37454220</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-023-05972-0</pub-id><pub-id pub-id-type="pmcid">PMC10349816</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR155"><label>155.</label><citation-alternatives><element-citation id="ec-CR155" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>C</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wei</surname><given-names>M</given-names></name><etal/></person-group><article-title>A self-amplified ferroptosis nanoagent that inhibits the tumor upstream glutathione synthesis to reverse cancer chemoresistance</article-title><source>J Control Release</source><year>2023</year><volume>357</volume><fpage>20</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">36940774</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2023.03.030</pub-id></element-citation><mixed-citation id="mc-CR155" publication-type="journal">Yang C, Chen Z, Wei M, et al. A self-amplified ferroptosis nanoagent that inhibits the tumor upstream glutathione synthesis to reverse cancer chemoresistance. J Control Release. 2023;357:20&#8211;30.<pub-id pub-id-type="pmid">36940774</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2023.03.030</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR156"><label>156.</label><citation-alternatives><element-citation id="ec-CR156" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>S</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name></person-group><article-title>Overcoming chemoresistance in triple-negative breast cancer (TNBC): targeting PD-L1 stability and ferroptosis through integrated lipid metabolism and immune modulation</article-title><source>J Clin Oncol</source><year>2024</year><volume>42</volume><issue>16suppl</issue><fpage>e15149</fpage></element-citation><mixed-citation id="mc-CR156" publication-type="journal">Yang S, Tang J, Zhang J. Overcoming chemoresistance in triple-negative breast cancer (TNBC): targeting PD-L1 stability and ferroptosis through integrated lipid metabolism and immune modulation. J Clin Oncol. 2024;42(16suppl):e15149.</mixed-citation></citation-alternatives></ref><ref id="CR157"><label>157.</label><citation-alternatives><element-citation id="ec-CR157" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qi</surname><given-names>X</given-names></name><name name-style="western"><surname>Wan</surname><given-names>Z</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>B</given-names></name><etal/></person-group><article-title>Inducing ferroptosis has the potential to overcome therapy resistance in breast cancer</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><fpage>1038225</fpage><pub-id pub-id-type="pmid">36505465</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.1038225</pub-id><pub-id pub-id-type="pmcid">PMC9730886</pub-id></element-citation><mixed-citation id="mc-CR157" publication-type="journal">Qi X, Wan Z, Jiang B, et al. Inducing ferroptosis has the potential to overcome therapy resistance in breast cancer. Front Immunol. 2022;13:1038225.<pub-id pub-id-type="pmid">36505465</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.1038225</pub-id><pub-id pub-id-type="pmcid">PMC9730886</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>